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ABSTRACT
Background: Dietary fish oil is associated with many health benefits. Changes in
membrane composition in the heart with incorporation of n-3 polyunsaturated
fatty acids (n-3 PUFA), especially docosahexaenoic acid (22:6n-3, DHA) have
been associated with improved function and reduced cardiac disease morbidity
and mortality. Although similar incorporation of DHA is observed in skeletal
muscle, very little is known about the effects of fish oil on skeletal muscle
function. Preliminary work suggests an important role for fish oil in improving
muscle function in rats. If dietary fish oil can affect skeletal muscle similarly to
the heart, the potential applications are huge, including improving muscle function
and quality of life in those with a sedentary lifestyle, athletes and sportspeople as
well as patients with secondary skeletal muscle dysfunction, for example in heart
failure and respiratory disorders. A general concern however with previous animal
mechanistic studies (both in the heart and skeletal muscle) that show an effect of
fish oil, use high doses of dietary fish oil that are generally not comparable to
human intakes. The purpose of this PhD was to therefore assess the effects of low,
human equivalent doses of dietary fish oil on skeletal muscle membrane
composition, function and fatigue. Muscle function and fatigue was assessed in
normal physiological conditions, in muscle already fatigued by prior activity
(post-fatigue) and in muscle subjected to restricted blood flow (model of
claudication). In addition, we set out to extend this study to apply it to a model of
heart failure.
Methods/Design: 144 Male Sprague-Dawley rats were assigned to one of three
pre-fabricated diets. Rats were fed 10% fat diets containing either fish oil (FO) in
olive oil (LowFO-0.31% or ModFO-1.25%) or olive oil diet alone (OO) for at

xiii

least 4 weeks prior to experimentation. Skeletal muscle function was assessed in
vivo using the constant flow auto-perfused hindlimb set up with different
stimulation protocols including single tetanic contractions, continuous low
frequency (2Hz) twitch stimulation and repeated bouts of low frequency (5Hz)
stimulation. The repeated bouts stimulation protocol (5Hz) was used to assess
function in muscle post-fatigue and in the claudication model, as it is more
representative of human muscle activity. Abdominal aortic banding was chosen as
the most relevant model of cardiac hypertrophy and heart failure for the current
study. As it has not previously been used for assessment of the skeletal muscle
dysfunction associated with heart failure, preliminary work sought to identify this
model as one that causes significant skeletal muscle dysfunction. In addition, the
effect of FO on the development of cardiac hypertrophy was examined by
measuring heart size. Echocardiography was later introduced as a tool to improve
the assessment of heart function in the aortic banding model.
Outcomes: Both low and moderate dose FO diets resulted in significant changes
in membrane composition, including a marked increase in DHA incorporation in
gastrocnemius (OO: 9.26±0.74%; LowFO: 19.89±0.36%; Mod FO: 24.25±1.03%)
and soleus muscle (OO: 5.14±0.23%; LowFO 14.27±0.65%; ModFO:
18.04±1.40%) comparable to the myocardium (OO: 6.62±0.34%; LowFO:
16.84±0.38%; ModFO: 20.35±0.68%). Skeletal muscle force development was
higher in FO fed animals during tetanic contractions and repetitive single twitch
contractions. The FO fed animals were resistant to fatigue during repetitive single
twitch contractions and during repeated trains of contraction with a higher force
maintained throughout each 5min stimulation protocol, both in normal and postfatigue muscle. This effect was less obvious in a model of low flow. Associated
xiv

with these improvements in muscle contractile function were improvements in O2
consumption in FO animals. Low dose FO prevented cardiac hypertrophy after
aortic banding when introduced prior to surgery and produced a small reduction in
hypertrophy when the FO diet was introduced after the hypertrophic stimulus in
comparison to OO controls. The abdominal aortic banding model of heart failure
did not result in any observed differences in skeletal muscle function in the time
frame investigated. Echocardiography indicated reduced HR and increased stroke
volume in FO fed animals not subjected to aortic banding.
Conclusion: This study established that dietary FO improved skeletal muscle
force development and promoted fatigue resistance that was universally applicable
over a range of contraction patterns. This was achieved with very low FO doses
equivalent to human intakes (in energy terms), which nevertheless produced
marked increases in muscle DHA incorporation. These low fish oil doses were
also sufficient to slow resting heart rate and improve cardiac function in vivo.
Heightened O2 consumption likely contributes to the improved muscle
performance. Low dose fish oil was also beneficial in reducing the development
of cardiac hypertrophy, however no skeletal muscle dysfunction was observed at
the time point examined in this model, preventing the assessment of the potential
for fish oil to improve muscle function associated with heart failure. These studies
confirm and extend previous findings pertaining to the effect of n-3 PUFA on
heart and skeletal muscle function achieved previously using high fish oil intakes.
The use of fish oil doses achievable in the human diet confirms a relevance to
human physiology that was previously questionable.
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Chapter 1 INTRODUCTION
Dietary fish oil is associated with many health benefits (Gogus & Smith 2010;
Yashodhara et al. 2009). One well documented benefit is its cardioprotective
effect, where improved cardiac function and a reduction in cardiovascular
morbidity and mortality has been associated incorporation of n-3 polyunsaturated
fatty acids (PUFA), found in fish oil, into cardiac membranes (McLennan 2004;
McLennan & Abeywardena 2005). Similar incorporation of n-3 PUFA, especially
DHA, is also observed in skeletal muscle however much less is known about the
effects of n-3 PUFA on skeletal muscle function. There is preliminary evidence to
suggest an important role for fish oil in improving skeletal muscle function in rats
(Peoples 2004). If fish oil fatty acids have a similar essential role in skeletal
muscle as they do in cardiac muscle, the potential applications are huge, not only
improving muscle function in athletes and sportspeople but improving quality of
life in those with a sedentary lifestyle or those patients with secondary skeletal
muscle dysfunction, such as in heart failure or respiratory disorders. This thesis
will begin to address the potential effects of fish oil on skeletal muscle function in
both physiological and pathophysiological conditions.

1.1 Polyunsaturated fatty acids and fish oils
There are three classes of fatty acids based on the presence of double bonds in the
hydrocarbon chain. Saturated, monounsaturated and polyunsaturated fatty acids
have zero, one and two or more double bonds in the hydrocarbon chain
respectively. PUFA are further classified based on the location of the first double
bond from the methyl group chain ending. n-6 PUFA and n-3 PUFA have their
first double bond located 6 and 3 carbons from the terminal methyl group

1

respectively (Leaf et al. 2005; Ruxton et al. 2004; Schmidt et al. 2001; Seo et al.
2005). Fatty acids are incorporated into cell membranes in varying proportions in
different tissues and play an important role in cellular function (Spector & Yorek
1985).

While some fatty acids can be formed de novo, PUFA cannot and therefore they
must be obtained from the diet or formed by metabolism of other PUFA from the
diet. These fatty acids that must be obtained from the diet are called essential fatty
acids. Linoleic acid (LA) and α-linolenic acid (ALA), essential fatty acids in
mammals (Wallis et al. 2002), are the precursors of other PUFA in their
respective n-6 and n-3 families (Figure 1-1). The biosynthesis pathway from LA
and ALA to the longer chain fatty acids of AA and EPA involves a series of
desaturase (Δ6 and Δ5 desaturase) and elongase reactions (steps 1-4). The
following steps for the synthesis of DHA from EPA were originally thought to be
Δ4 desaturation followed by elongation however it is now known that Δ4
desaturase does not exist in mammals and therefore the DHA synthesis is a more
indirect process involving elongation, Δ6 desaturation and peroxisomal βoxidation (steps 5-7) (Wallis et al. 2002). Most of the biosynthesis of longer chain
n-6 PUFA and n-3 PUFA occurs in the endoplasmic reticulum however the final
step (partial β oxidation) occurs in the peroxisome.

Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are both very long
chain n-3 PUFA found in fish oils. There is now strong evidence to suggest that
these n-3 PUFA have positive effects on health (Connor 2000; Gogus & Smith
2010; Riediger et al. 2009; Yashodhara et al. 2009) They have previously been
2

associated with favourable outcomes in heart disease, retinal and brain
development, autoimmune disorders, Crohn’s disease, breast, colon and prostate
cancers, hypertension, rheumatoid arthritis, asthma, diabetes, psoriasis and
depression (Connor 2000; Riediger et al. 2009; Ruxton et al. 2004; Seo et al.
2005; Uauy-Dagach & Valenzuela 1996).

n-6 PUFA

n-3 PUFA

18:2n6 (LA)
↓

18:3n3 (ALA)
1. ∆6 desaturase

18:3n6
↓

2. elongase

20:3n6
↓

3. ∆5 desaturase

↓
20:5n3 (EPA)

↓

4. elongase

22:4n6

↓
22:5n3

↓

5. elongase

24:4n6

↓
24:5n3

6. ∆6 desaturase

24:5n6
↓

↓
20:4n3

20:4n6 (AA)

↓

↓
18:4n3

↓
24:6n3

7. Peroxisomal β-oxidation

22:5n6

↓
22:6n3 (DHA)

Figure 1-1 Biosynthesis of n-6 and n-3 fatty acids from their precursors linoleic acid
(LA) and α-linolenic acid (ALA).
Steps 1-6 occur in the endoplasmic reticulum. Step 7 occurs in peroxisomes. Adapted
from (Wallis et al. 2002).

1.2 Fish oils and cardioprotection
1.2.1. Epidemiology and clinical trials
Perhaps the strongest evidence for a beneficial role of n-3 PUFA involves their
cardioprotective effect. This was first proposed 40 years ago by Bang and
Dyerberg (Bang & Dyerberg 1972) who suggested that the low incidence of
coronary heart disease in Greenland Eskimos was related to their high fish and
marine mammal diet. Many population-based studies have demonstrated a
favourable role of fish oils in the prevention of cardiovascular disease. An inverse
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relationship between fish consumption and cardiovascular disease was found in
Greenland Eskimos, the Japanese and a Dutch population whose fish consumption
was estimated at 400, 100 and 20-45 grams per day respectively (Bang &
Dyerberg 1972; Kromhout et al. 1985). Other studies such as the Diet and
Reinfarction Trial (DART) (Burr et al. 1989) and the GISSI-Prevenzione Trial
(Marchioli et al. 2001) have focused on the role of fish or fish oil in secondary
prevention of heart disease, showing that a lower mortality rate in patients with a
recent myocardial infarction was associated with advice to eat fish at least twice a
week (DART) or a 1g/day fish oil capsule administered to subjects on a
Mediterranean style diet (which also included fish). n-3 PUFA have also been
associated with a reduced risk of sudden cardiac death (Christensen & Schmidt
2001) and heart failure (Mozaffarian et al. 2005a).

The cardioprotective role of fish oil can be attributed to many different effects on
the cardiovascular system including anti-atherogenic, anti-thrombotic, antiinflammatory, anti-hypertensive and anti-arrhythmic outcomes. More specifically
dietary fish oil lowers plasma triglycerides by inhibiting triglyceride synthesis
(Uauy-Dagach & Valenzuela 1996), lowers VLDL and increases HDL cholesterol
as well as increases the less atherogenic form of LDL cholesterol (Robinson &
Stone 2006), reduces platelet aggregation and vasoconstriction due to altered
eicosanoid metabolism (Connor 2000), lowers blood pressure and heart rate
(Mozaffarian et al. 2005b; Mozaffarian et al. 2006) and improves heart rate
variability (Christensen et al. 1999; Christensen & Schmidt 2007). Evidence
suggests that the most significant effect likely contributing to the reduction in
cardiovascular mortality with fish oil supplementation is the anti-arrhythmic
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effect. Anti-arrhythmic effects of n-3 PUFA are observed at lower intakes
compared to the other effects and the consequences of these effects are potentially
more important (Harris et al. 2009). While there are obvious benefits for the antithrombotic, anti-atherogenic, anti-inflammatory and anti-hypertensive effects of
n-3 PUFA in terms of reducing disease progression, these effects are more
modest, require higher doses of fish oil and occur earlier in the development of
cardiovascular disease. As such they are unlikely to significantly contribute to the
profound effect of fish oil on cardiovascular mortality, which is probably due to
the reduction of fatal arrhythmias. This is evidenced in the GISSI and DART trials
that show a reduction in cardiac events and/or sudden cardiac death with little or
no effect on BP and triglycerides (Burr et al. 1989; Marchioli et al. 2001).
Furthermore, this effect observed in these trials suggests that the major
mechanism by which n-3 PUFA exerts its effects is by directly acting on the heart,
as opposed to circulating effects of these fatty acids. Indeed, these major clinical
trials in post-myocardial infarction patients found the incidence of new ischaemic
events was not diminished, just the fatalities.

1.2.2 Animal and Cellular studies
The epidemiological studies and clinical trials are supported by a large body of
evidence in animal and cellular studies that attempts to identify the mechanisms
behind the cardioprotective effects. The likely mechanism behind the direct
effects on the heart involves the incorporation of n-3 PUFA into cardiac cell
membrane phospholipids and subsequent effects on cellular function, including
influencing various ion channels and pumps (McLennan 2004). The most
extensively studied cardioprotective effect is the anti-arrhythmic effect (Matthan
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et al. 2005), which has been observed in the rat (Abdukeyum et al. 2008;
McLennan 1993; McLennan et al. 1988; 1989; 1990), pig (Hartog et al. 1987)
marmoset monkey (McLennan et al. 1992b; 1993)and dog (Oskarsson et al.
1993). These dietary supplementation studies suggest a role of membrane
incorporation of n-3 PUFA in altering cellular electrophysiology resulting in a
reduced susceptibility to arrhythmias (McLennan 2004). This idea of membrane
incorporation of n-3 PUFA being behind these effects is further strengthened by
effects observed in hearts, isolated from animals fed fish oil, with no circulating
n-3 PUFA at time of experimentation (Pepe & McLennan 1996).

Many cellular studies have further examined the effects of n-3 PUFA on various
aspects of electrophysiology including membrane ion channels and pumps, in
particular those related to calcium (Ca2+) homeostasis in the heart (McLennan &
Abeywardena 2005). The n-3 PUFA found in fish oil inhibit voltage gated Na+
channels (Leaf & Xiao 2001; Leifert et al. 2000; Leifert et al. 1999; Macleod et
al. 1998; O'Neill 2003; Xiao et al. 1995; Xiao et al. 2005), L-type Ca2+ channels
(Ferrier et al. 2002; Negretti et al. 2000; O'Neill 2003; Pepe et al. 1994; Rodrigo
et al. 1999; Xiao et al. 1997; Xiao et al. 2005), the transient outward and delayed
rectifier potassium currents (responsible for repolarization of the membrane)
(Macleod et al. 1998; O'Neill 2003; Xiao et al. 2005) and sarcoplasmic reticulum
(SR) Ca2+ release (Honen & Saint 2002; Honen et al. 2003; Negretti et al. 2000;
O'Neill et al. 2002; Swan et al. 2003). The Na+-Ca2+ exchanger (Leifert et al.
2001; Philipson & Ward 1985) and SR Ca2+ ATPase (SERCA) (Taffet et al. 1993)
may also be inhibited by n-3 PUFA. Indeed, the antiarrhythmic effects of n-3
PUFA have been attributed to their effects on these ion channels and pumps
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involved in Ca2+ handling (Leaf 2001; Leaf et al. 2005; McLennan 2004;
McLennan & Abeywardena 2005; O'Neill 2003; Xiao et al. 2005). The n-3 PUFA
may also act on cell signalling pathways in the heart. Studies in vascular smooth
muscle cells and cardiac myocytes have found that n-3 PUFA inhibit protein
kinase C (Nair et al. 2001; Nyby et al. 2003). The result of this would be reduced
SERCA inhibition and therefore an increase in SR Ca2+ uptake (Wehrens et al.
2005).

It is important to note that most of these cellular studies focus on acute
administration of EPA and DHA in the experimental medium of cultured
cardiomyocytes. While these studies have provided valuable insight into the
mechanisms of action, they may not be representative of dietary supplementation,
which relies on the incorporation of n-3 PUFA into membrane phospholipids.
Therefore, care must be taken in the interpretation of results, especially since
some of these results have been mimicked by benzyl alcohol or detergents (Leifert
et al. 1999; Xiao et al. 2005), suggesting they might be non-specific effects.
Despite this however, few cellular studies have examined ion channel and pump
function in cardiomyocytes isolated from rats fed fish oil diets (Honen & Saint
2002; Leifert et al. 2001; Leifert et al. 2000; Taffet et al. 1993). These dietary
studies verify the effects of n-3 PUFA observed in the acute studies pertaining to
cellular Ca2+ handling (Honen & Saint 2002; Leifert et al. 2001; Taffet et al.
1993) but not Na+ channels (Leifert et al. 2000). They support a role for
incorporation of n-3 PUFA in influencing electrophysiological properties of the
cell and although still not clarified, they demonstrate some specificity of action.
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1.2.3 Membrane Fatty Acid Incorporation vs. Free Fatty Acids
Under normal circumstances the major n-6 PUFA in animal tissue membranes are
18:2n-6 (LA) and 20:4n-6 (arachidonic acid, AA) while the major n-3 PUFA is
docosahexaenoic acid (DHA) (Hagve & Christophersen 1984). The AA is
incorporated into membranes preferentially over EPA whilst EPA is further
metabolised to DHA, which is abundant in membranes compared to the final
product of n-6 PUFA synthesis, 22:5n-6 (see Figure 1-1) (Tran et al. 2001). The
literature suggests however that when available, for example from fish oil feeding,
n-3 PUFA are preferentially incorporated into cell membranes at the expense of n6 PUFA such as AA and LA. The case for incorporation of n-3 PUFA into cell
membranes is well established as a mechanism for the cardioprotective, especially
anti-arrhythmic, effect of fish oil in both animal and cellular studies with these
changes in membrane fatty acid composition being associated with improvements
in function (McLennan 1993; 2001; McLennan et al. 1993).

There is however debate as to the role of free fatty acids in a fish oil effect. Some
studies have found that n-3 PUFA do not have to be incorporated into myocardial
membranes to exert beneficial effects. When administered intravenously, n-3
PUFA have been shown to protect from fatal arrhythmias in dogs (Billman et al.
1999). The acute administration cellular studies add weight to these results in
terms of a free fatty acid effect on ion channels and pumps (Xiao et al. 2005).
These results are achieved with high infusion concentrations. They also produce
profound heart rate slowing effects on dog heart and even stop isolated
spontaneously beating cells. Both of these extreme effects are not truly
representative of what occurs with dietary fish oil supplementation. Furthermore,
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the antiarrhythmic effects of diet and effects on cardiac function and oxygen
consumption have all been demonstrated in vitro under conditions devoid of
circulating fatty acids (Abdukeyum et al. 2008; Pepe & McLennan 2002; 2007).
This highlights the prospects of dietary induced membrane change contributing to
altered physiology and given the marked changes in membrane composition
observed with dietary fish oil, such as preferential incorporation of n-3 PUFA
over n-6 PUFA when n-3 PUFA are in abundance, it is probable that
incorporation of n-3 PUFA into cardiac cell membranes is a major mechanism of
the cardioprotective role of fish oil. It is however possible that due to their
abundance, n-3 free fatty acids released from the membrane by phospholipase A2
contribute to some of the beneficial effects of n-3 PUFA observed in the heart.

1.2.4. Fish oil and oxidative stress
Despite the well documented numerous benefits of fish oil consumption, the
highly unsaturated chemical structure of n-3 PUFA would suggest that they are
more susceptible to oxidation (Markley 1947). The higher concentrations of these
compounds in cell membranes therefore increases membrane unsaturation, thus
theoretically increasing the susceptibility of the cell to lipid peroxidation and the
associated damage (Javouhey-Donzel et al. 1993). Oxidation-reduction reactions
(redox reactions) are important in normal cell functioning, for example in cell
signalling and inflammation (Gabbita et al. 2000; Sacheck & Blumberg 2001;
Scandalios 2002). Highly reactive intermediates (reactive oxygen species, ROS)
may be formed as a consequence of these reactions. Cells possess defence
mechanisms to cope with these intermediates, namely antioxidants, so that a redox
balance is maintained. Either excessive oxidation or insufficient antioxidant
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defence can disrupt cellular redox balance and the imbalance between pro- and
anti-oxidants has the potential to cause tissue damage and altered physiological
functioning (De Zwart 1999). Of particular interest in regards to n-3 PUFA is
membrane lipid peroxidation or damage to membrane lipids as a result of attack
by ROS.

Membrane lipid peroxidation induced by ROS is a chain reaction event in which
additional reactive species generated by ROS attack subsequently cause further
damage to neighbouring lipids and other molecules (Beckman & Ames 1998).
Isoprostanes and hydroperoxides are both formed by lipid peroxidation with
hydroperoxides, the major product, being rapidly converted to a variety of
products including conjugated dienes, alkanes and aldehydic compounds such as
malondialdehyde (MDA) and 4-hydroxyalkenals (De Zwart 1999).

The literature regarding fish oil and oxidative stress is divided. Many different
biomarkers of oxidative stress have been measured to determine if fish oil is
associated with increased oxidative stress. Results are varied and sometimes
inconsistent, most likely due to differences in tissue type, animal species, the type
of fish oil used, the methods employed to measure these biomarkers and/or
experimental conditions. Despite the discrepancies in the literature, a general
picture of fish oil effects in oxidative stress is emerging.

It is thought that diminished vitamin E levels in various rat tissues with fish
consumption is indicative of increased oxidative stress (Calviello et al. 1997; Cho
& Choi 1994; Javouhey-Donzel et al. 1993; Kaasgaard et al. 1992). Furthermore,
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dietary fish oil has been associated with elevated thiobarbituric acid reactive
substances (TBARS), a measure of the lipid peroxidation product MDA, in
various tissues in rats (liver, plasma, heart and kidney) (Adler et al. 2003;
Calviello et al. 1997; Javouhey-Donzel et al. 1993; Leibovitz et al. 1990; Saito &
Kubo 2002; Song et al. 2000; Song & Miyazawa 2001), mice (liver, kidney, heart
and skeletal muscle) (Gonzalez et al. 1992; Ibrahim et al. 1997; Oarada et al.
2008), monkeys (liver) (Kaasgaard et al. 1992) and rabbits (plasma) (Hsu et al.
2001). Although dietary fish oil is associated with enhanced lipid peroxidation,
there is evidence to suggest that it is less than the theoretical predictions of
unsaturation and peroxidation indices, calculated based on tissue fatty acid profile
(Kubo et al. 1998; Saito 2000; Saito & Kubo 2003).

Despite these elevations in peroxidation associated with fish oil in animals,
numerous benefits of fish oil supplementation are well documented. It has been
suggested that n-3 PUFA from fish oils may have an antioxidant effect, which
may contribute to lipid peroxidation not being observed to the extent predicted
theoretically in animals. (Richard et al. 2008). Another possibility that may
explain the apparent paradox associated with fish oil consumption and its effects
on oxidative stress and tissue function is the phenomenon of preconditioning,
whereby, after a previous mild exposure to a particular stress, a tissue has the
ability to better cope with subsequent exposure to that stressor. The most well
documented example of preconditioning occurs in the heart as ischaemic
preconditioning. In this case, exposure to brief non-lethal ischaemia improves the
heart’s ability to cope with a subsequent larger episode of ischaemia (Hoshida et
al. 1993). In the heart there are two stages of preconditioning, early and delayed.
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In the minutes following the first mild exposure to a stress the tissue is protected
from further insult for about two to three hours. Similarly protection seems to be
evident approximately twelve to twenty four hours following the first exposure
however there is no obvious protection between these early and late phases (Bolli
2000). One possible mechanism of preconditioning is that an increase in ROS
produced during the first stressful stimulus may stimulate the upregulation of
antioxidants that protect the tissue during the late phase of preconditioning.
Studies in the heart have supported this notion (Hoshida et al. 1993; Hoshida et al.
2002; Sun et al. 1996; Zhou et al. 1996), in particular manganese-superoxide
dismutase, usually located in the mitochondria, seems to be the antioxidant
enzyme involved (Hoshida et al. 1993; Hoshida et al. 2002; Zhou et al. 1996).

Similar to ischaemic preconditioning, fish oil may induce nutritional
preconditioning (Abdukeyum et al. 2008) where the oxidative stress associated
with fish oil consumption may stimulate adaptations in antioxidant defence
systems so that tissues are less vulnerable to damage caused by ROS. Indeed, fish
oil feeding results in increased activity (Aguilera et al. 2003; Atalay et al. 2000;
Hsu et al. 2001; Leonardi et al. 2007; Ruiz-Gutierrez et al. 1999; Ruiz-Gutierrez
et al. 2001; Venkatraman et al. 1994; Wang et al. 2004) and expression (Jahangiri
et al. 2006; Venkatraman et al. 1994) of the antioxidant enzymes catalase,
superoxide dismutase and glutathione peroxidase in various tissues and species.
This upregulation of antioxidant defence systems has been suggested as a
potential mechanism for the beneficial effects of fish oil in pathophysiological
conditions where ROS are a major contributor to dysfunction. For example this is
evident in cardiomyocytes with ROS-induced asynchronous contractile activity
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(Jahangiri et al. 2006), in hypercholesterolemic (Hsu et al. 2001) and
spontaneously hypertensive rats (Ruiz-Gutierrez et al. 2001), atherosclerotic mice
(Wang et al. 2004) and rabbits (Aguilera et al. 2003), and in mice with
autoimmune

disorders,

lacking

sufficient

antioxidant

defence

systems

(Venkatraman et al. 1994). Although probably not the only explanation, it is
likely that nutritional preconditioning contributes to the apparent paradox
associated with fish oil consumption and its contradictory effects on oxidation,
oxidative stress and tissue function. Indeed, ROS may provide the link between n3 PUFA and altered Ca2+ handling (Jahangiri et al. 2006).

The literature in humans is also inconsistent. While there is some evidence for
increased peroxidation in humans supplemented with fish oil (Grundt et al. 2003;
Hansen et al. 1998; Palozza et al. 1996; Wander et al. 1996), many clinical
studies report only little or no increase in peroxidation associated with increased
n-3 PUFA consumption (Bonanome et al. 1996; Calviello et al. 1997; Eritsland et
al. 1995; Frankel et al. 1994; Hansen et al. 1998; Higdon et al. 2000; Nenseter et
al. 1992; Nordoy et al. 1998; Palozza et al. 1996), suggesting that the theoretical
concern of elevated oxidation with increased fish oil consumption may not be a
large issue in reality. There are however some factors in humans that may
contribute to the observed lack of oxidative stress in human studies after increased
n-3 PUFA intake. These must be considered before dismissing any effect of n-3
PUFA

on

oxidative

stress.

The

aforementioned

potential

nutritional

preconditioning effect may be involved, whereby initial increases in peroxidation
stimulate the upregulation of antioxidant systems to cope with any further
increased peroxidation associated with n-3 PUFA intake. The study by (Hansen et
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al. 1998) supports this idea. Chylomicrons isolated in the hours immediately
following a DHA or EPA supplemented meal showed increased peroxidation,
however there was no evidence of heightened peroxidation after 5 weeks of
supplementation (Hansen et al. 1998). Furthermore, many clinical studies
administer fish oil/n-3 PUFA with vitamin E, an antioxidant, to prevent any
increased oxidation (Bonanome et al. 1996; Eritsland et al. 1995; Grundt et al.
2003; Hansen et al. 1998; Higdon et al. 2000)(REF). This may mask any effect of
n-3 PUFA on oxidation. Inconsistencies in the literature may also be due to the
different study designs, intakes of n-3 PUFA and measurements of different
biomarkers of oxidative stress (Palozza et al. 1996).

To date, very little has been done to examine the effects of fish oil in skeletal
muscle with no information pertaining to oxidative stress. Exercise however has
similar paradoxical effects, with an acute bout of exercise increasing oxidation but
exercise training reducing this effect (Sen 1995). This suggests a possible fish oil
effect in skeletal muscle, which will be explored later in this thesis.

1.3. Linking animal studies to human epidemiology studies
The challenge in explaining the effects of fish oil in terms of physiological
changes and mechanisms of action lies in translating the animal and cellular work
to humans. It is well established in humans that dietary fish oil exerts numerous
beneficial effects, especially in the cardiovascular system (Mozaffarian & Rimm
2006). Animal dietary and cellular studies have attempted to elucidate the
mechanisms by which n-3 PUFA exert their effects however these studies have
historically used high doses of fish oil in the range of 5-12% of the diet (Matthan
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et al. 2005). Rat diets that are equivalent to what can be achieved in the human
diet via fish consumption or dietary fish oil supplementation range from 0.161.25% with 1.25% being at the high end of human intake (Table 1-1).

Rat diet
Fish oil
% weight

*
‡

Table 1-1 How much is that for humans?
Rat diet
Rat diet
Human*
Human†
EPA+DHA
EPA+DHA
EPA+DHA
serve (100g)
mg/100g
% energy
per day (g)
salmon/wk

Human‡
Fish oil
caps/day

5.0

1791

3.91

9.1

33

28

1.25

448

0.98

2.3

8

6.8

0.63

226

0.49

1.2

4

3.5

0.31

111

0.24

0.57

2

1.7

0.16

57

0.13

0.28

1

<1

†

Based on human energy intake of 8700 kJ per day, Based on salmon n-3 content of 1.9g/100g,
Based on typical fish oil capsule content of 330mg EPA+DHA. Adapted from (Slee et al. 2010).

A concentration of 0.16% fish oil is the lowest that has been experimentally
studied. This low concentration was found to still markedly affect cardiac
membrane composition (Figure 1-2), however it has been predicted that just
0.0027% is the threshold, with any increase above this being sufficient to increase
incorporation of DHA into myocardial membranes (Slee et al. 2010). Being well
above the range of human intake, the question remains, can the greater body of
results of animal and cellular studies be applied to human observations of
physiological effects of fish oil?
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Figure 1-2 Effect of dietary fish oil on DHA content in the rat heart.
EPA+DHA is expressed as % energy. Arrows indicate the doses used in the present
study. Adapted from (Slee et al. 2010).

There is very little animal data on the role of doses of fish oil that are equivalent
to that readily obtainable in the human diet. However, the results of those studies
are similar to that observed at higher doses. Doses of 1.25% fish oil or 0.5%
purified DHA prevent ischaemia-induced ventricular fibrillation as effectively as
higher doses (McLennan et al. 1996; McLennan et al. 2007). Furthermore, the
arrhythmias were similarly prevented and myocardial O2 consumption dose
dependently reduced at doses of 3, 6 and 12% fish oil (Pepe & McLennan 2007).
Cardiac remodelling and dysfunction induced by pressure overload was prevented
by doses equivalent to human intake of 1.6, 5.1 and 15.5g.d-1 EPA+DHA (Duda et
al. 2009).

The limited evidence so far suggests that only small amounts of dietary fish oil,
within the human intake range, are required to produce physiological effects
previously observed with higher doses. The physiological effects seen at these
lower doses are supported by the significant changes in membrane fatty acid
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composition that also occur with low doses dietary fish oil in the rat (Slee et al.
2010). Further increases in dietary fish oil (above 1.25%) do not result in parallel
increases in membrane DHA, suggesting a saturation point and a potential
explanation for the similarities in physiological effects seen at both low and high
doses of dietary fish oil (Figure 1-2). It is interesting to note that human
epidemiological studies often report little increase in cardioprotective effects as
intake is increased above 1-2 fish meals per week (Albert et al. 1998; Harris et al.
2009; Hu et al. 2002; Hu et al. 2003; Kris-Etherton et al. 2002; Kromhout et al.
1985; Mozaffarian & Rimm 2006).

1.4 Fish oil and skeletal muscle function and fatigue
1.4.1 Cardiac vs. Skeletal Muscle Type
It is well established that fish oil affects cardiac membrane composition and
favourably affects function (McLennan et al. 2007). Similar to cardiac muscle,
skeletal muscle is an excitable tissue that exhibits common physiological
properties. It is well established that the membrane composition of excitable
tissues, including cardiac and skeletal muscle is similar, compared to other nonexcitable tissues (Ando et al. 2000; Charnock et al. 1989; Nikolaidis et al. 2006).
This is likely related to the similarities in excitation-contraction (E-C) coupling.
Figure 1-3 illustrates E-C coupling in both cardiac and skeletal muscle. Although
the activation of an action potential is different, directly from an adjacent cell in
the heart and via the neurotransmitter Acetylcholine in skeletal muscle, the
process of the action potential triggering the release of Ca2+ from the sarcoplasmic
reticulum, and subsequent contraction is quite similar (Berchtold et al. 2000;
Wasserstrom 1997; Wasserstrom & Eick 1991). In the heart, this process is called
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Figure 1-3 Excitation Contraction Coupling in Cardiac Muscle (a) and Skeletal
muscle (b).
LTCC: L-type Calcium Channel, CICR: Calcium–Induced-Calcium-Release, NCX:
Sodium-Calcium exchanger, RyR: Ryanodine Receptor (sarcoplasmic reticulum calcium
release channel), SERCA: Sarcoplasmic Reticulum Calcium ATPase pump,
Na+K+ATPase: Sodium-Potassium ATPase pump. Modified from (Barry & Bridge 1993;
Silverthorn 2001)
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calcium-induced–calcium-release, whereby Ca2+ entering the cell from the
activation of L-type Ca2+ receptors triggers the release of Ca2+ from the
sarcoplasmic reticulum (Barry & Bridge 1993; Wasserstrom & Eick 1991). In
skeletal muscle, the sarcoplasmic reticulum Ca2+ release is triggered by the action
potential activation of the DHP-receptor on the cell membrane (Berchtold et al.
2000). The relaxation process is also similar, with Ca2+ being pumped back into
the sarcoplasmic reticulum via the sarcoplasmic reticulum Ca2+ATPase (Barry &
Bridge 1993; Berchtold et al. 2000). In the heart, relaxation is also assisted by
removal of Ca2+ from the cell via the sodium-calcium exchanger (Barry & Bridge
1993). Despite the differences, there is evidence to suggest that E-C coupling,
especially related to Ca2+ cycling in cardiac and skeletal muscle, is more similar
than originally thought (Wasserstrom 1997).

1.4.1.a Muscle Fibre Types
Although it is established that cardiac and skeletal muscle have similarities, all
skeletal muscle is not the same. Skeletal muscle is classified into 3 types, based on
different properties of the muscle fibre in relation to the rate of contraction,
metabolism and fatigue resistance. These are outlined in Table 1-2. Slow twitch
oxidative fibres (type I) exhibit slower rates of contraction, predominately
oxidative metabolism and resistance to fatigue. Fast twitch fibres, characterised by
fast rates of contraction, are further classified into fast twitch oxidative (type IIa)
or fast twitch glycolytic (type IIb). Fast twitch glycolytic exhibit predominately
glycolytic metabolism and are the most fatigable. Fast titch oxidative exhibit
properties in between the slow oxidative and fast glycolytic fibres. The most
similar to the heart is the slow twitch oxidative fatigue resistant fibres (Silverthorn
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2001). The muscle group used in the present study is the gastrocnemius-soleusplantaris. It was chosen, based on earlier models, for its ease of isolation and
because it represents a muscle bundle containing all muscle types, type I in the
soleus and mixed in the plantaris and gastrocnemius (Delp & Duan 1996).

Table 1-2 Muscle Fibre Types
Type I

Type IIa

Type IIb

Characteristic
Rate of contraction

Slow

Fast

Fast

Metabolism

Oxidative

Oxidative

Glycolytic

Fatigue Resistance

High

Intermediate

Low

Colour

Red

Red

White

Adapted from (Silverthorn 2001)

1.4.2 A role for FO in skeletal muscle?
Little is known regarding the effects of FO on skeletal muscle however given the
similarities in skeletal muscle and cardiac membrane fatty acid composition, as
well as excitation-contraction (E-C) coupling physiology, a significant role for n-3
PUFA in skeletal muscle is highly plausible. Furthermore, there is literature to
support this notion, although limited and drawing from studies focusing on a wide
range of topic areas. Early work in isolated muscle has established a role of
essential FA (both n-6 PUFA and n-3 PUFA) in maintaining muscle function,
showing that muscle from animals fed an essential fatty acid deficient diet
performed poorly compared to those from diets high in n-6 PUFA or n-3 PUFA
supplementation (Ayre & Hulbert 1996b). While no differences between n-3
PUFA and n-6 PUFA muscle performance were observed in that study (Ayre &
Hulbert 1996b), others have shown significant effects of fish oil supplementation
on whole body O2 consumption during exercise in healthy humans (Peoples et al.
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2008) and on exercise performance in those with impairment caused by chronic
obstructive pulmonary disease (Broekhuizen et al. 2005) or paraplegia (Javierre et
al. 2006). Furthermore, n-3 PUFA are incorporated into skeletal muscle
membranes, resulting in improved muscle function, fatigue resistance and reduced
O2 consumption in rats (Peoples 2004; Peoples & McLennan 2010). The reason
behind the contrasting lack of effect of n-3 PUFA vs. n-6 PUFA in the earlier
study may be due to the fact that the n-3 PUFA diet was high in EPA.
Incorporation of EPA in muscle membranes is very small in comparison to DHA
and as such EPA is not likely to contribute significantly to the improved
performance observed with fish oil supplementation. Furthermore, in the heart,
purified EPA has been shown to be ineffective at replicating the beneficial
antiarrhythmic and negative chronotropic effects observed with purified DHA
(McLennan et al. 1996; Rousseau-Ralliard et al. 2009).

These preliminary studies suggest a role for fish oil in skeletal muscle function
and fatigue. In both cardiac and skeletal muscle, the n-3 PUFA are incorporated
into cell membranes (Andersson et al. 2002; Ayre & Hulbert 1996a; b; McLennan
1993; McLennan et al. 1993), improve contractile function (Peoples 2004) and
reduce O2 consumption (Peoples 2004; Pepe & McLennan 2002). Although the
physiology is slightly different as the heart is fatigue resistant, the similarities
observed indicate a potential role of fish oil in muscle function and fatigue
resistance. To further investigate the potential role of fish oil in skeletal muscle, it
is important to consider the processes involved in skeletal muscle fatigue.
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1.4.3. Skeletal muscle fatigue
Muscle fatigue is defined as any reduction in the ability of a muscle to generate
force, resulting in the progressive decline in performance from the onset of
activity (Allen et al. 2008b; Gandevia 2001). The conscious process of muscle
activation and contraction begins centrally in the cortex and extends through the
spinal cord to the neuromuscular junction and into the muscle cell (Gandevia
2001). Fatigue can potentially occur at any point along this pathway. That which
occurs in the spinal cord and above is classed as central fatigue. Fatigue arising
from alterations at the neuromuscular junction and beyond, within the muscle cell,
is defined as peripheral fatigue (Allen et al. 2008b; Gandevia 2001).

Figure 1-4 Flow chart identifying the process of muscle activation and potential sites
of fatigue. Adapted from (Gandevia 2001).
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There are theories pertaining to both central and peripheral causes of fatigue but
controversy exists surrounding the relative role of each in the fatigue process.
This debate surrounding central vs. peripheral fatigue is not new, having been
around for over 100 years (Fitts 1994). A resurgence of the ‘central fatigue
theory’ has emerged in recent years with the concept of the ‘central governor
model’ being used to explain fatigue in general. This model ‘proposes that
exercise performance is regulated by the central nervous system, specifically to
ensure that catastrophic physiological failure does not occur during normal
exercise in humans’ (Noakes et al. 2004). While there is evidence to support
alterations in central processes during exercise in terms of reduced motor neuronal
drive, motor neuron firing rate and muscle fibre activation (Ament & Verkerke
2009; Gandevia 2001), these central theories do not explain fatigue in all
situations (Weir et al. 2006). Therefore, while the debate continues, it is becoming
more accepted that most fatigue occurs peripherally within the muscle cell itself
(Allen et al. 2008b; Bigland-Ritchie & Woods 1984; Fitts 1994). Peripheral
fatigue is targeted in the current study where central input and output are excluded
through direct stimulation of motor neurons to elicit muscle contraction.

Two different types of peripheral fatigue have been identified, based on the
stimulation frequency and characterised by recovery of force. High frequency
fatigue is associated with high frequency stimulation (>50Hz) and is rapidly
reversible (Jones 1996). It is generally not representative of the situation in
humans where lower frequencies are involved in most daily activities. Therefore it
is not of interest in the current study. Fatigue from low-frequency stimulation, low
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frequency fatigue, is characterised by slow recovery (Jones 1996; Keeton &
Binder-Macleod 2006). Unless otherwise stated, this thesis will focus on fatigue
induced by low frequency stimulation.

1.4.4. Contributors to fatigue within the muscle cell.
There are a number of changes that occur within the muscle cell during exercise
or prolonged stimulation that may play a role in fatigue. The major contributors
include: metabolic alterations; changes in Ca2+ cycling; and the production of
ROS (Allen et al. 2008b). There are other changes that occur, such as extracellular
K+ accumulation and reduced excitability (McKenna et al. 2008), however they
are thought to be involved more in high frequency fatigue and not significantly
contribute to low frequency fatigue (Allen et al. 2008b; Jones 1996). It is
important to note that these processes and alterations are not mutually exclusive
and each alteration may affect another aspect of the fatigue process.

1.4.4.a Metabolic alterations
Any activity resulting in fatigue may be associated with changes in the
concentrations of various metabolites, including accumulation of metabolic
breakdown products such as lactate and H+ and a reduction of high energy
compounds (PCr and ATP). The degree of change varies with the intensity, type
and duration of activity, muscle fibre type and O2 supply, however some degree of
change can generally be observed, especially in high-intensity activity and fasttwitch muscles where metabolic changes are more marked (Allen et al. 2008b).
These metabolic alterations are not likely to play a large role in the present study,
which will focus on low intensity activity.
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Historically, early theories suggested accumulation of lactate to be the major
cause of fatigue due to the close relationship between lactate and reduced force
production (Allen et al. 2008b; Fitts 1994). Further study, however, has revealed
that it is the increase of H+ (and associated decrease in pH) associated with lactic
acid production that has greater effects on muscle force production than does
lactate itself (Fitts 1994), resulting in a reduction in SR Ca2+ release, a reduction
in Ca2+ sensitivity, specifically preventing Ca2+ from binding to troponin and a
reduction in cross-bridge force (Allen et al. 2008b; Fitts 2008). Furthermore,
increased H+ inhibits resynthesis of PCr and subsequent ATP production (Fitts
1994). Although it is well established that lactate and H+ accumulate significantly
during intense activity and have various effects within the muscle cell, there is
debate regarding the causal role of these changes in fatigue (Allen et al. 2008b;
Fitts 1994). Further research is required to establish the exact role (if any) of
lactate and H+ in fatigue but one thing that is agreed upon is that original theories
suggesting lactate is the major cause of fatigue have been proven to be incorrect.

Altered concentrations of high energy compounds during activity have also been
implicated in the fatigue process, especially during high-intensity exercise and
more specifically in fast-twitch muscle fibres, where [ATP] and [PCr] are
relatively higher compared to slow-twitch fibres (Fitts 1994). At the onset of
prolonged activity, ATP consumption (ATP + H2O Æ ADP + Pi + H+ + energy)
stimulates the creatine kinase catalysed reaction PCr + ADP + H+ Æ Cr + ATP
such that PCr is depleted and Cr is elevated. This reaction initially balances the
ATP pool within the muscle, as ATP is not depleted in the early stages of activity
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(Fitts 1994). During continued activity, ATP consumption may exceed
resynthesis, resulting in a decrease in [ATP] and accumulation of inorganic
phosphate (Pi) (Allen et al. 2008b). These changes can have detrimental effects on
muscle function. Reduced [PCr] is associated with decreased SERCA activity and
enhanced pump leakage (Allen et al. 2008b). The reduction in ATP may affect the
functioning of ATP-dependent processes such as cross-bridge force production,
Ca2+ cycling (both SERCA and SR Ca2+ release) and maintenance of membrane
potential via the Na+K+ pump (Fitts 1994). Increased Pi reduces force production
via interaction with cross-bridge function, reduces Ca2+ sensitivity and SR Ca2+
release and reuptake (Allen et al. 2008b; Westerblad & Allen 2002).

1.4.4.b Reactive Oxygen Species
Oxidation-reduction reactions (redox reactions) and their intermediates are
important for normal cell functioning, including metabolism, cell signalling and
inflammation (Gabbita et al. 2000; Sacheck & Blumberg 2001; Scandalios 2002).
The highly reactive intermediates produced from these reactions, such as ROS,
are potentially damaging at high concentrations, however cells possess defence
mechanisms (antioxidants) to cope with these intermediates so that a redox
balance is maintained. Either excessive oxidation or insufficient antioxidant
defence can disrupt cellular redox balance and lead to oxidative stress and tissue
damage. Lipids, proteins and nucleic acids are all susceptible to attack by ROS
and the effects can be devastating (De Zwart 1999).

In skeletal muscle, ROS are produced in small quantities under basal conditions.
A role for ROS in skeletal muscle function was first proposed in the early 1990’s
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(Reid et al. 1993). The theory describes the effect of ROS on force production as
biphasic. In normal muscle, a reduction in ROS from basal conditions results in
reduced force production, indicating that some level of ROS is required for
normal contractile function. Furthermore, a slight increase in ROS above basal
levels increases force production, indicating an optimal cellular redox state for
optimal force production. However, further increases in ROS to excessive levels
decreases skeletal muscle force production (Reid 2001; Reid et al. 1993).

Muscle activity increases O2 consumption and subsequently increases production
of ROS. Furthermore, increases in temperature, CO2 and [H+], all associated with
prolonged activity, also enhance the production of ROS (Ferreira & Reid 2008).
As described previously, while small increases may actually improve contractile
function to an optimal level, further increases in cellular ROS can be detrimental.
It is this excessive ROS production associated with prolonged muscle activity that
is thought to significantly contribute to the fatigue process (Reid 2001). The exact
sources of ROS production and the mechanisms by which ROS contribute to
fatigue are not well known, however extensive research in the past 15-20 years is
significantly contributing to the current knowledge on the role of ROS in fatigue
(Ferreira & Reid 2008). There are numerous sites within the cell that may be
detrimentally targeted by ROS during prolonged exercise however it seems that
changes in Ca2+ handling (involving the ryanodine receptor and SERCA) or a
change in myofibrillar Ca2+ sensitivity are the predominant effects of ROS
implicated in contractile dysfunction and fatigue (Allen et al. 2008b; Powers &
Jackson 2008).
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1.4.4.c Ca2+ cycling alterations
The Ca2+ ion plays an integral role in many facets of skeletal muscle function
(Berchtold et al. 2000), especially regarding muscle contraction. Therefore, an
alteration in any aspect of cellular Ca2+ handling has the potential to affect muscle
performance. Indeed, alterations in Ca2+ cycling within the cell have been
implicated in the muscle fatigue process. As mentioned previously in 1.4.2.a,
various metabolic changes within the cell during activity contribute to fatigue by
interacting with aspects of Ca2+ cycling. Similarly, excessive ROS can also
interfere with cellular Ca2+ handling (Allen et al. 2008b; Powers & Jackson 2008).
Furthermore, reductions in the intracellular Ca2+ transient, SR Ca2+ release, SR
Ca2+ content, myofilament Ca2+ sensitivity, SERCA activity as well as impaired
coupling between t-tubule depolarisation and SR Ca2+ release all occur in
stimulated muscle (Allen et al. 2008a; b; Fitts 1994). These effects are dependent
on the type and duration of the stimulation protocol with changes being more
obvious in low frequency fatigue as opposed to high frequency fatigue. Despite
these differences between protocols however, there is a general consensus that
alterations in cellular Ca2+ cycling are related to disturbed muscle performance
and fatigue (Allen et al. 2008a; b; Fitts 1994; Westerblad & Allen 2002).

1.4.5. Potential mechanisms of fish oil action in skeletal muscle.
Given that the major contributors to fatigue, may be Ca2+ cycling and excessive
ROS generation and fish oil is associated with affecting various aspects of Ca2+
handling and redox balance in the heart, there is a very distinct possibility that it
will affect these mechanisms in skeletal muscle.
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1.4.5.a. Membrane incorporation
Similar to other excitable tissues, such as heart, brain and retina, n-3 PUFA are
present in skeletal muscle membranes in relatively high proportions, with slow
twitch muscles generally having slightly higher levels than fast twitch muscles
(Kriketos et al. 1995; Peoples 2004). Moreover, when supplied in the diet DHA is
preferentially incorporated over EPA into excitable tissues, including skeletal
muscle membranes, regardless of whether the major n-3 PUFA supplied in the
diet is EPA (Ayre & Hulbert 1996a) or DHA (Peoples 2004) in rats or marmoset
monkeys (Charnock et al. 1992). In humans, a similar relationship between
dietary n-3 PUFA supplementation and skeletal muscle membrane composition is
also evident (Andersson et al. 2002). Furthermore, a comparative study has
revealed a much higher DHA content in high frequency contraction muscles of the
hummingbird and rattlesnake (Infante et al. 2001). Combined, this signifies a role
of n-3 PUFA, especially DHA as a potentially important regulator of membrane
function in skeletal muscle.

1.4.5.b. Ca2+ homeostasis
One mechanism suggested to contribute to the beneficial effects of fish oil in the
heart is the alteration of cellular Ca2+ handling, as n-3 PUFA affect many aspects
of Ca2+ homeostasis (Leaf et al. 2005; McLennan & Abeywardena 2005; Xiao et
al. 2005). In skeletal muscle, n-3 PUFA effects on aspects of Ca2+ handling have
been observed in pigs (Nurnberg et al. 1998) and mice (Dulloo et al. 1994).
Although the effects of fish oil on skeletal muscle function and physiology have
not been extensively studied, the similarities in cardiac and skeletal muscle in
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regards to Ca2+ homeostasis allow us to suspect a similar role of fish oil in
improving skeletal muscle function.

1.4.5.c. Reactive oxygen species
Oxidation is another aspect of the fish oil story that is of interest in the study of
muscle fatigue. As mentioned previously, fish oil is implicated in altering cellular
redox balance. Elevated peroxidation due to high unsaturation of n-3 PUFA likely
stimulates the gradual upregulation of antioxidant enzymes (Saito 2000) resulting
in an improved ability to cope with subsequent increases in oxidative stress.

Preconditioning is a phenomenon observed in the heart whereby brief exposure to
a stressor improves the tissues ability to cope with subsequent stressors. ROS is
likely the mechanisms behind this effect. The idea of a preconditioning effect of
fish oil is relevant in the present study, as ROS significantly contributes to muscle
fatigue. Such an effect would enhance the muscle’s ability to deal with exerciseinduced oxidative stress and potentially improve function during contraction
protocols. Further support of a potential preconditioning effect of fish oil in
skeletal muscle comes in the form of exercise training. Exercise training induces
both early and late preconditioning in the hearts of dogs (Domenech et al. 2002;
Hamilton et al. 2001). Exercise training is also a well-documented example of
preconditioning in skeletal muscle. An increase in ROS production during an
acute bout of exercise stimulates the upregulation of antioxidants to increase the
tissue’s ability to cope with the oxidative stress associated with another, later bout
of exercise (Sen 1995). Moreover, chronic antioxidant supplementation may
actually hamper the health promotion effects of exercise by preventing the normal
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upregulation of antioxidant enzymes (Ristow et al. 2009). Removal of
supplementation would subsequently result in reduced performance, as the body
has not prepared its natural capacity to deal with acute exercise-induced oxidative
stress.

1.5. Aims and Hypotheses.
The main aim of the present study was to investigate the effects of human
equivalent doses of fish oil on skeletal muscle and cardiac function. More
specifically, this study aimed to determine:
a) the incorporation of n-3 PUFA into both skeletal and cardiac muscle
membranes, from small concentrations in the diet.
b) the effect of n-3 PUFA incorporation on skeletal muscle function and
fatigue under normal conditions and in the context of claudication and
heart failure.
c) if ROS and/or Ca2+ handling are involved in the FO effect on skeletal
muscle
d) the effect of fish oil on the development of cardiac hypertrophy induced by
abdominal aortic banding.

Based on the literature reviewed, it was hypothesised that these human equivalent
doses of fish oil will:
a) Result in significant incorporation of n-3 PUFA, in exchange for n-6
PUFA, increasing membrane unsaturation
b) Improve muscle function and promote resistance to fatigue under normal
conditions,
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c) Improve muscle function in the context of claudication (reduced perfusion
during muscle activity) and heart failure
d) Modify cardiac remodelling in the process of pressure overload induced
cardiac hypertrophy
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Chapter 2 GENERAL METHODS
This chapter covers all aspects of the methods that are common to the following
chapters of the thesis. Firstly, information will be introduced regarding the
animals used in this study. This will be followed by a description of the
experimental diets that underpin the entire thesis. Thirdly, the rat in vivo perfused
hindlimb is described as the experimental set-up chosen to study muscle function
and fatigue in the different physiological and pathophysiological models in this
study.
.
2.1. Animals
Adult male Sprague Dawley rats were obtained from Animal Resource Centre
(Western Australia). 144 animals were used across all studies within this thesis.
The number and age of animals used in each experiment will be outlined in each
following chapter. Animals were housed two per cage at 20±1ºC on a 12 hour
light-dark cycle in the University of Wollongong’s Animal facility. Experiments
were approved by the University of Wollongong Animal Care and Ethics
committee and were conducted according to the Australian Code of Practice for
the Care and Use of Animals for Scientific Purposes (NHMRC, 2004).

2.2 Diets
The general make up of the diets used throughout this study will be described in this
section. Specific dietary treatment protocols will be outlined in each following
chapter. Animals were assigned to one of three prefabricated diets, differing only in
their fatty acid composition. All diets were made by the candidate in the laboratory.
The diets were based on those previously developed for use in similar animal
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feeding studies (Abdukeyum et al. 2008; Slee et al. 2010). They contained a
balanced mix of macro and micronutrients to avoid any nutritional deficiencies. The
diets consisted of (as a percentage of dry weight) 56.5% cornstarch, 10% sucrose,
9% casein, 5% fibre, 10% oil, 1% vitamin mix and 3.5% mineral mix. Two
sources of fat were used in this study. Olive oil was provided as extra light olive
oil, being largely devoid of the antioxidant polyphenols found in less refined oils.
Olive oil consisted principally of oleic acid (75%) and provided a minimum
concentration of linoleic acid to prevent essential fatty acid deficiency. The fish
oil used in the diets was HiDHA tuna fish oil. It contained 29% DHA and 7%
EPA with the other major fatty acids being 16:0 (20%) and 18:1 (75%) Two doses
of fish oil were selected based upon previous work showing that the heart
responds to doses of fish oil that are within the human intake range (Table 1-1)
(McLennan et al. 2007; Slee et al. 2010). Calculations are based on human energy
intake of 8700kJ per day. The equivalent rat energy intake is approximately
325kJ/day, based on a 300g rat eating approximately 20g/day prefabricated food.
The LowFO dose (0.31%) was chosen as the dose at which DHA concentration in
the heart is doubled and the ModFO dose (1.25%) was chosen as the lowest dose
that has so far been examined physiologically and it is shown to be
cardioprotective. The ModFO dose has also been found to produce changes in n-3
PUFA concentration that are near the asymptote of the dose-response curve
(Figure 1-2) for n-3 PUFA incorporation in cardiac (McLennan 2001; Slee et al.
2010) and skeletal muscle (Owen et al. 2004). Both The fat sources and
concentrations of the control olive oil (OO), low fish oil (LowFO) and moderate
fish oil (ModFO) diets are illustrated in Table 2-1. The fatty acid profile of these
diets has been previously determined in our laboratory (Table 2-1).
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Table 2-1: Proportion of different oils and fatty acids that make up the 10% fat
component of all diets.
Fat
source
and OO
LowFO
ModFO
concentration
(10%)
(0.31%)
(1.25%)
100%
96.9%
87.5%
Olive Oil*
0%
3.1%
12.5%
Fish Oil^
Fatty Acid Profile
14:0
16:0
18:0
18:1
18:2n-6
18:3n-3
20:4n-6
20:5n-3
22:5n-6
22:5n-3
22:6n-3

ND
10.42
2.82
75.79
8.32
0.52
0.12
ND
ND
ND
ND

0.09
10.72
2.9
73.9
8.11
0.52
0.17
0.22
ND
0.03
0.9

0.38
11.61
3.12
68.24
7.46
0.53
0.33
0.87
ND
0.14
3.61

*Bertoli extra light Olive Oil. ^HiDHA®25N Tuna Fish Oil. ND=not detected

Casein was sourced from NZ Milk products Ltd., New Zealand. Vitamin mix
(AIN-93-VX) and mineral mix (AIN-93-MX) were obtained from MP
Biomedicals Inc., Australia. The fish oil (HiDHA®25N Tuna Fish Oil) was
kindly donated by Nu-Mega Ingredients Pty Ltd, Australia. All other ingredients
were commercially available. Rats were fed ad libitum and had free access to
water. They were maintained on these diets for a minimum of 4 weeks prior to
experimentation.
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2.3 Auto-perfused hindlimb set-up
Skeletal muscle function and fatigue has been examined across a range of animal
models with the in vitro isolated muscle preparations and in situ hindlimb models
the most common (Bonen et al. 1994). While each method has its purpose and has
significantly contributed to the understanding of muscle function and metabolism,
there are limitations that make them unsuitable for use in the current study. A
major concern of in vitro isolated muscle preparations is poor oxygenation. These
models rely on simple diffusion of O2 into the muscle from the incubation
medium, a process which is limited by the thickness of the muscle (Bonen et al.
1994). Deeper parts of the muscle may not be receiving adequate oxygenation,
which could influence contractile function. Indeed, limited O2 diffusion in the
mouse soleus accelerates the development of fatigue (Zhang et al. 2006). At times
these limitations are compensated by conducting experiments below normal body
temperature to moderate O2 demand.

The in situ perfused hindlimb model, first described by (Ruderman et al. 1971)
uses the animal’s own vascular network to perfuse the hindlimb with an
experimental perfusate. The benefits of this model are that normal muscle, bone
and nerve relationships are maintained, muscles are adequately oxygenated and
the perfusate can be tightly controlled. This model however is associated with
supraphysiological flow rates that are required to maintain normal perfusion
pressure and also unphysiological metabolic responses associated with the type of
perfusion system that may be used, recirculation or one-pass (Bonen et al. 1994).
.
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The main goal of the present study into the effects of long-term dietary
intervention on muscle function and fatigue is to maintain, as closely as possible,
normal physiological conditions, in vivo. For this reason in vitro and in situ
models were deemed unsuitable. Widely used in the study of O2 dynamics
associated with muscle contraction, the canine auto-perfused hindlimb model
more closely resembles near in vivo conditions while still maintaining some
experimental control of parameters such as blood flow (Hogan et al. 1992; Hogan
et al. 1998; Hogan et al. 1999a; Hogan et al. 1996; Hogan et al. 1994; Hogan &
Welch 1986). This model involves controlled perfusion of the hindlimb with the
animal’s own blood.

This canine model has been adapted in our laboratory for use in anaesthetised rats
(Hoy et al. 2009; Peoples 2004). As with the canine model, this model has
advantages over other models used to assess skeletal muscle function in that it
maintains sufficient oxygenation by using the animal’s own blood and vascular
network to perfuse the hindlimb at physiological flow rates. This allows us to
assess the effect of fish oil on contractile function in relation to O2 consumption
and vascular function.

2.3.1 Anaesthesia and Animal Preparation
Rats (16-25 weeks old) were initially anaesthetised (Pentobarbitone Sodium,
60mg/kg i.p.) and maintained throughout the procedure with supplementary
injections (20mg/kg i.p.) as necessary. All preparation and experimentation was
carried out in a heated perspex chamber maintained at 31±1ºC. Rat body
temperature was maintained at 37ºC with the additional aid of a heat lamp placed
over the animal’s body.
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2.3.2 Surgical Preparation
Animals were shaved across the anterior neck, abdomen and both hindlimbs.
Figure 2-1 represents a diagrammatic view of the set up for the entire procedure
including ventilation, blood pressure monitoring, nerve and muscle isolation and
stimulation and blood flow.

2.3.2.a Ventilation
An incision was made down the midline of the animal’s neck on the underside.
The trachea was intubated (polyethylene tubing, Internal Diameter 0.20mm,
External Diameter 0.30mm) to allow for artificial ventilation (Rodent Ventilator
7025, Ugo Basile, Italy) for maintenance of constantly high arterial O2
concentration. Rats were ventilated in vivo at a rate of 60 breaths per minute, with
tidal volume based on the animal’s body weight (1mL/200g).

2.3.2.b Systemic Pressure
The left internal carotid artery was cannulated towards the heart through the same
incision made for the tracheotomy. A pressure transducer (Argon CDXIII, Maxim
Medical, USA) was attached to the carotid artery cannula for direct monitoring of
systemic blood pressure.

2.3.2.c Nerve and muscle isolation
With the rat on its right side, an incision was made just below the iliac crest and
gluteal muscles separated to expose the sciatic nerve. An electrode (Grass
Instrument Division, USA) was placed under the nerve and secured for electrical
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stimulation of the nerves supplying the gastrocnemius-soleus-plantaris (GSP)
muscle bundle. Any retrograde signals were prevented by crushing the nerve
proximal to the stimulator electrode.

Figure 2-1 Autologous Hindlimb Perfusion set-up
Arrows indicate direction of blood flow.
1.
Peristaltic perfusion pump
2.
Pressure transducer
3.
Femoral artery, Control (right)
4.
Femoral artery, Perfused (left)
5.
Carotid artery
6.
Jugular vein
7.
Femoral vein, Perfused (left)
8.
Rodent ventilator
9.
Stimulator (attached to sciatic nerve)
10.
Force transducer (attached to GSP muscle bundle)
11.
Windkessel pressure dampener
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The animal was turned on its back following nerve isolation and its perfused leg
was securely attached at the knee and foot to a platform in the chamber. The GSP
tendon was exposed at the ankle and tied to a force transducer (FT03C, Grass
Instrument Division, USA) with non-stretch silk (DYNEK, Australia) in-line with
the direction of muscle contraction.

2.3.2.d Blood flow
A perfusion system was set up to supply the hindlimb muscles with a controllable
and adjustable rate of oxygenated blood flow via a peristaltic pump (Gilson,
minipuls3) (Figure 2-1). All cannulae (Dural Plastics Internal Diameter 0.58mm
External Diameter 0.96mm) were flushed and filled with a saline solution
containing dextran (6% w/v) and heparin (5000IU per 100mL) prior to
cannulations. The total volume of the system was approximately 3-4mL.

For the arterial side of the system, an incision was made in the crease of both legs
and adipose tissue was cleared to expose the femoral vessels. The right femoral
artery was cannulated towards the heart to obtain access to oxygenated blood. The
left femoral artery was cannulated away from the heart (towards the leg) to supply
the perfused leg with oxygenated blood at a controlled flow rate. The left femoral
artery cannula was inserted far down to restrict flow to the muscles of interest
only.

For venous return to the systemic circulation, the right jugular vein was
cannulated towards the heart through the same incision made for the tracheotomy.
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To complete the venous side, a cannula was inserted into the left femoral vein
away from the heart for collection of venous blood samples from the perfused
limb. This cannula was connected to the jugular cannula for passive return of deoxygenated blood.

When cannulations were complete, passive flow through the system was allowed
before the pump was turned on. Oxygenated blood from the heart flowed through
the right femoral artery and the peristaltic pump and into the perfused hindlimb
via the left femoral artery. Deoxygenated blood was allowed to flow passively
from the femoral vein of the perfused leg back to the systemic circulation via the
right jugular vein for re-oxygenation through the pulmonary circulation. The
hindlimb was perfused at a constant rate of 1mL.min-1 for 20-30min prior to any
stimulation protocols. This baseline recording allowed for perfusion pressure to
reach steady state. Saline-soaked gauze was placed over each incision point to
prevent tissues from drying out. The entire set up takes approximately 90 minutes.
Rats maintain stable cardiorespiratory parameters for over 3hrs under anaesthetic.

2.3.2.e Hindlimb Pressure
A T-connection attached to a pressure transducer (Argon CDXIII, Maxim
Medical, USA) was inserted into the circuit after the pump to record hindlimb
pressure. A Windkessel apparatus was included into the system to dampen the
pulsatile waves of pressure from the pump.
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2.3.2.f Optimal muscle length and stimulation voltage
Prior to the commencement of the stimulation protocols, optimal muscle length
and stimulation voltage was determined. Optimal muscle length is the length at
which the muscle can generate the highest isometric twitch force in response to
sciatic nerve stimulation. Initially at low tension, the muscle was stimulated in 2V
increments to determine the optimal voltage (7-12V). The muscle was then
gradually lengthened and stimulated until maximal force generation was achieved.
Between each stimulation the muscle was allowed to recover for 2min.

2.3.3 Equipment calibration
Equipment was calibrated prior to each experiment. The blood pressure transducer
and hindlimb perfusion pressure transducer were calibrated with a mercury
sphygmomanometer in the range of 0-300mmHg. The force transducer was
calibrated using weights in the range of 0-600g. The peristaltic pump was
calibrated for arbitrary units equalling the required experimental flow rates. The
blood gas analyser (ABL77) has an in-built auto-calibration feature. It was
referenced using quality control solutions (Qualicheck, Radiometer) in the range
required for this experiment.

2.3.4 Data Collection and analysis
Blood pressure, hindlimb perfusion pressure and force data was collected through
an amplifier (Onspot Australia) in to the Lab View for Windows data acquisition
software. Data was obtained continuously throughout all protocols at a sampling
rate of 200Hz. Data was stored on the computer for later analysis with LabView
for Windows display/analyse software.
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2.3.5 Blood and Tissue Sampling
Prior to cannulation the gastrocnemius, soleus, plantaris, EDL and tibialis anterior
were removed from the control leg, weighed and snap frozen in liquid nitrogen.
At the end of all protocols, rats were euthanased by rapid removal of the heart and
exsanguination. The lower hindlimb muscles of the perfused leg (gastrocnemius,
plantaris, soleus, tibialis anterior, extensor digitorum longus and other deep tibial
muscles) were excised, weighed and snap frozen in liquid nitrogen. The heart was
also removed, weighed and frozen. All tissues were stored at -80ºC for later
analysis.

Blood samples were taken during some protocols for blood gas analysis. Arterial
and venous samples (0.1-0.2mL) were collected anaerobically via in-line resealable tubing with a 25G needle attached to a 1m syringe. Blood was
immediately analysed using the ABL77 blood gas analyser (Radiometer,
Australia) for PO2, PCO2, and pH. There was a 12-15s delay in time for venous
blood to travel from the perfused hindlimb to the sampling point. As such, each
sample represents venous blood gases approximately 12-15s prior to the sampling
time.

2.4 General Calculations
Oxygen consumption was calculated according to the Fick equation.
Oxygen consumption = ((a-v)O2) x (hindlimb flow rate)
Weight of perfused muscle
Where:
•

Oxygen consumption is expressed in µmol/gram/min
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•

(a-v) O2 is the arterial-venous difference expressed in µmol

•

hindlimb flow rate is in mL.min-1

•

weight of perfused muscle is in grams (wet weight)

Arterial and venous O2 content (mL/100mL) were calculated using
Oxygen content = (1.39 x Hb x RBC saturation (%) + (0.03 x PO2)
Where:
•

1.39 = millilitres O2 bound to 1 gram haemoglobin

•

Hb is the blood haemoglobin concentration expressed in grams/100mL

•

RBC saturation (%) is the percentage of the haemoglobin that is saturated with
O2 calculated using measured PO2, PCO2 and pH for blood specific P50

•

PO2 is the partial pressure of O2 in whole blood expressed in mmHg

•

0.003 = constant for dissolved O2 in plasma at 38ºC

Vascular resistance (dyne.s.cm-5) was calculated as follows
Resistance = hindlimb pressure (dyne.cm-2)
flow rate (cm3.s-1)

2.5 Statistical Analysis
Results are expressed as mean ± standard error of the mean (SEM). Statistical
analysis of the effect of diet on each measurement parameter included a one-way
analysis of variance (ANOVA) with Tukey post hoc comparison of means. Linear
mixed models was used for repeated measures where equal numbers per group
were not available. p<0.05 was accepted as statistically significant. Statistix for
Windows (Analytical Software, USA) was used for all ANOVA. SPSS (version
15) was used for linear mixed models.
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Chapter 3 MEMBRANE FATTY ACID INCORPORATION
3.1 Introduction
3.1.1 Membrane phospholipid fatty acid composition
The fatty acid composition of phospholipids plays an important role in membrane
function (Spector & Yorek 1985). This is illustrated by the variations in
membrane fatty acid composition in tissues with different functions (Ando et al.
2000). Furthermore, tissues with common properties often exhibit similar
membrane fatty acid composition. The most notable example being the
similarities observed in excitable tissues such as the heart and skeletal muscle
(Charnock et al. 1989; Nikolaidis et al. 2006) in comparison to, for example, the
kidneys, liver, lungs, plasma or red blood cells (Ando et al. 2000; Charnock et al.
1992; Nikolaidis et al. 2006). The fatty acid composition of membrane
phospholipids in most tissues may be altered by internal and external factors,
having significant influence on cell function, for instance with exercise training
(Helge et al. 1999; Helge et al. 2001), in pathophysiological environments (Reibel
et al. 1986), or in response to stress (Emilsson & Gudbjarnason 1983;
Gudbjarnason & Benediktsdottir 1995; 1996). However, the most potent influence
on membrane fatty acid composition and subsequent cellular or tissue function is
dietary intervention.

3.1.2 Fish oil and membrane phospholipid fatty acid incorporation
Of particular interest in the present study is the incorporation of n-3 PUFA from
fish oil. Although there are different patterns of incorporation of fatty acids in
different tissues, membrane fatty acid composition, particularly in excitable
tissues such as the heart (Hartog et al. 1987; McLennan 1993; McLennan et al.
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1993; Slee et al. 2010) and skeletal muscle (Andersson et al. 2002; Ayre &
Hulbert 1996a; b; Owen et al. 2004; Stark et al. 2007), largely reflects dietary
intake in terms of n-3 PUFA, which are preferentially incorporated at high
concentrations, well above the circulating concentrations, regardless of the
amount of n-6 PUFA in the diet (Slee et al. 2010). The strongest evidence
supporting the relationship between dietary intervention, membrane incorporation
and function is in the heart, where the protective effects of fish oil are attributed to
this incorporation of n-3 PUFA into membrane phospholipids (McLennan 2001;
McLennan & Abeywardena 2005).

Historically, animal studies of physiological effects and mechanisms of fish oil
action have used high intakes of n-3 PUFA that are well established to produce
membrane change. Because these high intakes, commonly in the range of 5-12%
of the animal diet, are well above that which can be reasonably achieved in the
human diet, extrapolation of these studies to humans can be questioned. These
high intakes are well established to produce large changes in membrane
composition, however much less is known about the effects of lower doses that
are within the range of human intake, or indeed how much is needed to effect
membrane change.

3.1.2 Aims and Hypotheses
The purpose of the current study was to determine the effects of low doses (0.31
and 1.25%) of dietary fish oil on membrane phospholipid fatty acid composition
in both the heart and skeletal muscle to establish a basis for further studies in to
skeletal muscle and cardiac function.
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It was hypothesised that
a) cardiac and skeletal muscle would have similar membrane phospholipid
compositions in the animals fed the control diet
b) low doses of dietary fish oil (0.31 and 1.25%) would result in significant
incorporation of n-3 PUFA into both cardiac and skeletal muscle
membranes substituting for n-6 PUFA and resulting in a reduction in the
n-6/n-3 PUFA ratio

3.2 Methods
3.2.1 Animals and diets
Male Sprague Dawley rats were randomly assigned to OO, LowFO (0.31%) or
ModFO (1.25%) diets as described previously in Chapter 2.1. They were
maintained on these diets ad libitum for a period of at least 4 weeks. Animals (2225 weeks of age) were euthanased at the end of hindlimb perfusion experiments
without recovery from anaesthetic, by rapid removal of the heart and
exsanguination (Chapter 2.1). The heart and hindlimb muscles were excised,
weighed and snap frozen in liquid nitrogen before storage at -80°C. Given the
well documented similarities in fatty acid composition between cardiac and
skeletal muscle (Andersson et al. 2002; McLennan 1993; Owen et al. 2004;
Peoples 2004) and the potential similarities in function (Wasserstrom 1997) and
action of dietary fish oil (Dulloo et al. 1994; Leaf et al. 2005; McLennan &
Abeywardena 2005; Nurnberg et al. 1998; Xiao et al. 2005), fatty acid
composition was determined in both the heart and skeletal muscle (soleus and
gastrocnemius). The soleus and gastrocnemius were chosen as they are the major
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muscle groups of the calf, representing both red and mixed (red and white) fibre
types (Delp & Duan 1996), which was used throughout this study for assessment
of skeletal muscle physiology.

3.2.2 Membrane phospholipid fatty acid analysis
Cardiac and skeletal muscle tissues were analysed using gas chromatography for
their membrane fatty acid composition. Samples went through total lipid
extraction (Folch et al. 1957), separation into the phospholipid fraction and direct
transesterification of the fatty acids (Lepage & Roy 1986). All solvents used for
fatty acid analysis contained butylated hydroxytoluene (0.01%) as an antioxidant.

3.2.2.a Total lipid extraction
The extraction procedure involved homogenising a small amount (50-250mg) of
finely chopped tissue in 4.5mL of chloroform: methanol (2:1, v/v) in a glass
homogeniser. The homogenate was transferred to a screw cap tube and the
homogeniser was washed with a further 1mL chloroform: methanol (2:1). The
samples were then rotated for 3-4hrs at room temperature. After the addition of
2mL of 1M H2SO4 the tubes were shaken vigorously for 30s before centrifugation
at 1000rpm (210 x g) and 5ºC for 10min (Hettich Zentrifugen Rotina 46 R). The
top aqueous phase was discarded and the bottom solvent phase was collected. A
further 2mL of H2SO4 was added to the solvent phase and the shake and spin
procedure was repeated. The bottom layer was again collected and a small amount
of sodium hydrosulphite was added to remove any remaining aqueous phase,
before the sample was filtered through glass wool. Samples were stored overnight
at –20ºC.
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3.2.2.b Phospholipid separation
Following extraction, samples were dried down under nitrogen and redissolved in
5mL of hexane before being passed through phenomenex silica solid phase
extraction columns (Waters Corporation Australia, Rydalmere, NSW). The
sample tube was rinsed with another 5mL of hexane and this was passed through
the column also. Triglycerides were eluted with 3 x 5mL ethyl acetate and
discarded. Phospholipids were eluted with 3 x 5mL methanol.

3.2.2.c Direct Transesterification
Extracted phospholipids were dried down under N2 and redissolved in 2mL
methanol: toluene (4:1, v/v). Whilst vortexing 200µL of acetyl chloride was added
to methylate the fatty acids and then samples were put on a dry heat block at
100ºC for 1hr. Samples were then cooled in a sink of cold water before the
addition of 5mL 6%(w/v) K2CO3. Samples were then vortexed and centrifuged at
3000rpm (1895 x g) and 4ºC for 10min. The upper toluene phase was collected in
a glass gas chromatograph vial and stored at –20ºC until they were analysed using
a gas chromatograph.

3.2.2.d Sample Analysis (gas chromatography)
Samples were analysed using a Shimadzu 17A gas chromatograph with flame
ionisation detection. Hydrogen was the carrier gas and the column was a Restek
FAMEwax column (30m x 0.25mm x 0.25μm). Temperature rose from 150-240ºC
over 25.08min. Individual fatty acid peaks on the chromatogram were identified
by comparison to authentic fatty acid methyl ester standards (Sigma-Aldrich
Corporation, (Castle Hill, NSW) and Nu-Chek-Prep Inc. (Elysian, MN, USA).
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The area under the peak was integrated and divided by the total area of fatty acids
to give the relative amount of each fatty acid (% total fatty acids). The
peroxidation index for each fatty acid was calculated as the molar
percent*(number of double bonds-1). The total peroxidation index was calculated
as the sum of all individual peroxidation indices (Kubo et al. 1998). The purpose
of this calculation was to estimate the relative potential for increased lipid
peroxidation and generation of ROS in membranes from rats fed the fish oil diets
compared to the olive oil control diet.

3.2.3. Statistics
All data is mean ± SEM. A two-way ANOVA for diet was conducted with diet
and tissue as the main effects with diet*tissue interaction. p<0.05 was accepted as
statistically significant.

3.2.4. Chemicals
All solvents (analytical grade methanol, chloroform, hexane, ethyl acetate and
toluene) and Acetyl Chloride were obtained from Crown Scientific (Australia).
H2SO4 and K2CO3 were attained from Sigma Aldrich (Australia). Fatty acid
standards were obtained from Sigma Aldrich (Australia) and NuChek-prep
(USA).

3.3. Results
3.3.1. Tissue differences in membrane fatty acid composition
Both gastrocnemius and soleus muscles and the left ventricle exhibited similar
fatty acid composition with only small but significant differences evident (Tables
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3-1, 3-2 and 3-3). The greatest differences were observed in the gastrocnemius
muscle compared to the soleus muscle and left ventricle, which showed the most
similarities. The gastrocnemius muscle exhibited greater 22:6n-3, 20:5n-3, total n3 PUFA and lower 20:4n-6, 18:2n-6, total n-6 PUFA concentrations and n-6/n-3
PUFA ratio compared to the soleus and left ventricle (all p<0.001). The soleus
further differed from the left ventricle having lower concentrations of 20:4n-6 and
22:6n-3, total n-3 PUFA and n-6 PUFA (all p<0.001).

3.3.2. Effect of diet on membrane composition
Across all tissues, there were significant effects of both FO diets on skeletal
muscle and cardiac membrane composition (Tables 3-1, 3-2 and 3-3). The major
effect of dietary FO feeding was an increase in DHA (22:6n-3, p<0.001) and a
reduction in AA (20:4n-6, p<0.001). Smaller changes were observed in other fatty
acids including a rise in EPA (20:5n-3, p<0.001) and reduction in LA (18:2n-6,
p<0.001). These changes resulted in a general increase in n-3 PUFA (p<0.001)
and peroxidation index (p<0.001) and a decrease in n-6 PUFA (p<0.001) and the
n-6/n-3 PUFA ratio (p<0.001). The incorporation of n-3 PUFA in exchange for n6 PUFA was more obvious in the gastrocnemius muscle (all p<0.05-diet*tissue
interaction).
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Table 3-1 Fatty acid composition of the gastrocnemius muscle
Olive Oil

LowFO (0.31%)

ModFO (1.25%)

16:0

15.70 ± 0.83

20.39 ± 0.97*

21.98 ± 2.18*

16:1

0.63 ± 0.04

0.71 ± 0.08

0.88 ± 0.17

18:0

16.15 ± 0.76

15.83 ± 0.58

15.49 ± 0.66

18:1n-9

6.59 ± 1.05

12.81 ± 0.57*

13.14 ± 1.39*

18:2n-6

19.66 ± 0.85

16.80 ± 0.74

15.09 ±1.03*

20:3n-6

0.78 ± 0.03

0.51 ± 0.03*

0.51 ± 0.04*

20:4n-6

15.85 ± 0.53

11.47 ± 0.93*

7.01 ± 1.06*†

20:5n-3

ND

0.16 ± 0.04*

0.36 ± 0.10*†

22:4n-6

0.39 ± 0.09

0.19 ±0.05

0.03 ± 0.03*

22:5n-6

1.39 ± 0.11

0.35 ± 0.04*

0.40 ± 0.01*

22:5n-3

0.87 ± 0.05

0.86 ± 0.06

0.85 ± 0.09

22:6n-3

9.26 ±0.74

19.89 ± 0.36*

24.25 ± 1.03*†

Σ Sat

37.40 ± 1.16

38.84 ± 1.27

40.30 ± 2.54

Σ MUFA

11.15 ± 0.95

13.87 ± 0.61

14.39 ± 1.52

Σ PUFA

51.45 ± 0.89

47.29 ± 0.76

45.31 ± 2.16

Σ n-6 PUFA

41.23 ± 0.94

28.99 ± 0.99*

22.97 ± 1.59*†

Σ n-3 PUFA

9.75 ± 0.63

18.30 ± 0.30*

22.33 ± 1.02*†

n-6/n-3

4.33 ± 0.34

1.59 ± 0.08*

1.03 ± 0.07*

135.85 ± 2.85

155.99 ± 1.51*

161.78 ± 7.27*

PI

Values are mean ± SEM. n= 5-6 per group. *p<0.05 vs. OO diet. †p<0.05 vs. LowFO diet. Σ Sat =
sum of saturated fatty acids. Σ MUFA = sum of monounsaturated fatty acids. Σ Poly = sum of
polyunsaturated fatty acids. Σ n-3 PUFA = sum of n-6 polyunsaturated fatty acids. Σ n-6 = sum of
n-6 polyunsaturated fatty acids. PI = Peroxidation Index. ND = not detected.
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Table 3-2 Fatty acid composition of the soleus muscle
Olive Oil

LowFO (0.31%)

ModFO (1.25%)

16:0

9.83 ± 0.56

15.57 ± 0.63*

17.95 ± 0.68*

16:1

0.75 ± 0.09

1.28 ± 0.55

0.62 ± 0.05

18:0

18.77 ± 0.45

18.17 ± 0.65

19.98 ± 0.82

18:1n-9

12.35 ± 1.02

15.87 ± 0.68*

14.19 ± 0.64

18:2n-6

20.68 ± 0.55

18.78 ± 0.54

17.59 ± 0.26*

20:3n-6

0.80 ± 0.02

0.63 ± 0.07*

0.67 ± 0.01

20:4n-6

16.37 ± 0.41

13.61 ± 0.81*

9.36 ± 0.61*

20:5n-3

ND

0.06 ± 0.04

0.29 ± 0.07*

22:4n-6

0.66 ± 0.06

0.31 ± 0.08*

0.06 ± 0.06*†

22:5n-6

1.24 ± 0.08

0.41 ± 0.05*

0.23 ± 0.08*

22:5n-3

0.71 ± 0.03

0.95 ± 0.06*

1.01 ± 0.08*

22:6n-3

5.14 ± 0.23

14.27 ± 0.65*

18.04 ± 1.40*

Σ Sat

32.94 ± 0.73

35.79 ± 0.51

40.23 ± 1.41*

Σ MUFA

17.72 ± 1.29

17.59 ± 1.01

15.11 ± 0.62

Σ PUFA

49.34 ± 1.07

46.62 ± 1.36

44.66 ± 1.81

Σ n-6 PUFA

42.92 ± 1.10

33.27 ± 1.23*

27.72 ± 0.81*†

Σ n-3 PUFA

5.62 ± 0.21

13.35 ± 0.63*

16.93 ± 1.30*

n-6/n-3

7.71 ± 0.43

2.51 ± 0.14*

1.68 ± 0.12*

125.37 ± 1.38

143.14 ± 4.18*

144.66 ± 7.12*

PI

Values are mean ± SEM. n= 5-6 per group. *p<0.05 vs. OO diet. †p<0.05 vs. LowFO diet. Σ Sat =
sum of saturated fatty acids. Σ MUFA = sum of monounsaturated fatty acids. Σ Poly = sum of
polyunsaturated fatty acids. Σ n-3 PUFA = sum of n-6 polyunsaturated fatty acids. Σ n-6 = sum of
n-6 polyunsaturated fatty acids. PI = Peroxidation Index. ND = not detected.
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Table 3-3 Fatty acid composition of the Left Ventricle
Olive Oil

LowFO (0.31%)

ModFO (1.25%)

16:0

9.59 ± 0.18

11.57 ± 0.21

12.36 ± 0.10

16:1

0.36 ± 0.02

0.37 ± 0.04

0.31 ± 0.02

18:0

20.49 ± 0.13

19.88 ± 0.24

20.30 ± 0.36

18:1n-9

9.57 ± 0.27

11.26 ± 0.20*

10.28 ± 0.29

18:2n-6

21.17 ± 0.39

19.25 ± 0.71

18.08 ± 0.32*

20:3n-6

0.55 ± 0.02

0.51 ± 0.04

0.53 ± 0.02

20:4n-6

24.04 ± 0.37

18.41 ± 0.45*

15.65 ± 0.55*

20:5n-3

ND

0.05 ± 0.01

0.37 ± 0.04*†

22:4n-6

0.70 ± 0.04

0.32 ± 0.03*

0.12 ± 0.01*†

22:5n-6

2.07 ± 0.10

0.62 ± 0.04*

0.57 ± 0.03*

22:5n-3

0.68 ± 0.04

0.79 ± 0.05

0.91 ± 0.04*

22:6n-3

6.62 ± 0.34

16.84 ± 0.38*

20.35 ± 0.68*

Σ Sat

30.11 ± 0.12

33.46 ± 0.13

34.91 ± 0.30

Σ MUFA

13.79 ± 0.20

12.06 ± 0.20

11.01 ± 0.31

Σ PUFA

56.10 ± 0.15

54.49 ± 0.27

54.08 ± 0.47

Σ n-6 PUFA

48.54 ± 0.23

38.83 ± 0.56*

34.88 ± 0.67*†

Σ n-3 PUFA

7.30 ± 0.34

15.65 ± 0.35*

19.21 ± 0.60*

n-6/n-3

6.72 ± 0.34

2.49 ± 0.09*

1.83 ±0.09*

133.80 ± 1.79

165.70 ± 1.52*

172.52 ± 1.71*

PI

Values are mean ± SEM. n= 5-6 per group. *p<0.05 vs. OO diet. †p<0.05 vs. LowFO diet. Σ Sat =
sum of saturated fatty acids. Σ MUFA = sum of monounsaturated fatty acids. Σ Poly = sum of
polyunsaturated fatty acids. Σ n-3 PUFA = sum of n-6 polyunsaturated fatty acids. Σ n-6 = sum of
n-6 polyunsaturated fatty acids. PI = Peroxidation Index. ND = not detected.
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Figure 3-1 Effect of diet on incorporation of n-6 PUFA and n-3 PUFA into skeletal
muscle and myocardium.
Values are mean ± SEM. n= 6, 6 and 5 for OO, LowFO and ModFO groups respectively.
*p<0.05 vs. OO diet. †p<0.05 vs. LowFO diet. #p<0.05 vs. gastrocnemius. ^p<0.05 vs.
soleus.
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3.4. Discussion
The present study is the first to investigate the fatty acid composition of cardiac
muscle, soleus and gastrocnemius muscle of animals supplemented with very low
doses of dietary fish oil. Very low dose supplements were observed to produce
marked n-3 PUFA incorporation and increased unsaturation index in all three
tissues. In the past, dietary modification in animal models has largely been
restricted to relatively high doses of fish oil (5-12%)(see (Matthan et al. 2005),
unachievable in the human diet (Slee et al. 2010). It is well established that
marked differences in membrane composition are produced following fish oil
supplementation, with large increases in membrane n-3 PUFA concentration and
total unsaturation where dietary n-3 PUFA are in such abundance (Ando et al.
2000; Pepe & McLennan 1996). The confidence in relating membrane
incorporation and physiological measures in these animal studies to effects
observed in human epidemiological and clinical studies or to predict physiological
function changes with fish oil consumption in the human may be compromised by
the use of supraphysiological doses. Little is known about the incorporation
patterns when these n-3 PUFA are only available in small doses, especially in
cardiac and skeletal muscle. The present study indicates that marked incorporation
of n-3 PUFA is still possible even with low doses that are relevant to humans. The
LowFO diet (0.31%) is the equivalent to 1-2 fish meals (100g salmon) per week
or 1-2 fish oil capsules per day. The ModFO (1.25%) diet is at the higher end of
human consumption but is still achievable in the human diet representing
approximately 8 fish meals per week or up to 6 fish oil capsules per day (Slee et
al. 2010). These calculations are based on a human daily energy intake of 8300kJ,
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a fish portion of 100g salmon containing 1900mg EPA + DHA and a fish oil
capsule containing 330mg EPA + DHA.

The pattern of incorporation into cardiac and skeletal muscle in this study
supports the notion, first identified in the heart by our laboratory group (Slee et al.
2010), that only small doses are required for observable effects on membrane
composition. In that study, the lowest dose of 0.16% (representing 0.13% energy
as EPA + DHA) fish oil significantly increase the concentration of membrane
DHA by more than 60%, largely in exchange for AA. Furthermore, as observed in
the present study, a dose of 0.31% was sufficient to more than double membrane
DHA concentrations. The implications of these results are that any observed
alterations in cardiac and skeletal muscle function that may be associated with
these changes in membrane composition can be given more credence as predictors
of translation of the effects into humans.

3.4.1. Membrane incorporation of n-3 PUFA
The specific pattern of incorporation of n-3 PUFA into heart and skeletal muscle
membrane phospholipids in the present study was similar to that observed in
studies using high doses of fish oil. The increase in EPA, DHA and total n-3
PUFA and concomitant decreases in AA, total n-6 PUFA and the n-6/n-3 ratio are
common observations in tissues of fish oil fed animals, particularly in the heart
and skeletal muscle. (Andersson et al. 2002; Ayre & Hulbert 1997; Hartog et al.
1987; McLennan 1993; McLennan et al. 1993; Peoples 2004). It is likely that a
combination of interactions and mechanisms are involved in producing the pattern
of incorporation observed with fish oil feeding. These include preferential
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incorporation of DHA over EPA, retroconversion of DHA to EPA and
competition between n-3 PUFA and n-6 PUFA for desaturase enzymes.

Because the high DHA tuna fish oil used in the current study comprised almost
30% DHA and only 7% EPA, the diets used in the current study consisted of more
DHA than EPA. This however does not entirely account for the enhanced
incorporation of DHA, above dietary levels, relative to the moderate incorporation
of EPA observed in the current study. The DHA and EPA supplied by the diet can
both be directly incorporated into membranes. However, EPA is not readily
incorporated and was not detectable in the heart and skeletal muscle tissue from
animals fed the olive oil control diet). It undergoes elongation, desaturation and
peroxisomal β oxidation to eventually form DHA (Figure 1-1)(Wallis et al. 2002),
resulting in further increases in membrane DHA composition to levels well above
its dietary intake, as was seen in the current study. This preferential incorporation
of DHA has been observed previously, where it is the predominant n-3 PUFA
incorporated into heart membranes after fish oil feeding, regardless of whether it
is the major n-3 PUFA in the diet (McLennan et al. 1996)or is provided at lower
concentrations in an EPA-rich oil (Pepe & McLennan 1996). Furthermore, dietary
EPA alone significantly increases cardiac DHA (McLennan et al. 1996), further
supporting preferential incorporation of DHA and suggesting an important role for
DHA in heart function. The evidence suggests that this preferential incorporation
confers greater beneficial effects of n-3 PUFA in terms of cardiac physiology, that
are not seen in diets with EPA as the only source of long chain n-3 PUFA. For
example, hearts from rats fed diets including either purified DHA or mixed DHA
+ EPA, but not EPA alone, exhibit antiarrhythmic properties (McLennan et al.
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1996). Furthermore, DHA alone reduces heart rate and blood pressure, an effect
not observed in animals fed diets supplemented with EPA alone (RousseauRalliard et al. 2009). The present study extends these findings in the heart to
suggest similar preferential incorporation of DHA in to skeletal muscle
membranes with the potential to improve function.

It is possible for some dietary DHA to be retroconverted to EPA in the
peroxisome. Indeed, slight increases in cardiac membrane EPA have been shown
with a purified DHA diet (McLennan et al. 1996). This process is relatively slow
however and as such it is more likely that the majority of dietary DHA is directly
incorporated into cell membrane phospholipids, especially since tissue EPA levels
are lower than dietary levels.

With increasing n-3 PUFA in the membranes, there was concomitant reduction in
the n-6 PUFA. This was largely confined to reductions in arachidonic acid (20:4n6) with only small decreases in linoleic acid (18:2n-6). Therefore, the observed
decrease in arachidonic acid is likely due to the competition between n-6 PUFA
and n-3 PUFA for desaturase enzymes. The ∆6 and ∆5 desaturases are used in the
synthesis of both n-6 PUFA and n-3 PUFA. The n-6 PUFA and n-3 PUFA
substrates compete for these enzymes, with n-3 PUFA substrates being
preferentially desaturated (Geiger et al. 1993; Sprecher 2000; Tran et al. 2001).
Furthermore, it is thought that n-3 PUFA inhibit these desaturase enzymes to
prevent or slow down the production of the n-6 family of polyunsaturated fatty
acids. This is based on findings that ALA and EPA prevent or slow down the
synthesis of AA from LA by inhibiting desaturase activity (Garg et al. 1990;
Gronn et al. 1992).
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The elevated peroxidation index observed in fish oil animals is a common finding
that is related to the structure of the n-3 PUFA (Markley 1947). Due to the
number and position of double bonds, these compounds are more susceptible to
oxidation/peroxidation (Javouhey-Donzel et al. 1993). The peroxidation index
thus predicts the susceptibility to oxidative stress and risk of oxidative damage to
membranes. The apparent paradox surrounding the reported beneficial effects of
fish oil and the potentially harmful increased susceptibility to oxidation is well
documented for the heart. In fact, some of the favourable effects observed in the
heart have been attributed to the effect of fish oil on the body’s redox
balance(Aguilera et al. 2003; Hsu et al. 2001; Jahangiri et al. 2006; RuizGutierrez et al. 2001; Venkatraman et al. 1994; Wang et al. 2004). The
upregulation of the body’s own internal antioxidant system is stimulated by fish
oil feeding, resulting in an enhanced ability to deal with subsequent heightened
oxidative stress situations. This phenomenon is called preconditioning (Sun et al.
1996; Zhou et al. 1996). In skeletal muscle, ROS are implicated in normal muscle
function. A basal level of oxidation contributes to optimal muscle function while
reductions are associated with a decline in muscle contractile function and
excesses contribute to the development of muscle fatigue (Reid et al. 1993).
Although oxidation may not occur to the extent predicted by the peroxidation
index (Kubo et al. 1998; Saito 2000; Saito & Kubo 2003), the elevated
susceptibility to peroxidation with fish oil feeding has implications for skeletal
muscle function and fatigue.
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3.4.2 Essential fatty acid deficiencies
The presence of DHA in tissues from the olive oil control dietary group (diet
devoid of any long chain n-3 PUFA such as EPA and DHA) indicates that these
animals are not n-3 PUFA deficient. This is likely due to a couple of reasons.
Firstly, there is a small amount of ALA in the OO diet, of which a certain
proportion would be converted to DHA via elongase and desaturase enzymes.
Secondly, and perhaps most importantly, the presence of substantial DHA in
cardiac and skeletal muscle phospholipids of the OO dietary group reflects the
preferential incorporation and maintenance of DHA in these tissues. Prior to
dietary intervention, all animals were fed laboratory chow, which may contain
fish meal as a protein source. Although not directly assessed in the current study,
it is most likely that tissues obtained DHA from the chow diet prior to
intervention with OO diet (see reference chow diet (Pepe & McLennan 1996).
Furthermore, DHA seems to be maintained to a certain extent in the membranes
during the intervention that contains very little of the essential n-3 PUFA (Alam et
al. 1995).

The fish oil diets contained predominantly olive oil, which is not a rich source of
n-6 PUFA. However, the tissue fatty acids indicate that these animals are not
deficient in n-6 fatty acids. Specifically, all diets contained similar amounts of n-6
PUFA (Table 2-1) and the relatively large amounts of linoleic acid (18:2n-6) and
arachidonic acid (20:4n-6) is evident in all tissues analysed. Similar
concentrations have been reported in myocardium of rats fed chow diets, and n-6
PUFA enriched diets (McLennan 1993; Pepe & McLennan 1996)
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3.4.3 Tissue fatty acid differences
Although the pattern of incorporation of n-3 PUFA was similar in both cardiac
and skeletal muscle, comparison of membrane fatty acid composition between the
muscles and the left ventricle revealed significant differences. Of particular
interest are the parallel differences between the gastrocnemius and soleus and the
gastrocnemius and the left ventricle as well as the similarities between the soleus
and left ventricle.

The differences between the gastrocnemius and soleus may be associated with the
different fibre types and metabolic characteristics of these muscles. The soleus is
representative of a red, slow-twitch fibre type while the gastrocnemius is a mixed
red and white fibre type. Due to the close relationship between membrane
composition and cell function, it is reasonable to expect that these two tissues,
with different characteristics regarding function, may exhibit different membrane
composition. There is limited evidence to suggest that slow-twitch oxidative
fibres contain more DHA than do fast-twitch fibres (Kriketos et al. 1995; Peoples
2004). Our results are in contrast to these reports, showing the mixed muscle fibre
type to have a higher proportion of membrane DHA than the slow-twitch
oxidative muscle. A similar trend to the current results however has been
previously observed showing higher DHA levels in the EDL (fast-twitch)
compared to the soleus (slow-twitch) (Nikolaidis et al. 2006). The reasons for the
disparities are unknown and may relate to variations in the sampled mixed fibre
type tissues. Further insight may be drawn from comparison of the skeletal muscle
with the heart. It is interesting to note that the greatest similarities in the present
study in regards to membrane composition were between the soleus muscle and
the left ventricle, both exhibiting similar differences compared to the
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gastrocnemius. The soleus and left ventricle are similar in terms of function, being
highly oxidative and more fatigue resistant tissues. It is possible that the fatty acid
composition of these tissues reflects their similar characteristics and functions,
however it has been suggested that muscle fibre type and metabolic characteristics
are not major determinants of muscle membrane composition, given the
similarities when compared to other tissues in the body that are non-excitable
(Nikolaidis et al. 2006). One likely possibility is that the differences between the
gastrocnemius and more fatigue resistant muscles are related to cellular
mitochondrial content. Both soleus and the left ventricle muscles contain higher
mitochondria content compared to white muscles and mitochondrial membranes
are low in PUFA content compared to cellular membranes (Tsalouhidou et al.
2006). Therefore, in the oxidative tissues with more mitochondria, the DHA
content of cellular membranes may be masked by the low mitochondrial PUFA
content, resulting in lower percentage of DHA.

Despite the differences, compared to non-excitable tissues, membrane
composition was actually quite similar across the three tissues measured, with all
having high DHA compared to the kidneys, liver, lungs or serum for example
(Ando et al. 2000; Charnock et al. 1992; Nikolaidis et al. 2006). It has been
established previously that DHA is present in higher concentrations in membranes
of excitable tissues, compared to non-excitable tissues and that this is related to
vital functions within these tissues. The brain, another example of excitable tissue,
is enriched with DHA. Furthermore, fatty acid composition in the brain is tightly
maintained and very difficult to influence externally (Contreras & Rapoport 2002)
thus further strengthening the importance of DHA as an important mediator of
function of these excitable tissues.
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3.4.4 Conclusion
In summary, low supplemental doses of dietary fish oil, equivalent (in energy
terms) to human intakes, produced marked changes in cardiac and skeletal muscle
membrane phospholipids. The patterns of incorporation of n-3 PUFA from fish
oils were similar to that observed with high doses, indicating potential saturation
of the incorporation at higher doses. The abundance of DHA in these excitable
tissues, when compared to non-excitable tissues, highlights the potential
importance of DHA in the physiology of these tissues.

These results are just the beginning in the attempt to link the fish oil effects
observed in animal studies (with high doses) to those observed in epidemiological
and clinical studies (using lower doses). Marked changes in membrane
composition with only small increments of fish oil feeding suggests that changes
in physiological function seen with high doses may well be predicted for the low
intakes as well.
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Chapter 4 SKELETAL MUSCLE FUNCTION AND FATIGUE
4.1 Introduction
The fatty acid composition of skeletal muscle and the ability of skeletal muscle
membranes to respond to dietary fish oil intervention (Chapter 3) suggests
potential effects on muscle function, given the relationship between membrane
composition and cell function. Furthermore, in the heart, similar changes in
membrane composition have been observed with fish oil feeding (McLennan
1993; Pepe & McLennan 1996) and these changes in cardiac membrane
composition are associated with beneficial alterations in cardiac physiology and
function such as a reduction in heart rate (Mozaffarian et al. 2005b) and O2
consumption, improved post-ischaemic recovery and prevention of arrhythmias
(McLennan 1993; Pepe & McLennan 1996; 2002). Therefore, the observations in
the heart, coupled with the similarities between skeletal muscle and myocardial
function (Wasserstrom 1997) and similarities in fatty acid incorporation of n-3
PUFA (observed in Chapter 3), reveal a potentially important role for n-3 PUFA
in skeletal muscle physiology.

Indeed preliminary evidence that suggests that membrane incorporation of n-3
PUFA after dietary fish oil feeding reduces skeletal muscle fatigue (Peoples
2004). In a repetitive single twitch model of muscle stimulation, fish oil improved
contractile performance by enhancing and maintaining force production and
improving O2 efficiency (reduced O2 consumption for a given force development)
resulting in fatigue resistance (Peoples 2004). Although these results are positive
and suggest a similar role of fish oil in skeletal muscle as that already established
in the heart, twitch stimulation protocols represent the most basic form of muscle
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contraction. It may be argued that that particular model of muscle stimulation is
not truly representative of normal human muscle activity (Jones 1996). Other
stimulation protocols that go beyond twitch contractions are potentially more
relevant for determining an effect of fish oil on muscle function and fatigue that is
representative of human muscle activity. There is therefore a need to expand on
this preliminary work and investigate several models of muscle stimulation and
identify potential mechanisms of fish oil action. Low frequency single twitch
protocols, as used in the preliminary study that first identified a role of fish oil in
skeletal muscle (Peoples 2004), are not generally used to assess skeletal muscle
fatigue. High-frequency (>50Hz) tetanic contractions are commonly used to
assess skeletal muscle fatigue, however, these protocols use stimulation
frequencies that are also regarded as unphysiological and unlikely to be reached in
humans (Allen et al. 2008b; Jones 1996). Although these models provide valuable
information regarding muscle function, they are not of interest in the present study
due to the lack of direct comparison to humans. The model chosen in the current
study represents repeated bouts of submaximal contraction. This type of muscle
activity has been examined in both animals and humans (Bigland-Ritchie et al.
1986; Lunde et al. 2002; Verburg et al. 2001; Vollestad et al. 1997) and is more
representative of normal muscle activation patterns. In addition to using relevant
stimulation protocols, it is ideal to use a model that is as close to representative of
normal human physiology as possible for assessing the effects of n-3 PUFA on
muscle function that may be transferable to humans. As discussed in Chapter 2,
the auto-perfused hindlimb preparation used in this study to assess skeletal muscle
contractile function in vivo is representative of near in vivo perfusion conditions.
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Based on the literature and the preliminary evidence pertaining to a fish oil effect
on skeletal muscle twitch function, the current study addressed two important
questions: Do n-3 PUFA favourably affect muscle function in situations that are
relevant to human activity? And can this be achieved with fish oil intakes relevant
to human dietary patterns. In Chapter 3 it was established that small supplemental
intakes of fish oil have marked effects on skeletal muscle membrane composition.
We therefore aim to re-establish the effect of n-3 PUFA, especially at low dietary
intakes, on twitch performance as well as extend our investigation to include other
models of fatigue such as low frequency fatigue. Low frequency fatigue is
characterised by slow recovery of contractile function, likely associated with
disruption of Ca2+ handling and E-C coupling (Jones 1996; Keeton & BinderMacleod 2006).

4.1.1 Skeletal muscle fatigue
As described in Chapter 1, skeletal muscle fatigue is defined as any reduction in
the ability of a muscle to generate force, resulting in the progressive decline in
performance from the onset of activity (Allen et al. 2008b; Gandevia 2001).
Peripheral fatigue is targeted in the current study by excluding central input and
output through direct stimulation of motor neurons to elicit muscle contraction.
More specifically, low frequency fatigue will form the basis of this investigation
given the type of stimulation protocols used (2Hz and 5Hz). There are many
mechanisms that could potentially contribute to low frequency fatigue. Two of the
main mechanisms that may be implicated in the present study relate to Ca2+
cycling and the production of ROS (Allen et al. 2008b; Jones 1996). The interest
in these two mechanisms involved in fatigue in the present study is that they are
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potentially targets for the effects of fish oil in skeletal muscle (Dulloo et al. 1994;
Javouhey-Donzel et al. 1993; Leaf et al. 2005; McLennan & Abeywardena 2005;
Nurnberg et al. 1998; Venkatraman et al. 1994; Xiao et al. 2005).

4.1.2 Fish oil and skeletal muscle
The literature on the effects of fish oil on skeletal muscle function is limited and
draws from studies focusing on a wide range of topic area. Early work in isolated
muscle has established a role of essential fatty acids (both n-6 PUFA and n-3
PUFA) in maintaining muscle function, showing that muscle from animals fed an
essential fatty acid deficient diet performed poorly compared to those from diets
high in n-6 PUFA or n-3 PUFA (Ayre & Hulbert 1996b). There is now
preliminary evidence to suggest that incorporation of dietary n-3 PUFA from fish
oil, especially DHA, improves muscle function and fatigue resistance in rats
(Peoples 2004; Peoples & McLennan 2010). Additional support for a role of n-3
PUFA in muscle function comes from human studies showing significant effects
of increased fish oil supplementation on reducing O2 consumption during exercise
in healthy humans (Peoples et al. 2008) and on exercise performance in those with
impairment caused by chronic obstructive pulmonary disease (Broekhuizen et al.
2005) or paraplegia (Javierre et al. 2006).

Insights from work in other tissues with similar incorporation patterns, especially
the heart, also points towards an important advantageous role of fish oil in skeletal
muscle function. High amounts of n-3 PUFA, in particular DHA, in heart
membranes are associated with many improvements in heart function. One
suggested mechanism contributing to these effects in the heart is the alteration of
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intracellular Ca2+ handling (Leaf et al. 2005; McLennan & Abeywardena 2005;
Xiao et al. 2005). In skeletal muscle, Ca2+ is involved in many aspects of muscle
function, especially excitation-contraction coupling (Berchtold et al. 2000) and
alterations in intracellular Ca2+ handling have been implicated in the fatigue
process (Allen et al. 2008b; Jones 1996). The role of n-3 PUFA in skeletal muscle
has not been extensively studied however, some effects on various aspects of Ca2+
handling have been observed in pigs (Nurnberg et al. 1998) and mice (Dulloo et
al. 1994). Furthermore, the preliminary study that associated membrane changes
with improved muscle function in fish oil fed animals, also identified an indirect
role of Ca2+ cycling in the effect of n-3 PUFA on muscle function, indicating that
n-3 PUFA caused an improved recovery of contractile force in response to
caffeine in the fatigued state (Peoples 2004). Caffeine stimulates the release of
Ca2+ from the sarcoplasmic reticulum (Allen et al. 2008a). Improved response to
caffeine in fish oil fed animals may indicate better intracellular Ca2+ cycling and
retention of SR Ca2+ in these animals. Therefore, if n-3 PUFA favourably affects
Ca2+ handling in skeletal muscle, it may improve function and prevent or reduce
the development of fatigue.

Oxidation of polyunsaturated fatty acids is another aspect of fish oil that is of
interest in the study. As discussed in Chapter 1, despite the well documented
numerous benefits of fish oil consumption, the highly unsaturated chemical
structure of n-3 PUFA would suggest that they are more susceptible to oxidation
(Markley 1947). The higher concentrations of PUFA in cell membranes
theoretically increase the susceptibility of the cell to lipid peroxidation and the
associated damage (Javouhey-Donzel et al. 1993). Indeed, fish oil is associated
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with increased markers of oxidative stress, in particular lipid peroxidation (Adler
et al. 2003; Calviello et al. 1997; Gonzalez et al. 1992; Hsu et al. 2001; Ibrahim et
al. 1997; Javouhey-Donzel et al. 1993; Kaasgaard et al. 1992; Leibovitz et al.
1990; Oarada et al. 2008; Saito & Kubo 2002; Song et al. 2000; Song &
Miyazawa 2001). However, the enhanced lipid peroxidation associated with fish
oils is less than that predicted theoretically based on tissue fatty acid profile
(Kubo et al. 1998; Saito 2000; Saito & Kubo 2003).

It has been suggested that n-3 PUFA from fish oils may even have an antioxidant
effect, which may contribute to lipid peroxidation not being observed to the extent
predicted theoretically (Richard et al. 2008). Another possibility that may explain
the apparent paradox associated with fish consumption and its effects on oxidative
stress and tissue function is the concept of preconditioning. This phenomenon has
been extensively studies in the heart and may also be applied to skeletal muscle.

4.1.3 Preconditioning
Preconditioning is a phenomenon whereby, after a previous mild exposure to a
particular stress, a tissue has the ability to better cope with subsequent exposure to
that stressor. The best documented example of preconditioning occurs in the heart
with myocardial ischaemia. One possible mechanism of preconditioning is: an
increase in ROS produced during the first stressful stimulus stimulates the
upregulation of antioxidants that protect the tissue during the late phase of
preconditioning. Studies in the heart have supported this notion (Hoshida et al.
1993; Hoshida et al. 2002; Sun et al. 1996; Zhou et al. 1996).

70

The concept of preconditioning may also be applied to skeletal muscle. Evidence
to support this comes from effects of exercise training. Exercise training has been
shown to induce both early and late preconditioning in the hearts of dogs
(Domenech et al. 2002; Hamilton et al. 2001). With respect to exercise, late
preconditioning seems to be evident approximately twenty four to sixty hours
after exercise (Hoshida et al. 2002). It is feasible that the preconditioning effect
seen in the heart can be translated into skeletal muscle with the increase in ROS
production during acute exercise stimulating upregulation of antioxidants to
increase the tissue’s ability to cope with the stress of a later bout of exercise. This
would mean that trained individuals, who have been exposed to many bouts of
acute exercise, could cope better with the exercise induced oxidative stress. This
idea is further supported by the fact that chronic antioxidant supplementation may
actually hamper the health promotion effects of exercise by preventing the normal
upregulation of antioxidant enzymes (Ristow et al. 2009). Removal of
supplementation would subsequently result in reduced performance, as the body
has not prepared its natural capacity to deal with acute exercise-induced oxidative
stress.

Similar to ischaemic preconditioning in the heart and exercise, the oxidative stress
associated with fish oil consumption may stimulate adaptations in antioxidant
defence systems so that tissues are less vulnerable to damage caused by ROS.
Indeed, fish oil feeding results in increased activity (Aguilera et al. 2003; Atalay
et al. 2000; Hsu et al. 2001; Leonardi et al. 2007; Ruiz-Gutierrez et al. 1999;
Ruiz-Gutierrez et al. 2001; Venkatraman et al. 1994; Wang et al. 2004) and
expression (Jahangiri et al. 2006; Venkatraman et al. 1994) of the antioxidant
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enzymes catalase, superoxide dismutase and glutathione peroxidase in various
tissues and species and this has been proposed as a potential mechanism for the
beneficial effects of fish oil in pathophysiological conditions where ROS are a
major contributor to dysfunction (Aguilera et al. 2003; Hsu et al. 2001; Jahangiri
et al. 2006; Ruiz-Gutierrez et al. 2001; Venkatraman et al. 1994; Wang et al.
2004). The idea of a preconditioning effect of fish oil is relevant in the present
study as ROS are thought to significantly contribute to muscle fatigue. Such an
effect would enhance the muscle’s ability to deal with exercise-induced oxidative
stress and potentially result in improved function during stimulation protocols.

4.1.4 Aims and Hypotheses
Although the effects of fish oil on skeletal muscle function and physiology have
not been extensively studied, the aforementioned literature leads us to suspect a
similar role of fish oil in skeletal muscle as in the heart that may be related to
effects on cellular Ca2+ handling and generation of ROS. Therefore, the purpose
of the present study was to extend the preliminary findings to further assess the
effects of low doses of fish oil on various aspects of skeletal muscle function.
Specifically, this study aimed to firstly determine the effects of fish oil on force
production during different stimulation protocols including high frequency single
tetanic contractions, repeated low frequency single twitch stimulation and
repeated bouts of low frequency stimulation under normal physiological
conditions. Furthermore we aimed to determine if similar effects of fish oil were
observable in muscle post-fatigue. The final aim of this study was to begin to
identify potential mechanisms of fish oil action in skeletal muscle.
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It was hypothesised that
a) incorporation of n-3 PUFA into skeletal muscle membranes will improve
contractile performance and provide fatigue resistance,
b) fatigue resistance in FO animals will be generalised across many
conditions.

4.2 Methods
4.2.1 Animals and diets
Procedures for animal care and dietary intervention are outlined in Chapter 2.1
and 2.2. Briefly, animals were assigned to one of three dietary groups: Olive oil
(OO) control; LowFO (0.31%) and ModFO (1.25%), fed for 4-5 weeks prior to
muscle function experimentation and euthanasia. Rat age at time of
experimentation ranged from 16-23w. Although animals at the lower end of the
age range were slightly smaller, preliminary work in our laboratory has shown
that this difference in size does not affect model set-up. Animals greater than 400g
are large enough for successful completion of the hindlimb experiments, in terms
of set-up and the proportion of blood in the extra-corporal loop, without affecting
the results (data not shown).

Animals were prepared for surgery and set up for experiments as described in
section 2.3. Rats were anaesthetised (pentobarbitone sodium, 60mg/kg i.p.) and
maintained throughout the experiment with supplementary injections of 20mg/kg
i.p. pentobarbitone sodium. The rat was set up in a heated perspex chamber for
assessment of skeletal muscle function via the auto-perfused hindlimb. Animals
were ventilated at 60 breaths per minute and systemic blood pressure was
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monitored via the carotid artery. The sciatic nerve was isolated for electrical
stimulation of the hindlimb and the GSP muscle bundle was attached to a force
transducer at the Achilles tendon. Once all cannulations were made and blood
flowed passively throughout the system, the pump was switched on to perfuse the
experimental leg at 1mL.min-1. Hindlimb perfusion pressure was monitored via a
pressure transducer after the pump. The hindlimb was perfused for 20-30min
before the stimulation protocols began. Following an initial 20-30min
equilibration period at a flow rate of 1mL.min-1 the hindlimb was perfused at
1.5mL.min-1 for the muscle contraction protocol.

4.2.2 2Hz continuous twitch stimulation
Thirty-nine animals were used for this protocol, 11 OO, 13 LowFO and 15
ModFO. The contraction protocol (Figure 4-1) consisted of:
•

tetanus (50Hz, 1s)
•

•

repetitive twitch contractions (2Hz, 5min)
•

•

60s rest
60s rest

tetanus (50Hz, 1s).
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Figure 4-1 Example trace of 2Hz stimulation protocol.
Tetanus 1 and Tetanus 2 represent the tetanic 50Hz, 1s contractions. First twitch, Peak
twitch and Last twitch represent the force generated in the first, peak and last twitches of
the 2Hz stimulation protocol.

4.2.3 5Hz repeated bouts stimulation
Seventeen animals were used in this protocol (6 OO, 4 LowFO and 7 ModFO).
This stimulation protocol (Figure 4-2) consisted of:
•

repetitive stimulation bouts (5Hz, 5s, repeated every 10s for 5min).

Figure 4-2 Example trace of 5Hz stimulation protocol.
Arrows indicate First (Ft) and Last (Lt) twitches of a 5s bout of stimulation.

It was conducted either:
•

immediately after the initial 20-30min equilibration period (normal) or

•

20min after an initial 2Hz protocol (post-fatigue, Figure 4-3)
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4.2.3.a Normal conditions
Blood samples (0.1-0.2mL) were taken at intervals throughout the protocol for
blood gas analysis. Resting blood samples were taken at both pump speeds
(1mL.min-1 and 1.5mL.min-1) prior to the stimulation protocol. Active blood
samples were taken at 60s into and at the end of the 5min contraction protocol.
Recovery blood samples were taken 4min after the completion of the contraction
protocol. There was a 12-15s delay in venous blood travelling from the perfused
hindlimb to the sampling point. The venous blood samples therefore represent
muscle activity just prior to the sampling time.

4.2.3.b Post-fatigue muscle
In this group of animals (6 OO, 8 LowFO and 8 ModFO), the 5Hz repeated bouts
stimulation protocol was performed 20min after an initial 2Hz protocol (Figure 43). The pump flow rate was 1.5mL.min-1 for this protocol. No blood samples were
taken.

Figure 4-3 Schematic representation of post-fatigue muscle protocol.
Schematic representation of post-fatigue muscle protocol.
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4.2.3.c Caffeine
In a subset of animals (4 OO, 4 LowFO and 4 ModFO), caffeine was injected inline following the normal 5Hz repeated bouts stimulation protocol in sequential,
increasing doses (2.5, 5 and 10μM). The muscle was stimulated immediately
following each injection at 5Hz (5s on/5s off) for a period of 90s with 2min rest
periods between each 90s bout (Figure 4-4). The first injection consisted of saline
only, given 2min following the end of the initial 5min of 5Hz repeated bouts
stimulation protocol. This served as a control for the caffeine injections. Caffeine
injections and subsequent 90s stimulation periods then followed. The entire
protocol was carried out at a flow rate of 1.5mL.min-1.

Figure 4-4 Timeline of events for caffeine protocol.
■ indicates period of 5Hz, 5s on/5s off stimulation. □ indicates rest period. The 5min
stimulation period represents the 5Hz repeated bouts protocol.

4.2.4 Data analysis and calculations
Force data and twitch characteristics were analysed using LabView for Windows
display/analyse software. Area under the curve for both the 2Hz and 5Hz 5min
stimulation bouts was calculated as the total area under all twitches over the 5min
period. This is a multi-factorial measure that gives a general analysis of the work
done by the muscle. It may be influenced by the twitch force amplitude as well as
the duration of each twitch and as such care must be taken in its interpretation.
The decline in force over the 5min period of 2 Hz stimulation was calculated as
(peak twitch force-last twitch force)/peak twitch force*100. The same equation
was used for calculating decline over the 5min of 5Hz stimulation but in this case,
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it was the decline of the first twitch of each 5s bout. The time to 50% was
calculated as the time (in seconds) for the twitch force (in the 2Hz protocol) or the
first force of each 5s bout (in the 5Hz protocol) to decline to 50% of peak twitch
force.

4.2.5 Malondialdehyde
Tissue malondialdehyde, a product of lipid peroxidation, was measured in the
gastrocnemius and soleus muscles from control and perfused hindlimbs from
animals that underwent the 5Hz repeated bouts stimulation protocol. A
Thiobarbituric Acid Reactive Substances (TBARS) assay kit (Cayman Chemical
Company, USA), was used to colorimetrically determine tissue MDA
concentration. The kit is based on the principle that MDA will form an adduct
with thiobarbituric acid (TBA) under acidic conditions at high temperatures. This
MDA-TBA adduct is measured colorimetrically at 530-540nM.

Briefly, muscle tissue (40-60mg) was homogenised in 250µL of a cell lysis buffer
(RIPA) and centrifuged at 1600*g for 10min at 4°C. MDA standards were
prepared as per kit instructions with a concentration range of 0.625uM to 50uM.
Tissue supernatants and MDA standards (100uL) were combined with an
equivalent amount of SDS solution (provided in kit) and 4mL of colour reagent
(containing thiobarbituric acid, acetic acid and sodium hydroxide) was added.
Samples and standards were placed in a water bath (100°C) for one hour for the
formation of the MDA-TBA adduct. The reaction was stopped by placing the
samples in an ice bath for 10min, followed by centrifugation at 1600*g at 4°C.
The supernatant (150uL) was transferred, in duplicate, to a 96-well plate and
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absorbance was read at 530-540nm using a Powerwave X340 plate reader with
KC Junior software (Bio-tek Instruments Inc. USA) Absorbance was corrected for
background (water blank) and MDA concentration was calculated from the
standard curve.

4.2.6 Statistics
Results are expressed as mean±SEM. One-way ANOVA with Tukey post-hoc
comparison of means was used to analyse any effect of diet on force production in
the 2Hz continuous twitch protocol, muscle function parameters and hindlimb
perfusion pressure and resistance in all protocols as well as blood gases and
electrolytes. Statistix for Windows (Analytical Software, USA) was used to
perform all ANOVA. Linear mixed models analysis was employed to assess any
dietary effect on force production in the 5Hz repeated bouts stimulation protocol.
Linear mixed models extends the general linear models (including repeated
measures ANOVA) to allow the use of data where observations are dependent.
Standard repeated measures ANOVA could not be conducted with the software
available (Statistix) unless equal numbers of animals was available for each
group. Therefore in the present case, linear mixed models analysis was used to
assess the diet*time interaction. SPSS (version 15) was used to perform the linear
mixed models analyses. Where trends for a fish oil effect were evident and there
were no significant differences between LowFO and ModFO diets, these two diets
were pooled and compared against the OO control group. p<0.05 was accepted as
statistically significant.
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4.3 Results
4.3.1 Effects of diet on body weight and muscle weight
There were no significant dietary differences in body weight or Gastrocnemiussoleus-plantaris/tibia length ratio (GSP/TL) at time of euthanasia within each
experimental group (Table 4-1). Regardless of diet, there was a significant
difference in body and muscle weight between the normal muscle and post-fatigue
muscle groups (all p <0.01). This is due to the difference in age, with the postfatigue muscle group being older and therefore having a larger body and skeletal
muscle mass.

Table 4-1 Effect of diet on baseline rat parameters at euthanasia
OO
LowFO
ModFO
Normal muscle
Body weight (g)

463 ± 30

457 ± 44

464 ± 12

Tibia Length (mm)
Gastrocnemius-soleus-plantaris
weight/ tibia length ratio

43.61 ± 0.46

43.03 ± 0.74

43.98 ± 0.52

6.91 ± 0.24

7.30 ± 0.24

6.89 ± 0.15

Post-fatigue muscle
Body weight (g)

506 ± 17

559 ± 24

540 ± 16

Tibia Length (mm)
Gastrocnemius-soleus-plantaris
weight/ tibia length ratio

43.54 ± 0.52

44.64 ± 0.91

44.52 ± 0.68

7.41 ± 0.15

7.60 ± 0.12

7.71 ± 0.09

Values are mean±SEM. n=4-7 per group for normal muscle and 6-8 per group for post-fatigue
muscle. Rat age ranged from 16-17 weeks in normal study group and 22-24 weeks in the postfatigue study group.

4.3.2. Force characteristics
4.3.2.a 2Hz continuous twitch stimulation
In all dietary groups the 50Hz tetanic contraction produced after 5min of 2Hz
stimulation produced significantly less force than the initial tetanic contraction
(Figure 4-5). There was a significant dietary effect of FO on tetanic force
production, with the ModFO group being significantly greater than the OO group
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in both the initial (p=0.022) and final (p=0.010) tetanic contractions. The response
to 2Hz continuous twitch stimulation was significantly greater in the ModFO
group than the OO group (First twitch p=0.019, Peak twitch p=0.001 and Last
twitch p=0.021). The force of the last twitch in the LowFO group was
significantly different to the OO group. There was a non-significant trend to
greater force production of the first and peak twitch contractions of the LowFO
group. Statistics revealed no difference between LowFO and ModFO groups and
therefore animals in these groups were pooled and compared to the OO diet. This
analysis revealed significantly greater force production in the combined FO group
compared to the OO group in all stages of the protocol (all p<0.01).

Figure 4-5 Effect of diet on tetanic force production and throughout 2Hz continuous
twitch stimulation protocol.
Force production in N/100g of GSP tissue. Tetanus 1 and Tetanus 2 represent the tetanic
50Hz, 1 sec contractions. First twitch, Peak twitch and Last twitch represent the force
generated in the first, peak and last twitches of the 2Hz stimulation. *p<0.05 vs. OO diet.
#p<0.05 all FO combined vs. OO. n=11-15 per group. Inset: example trace indicating
tetanus 1, the first, peak and last twitch of 2Hz stimulation and tetanus 2.
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There was a significant effect of diet on maximum rate of contraction for both
tetanic and twitch contractions (all p<0.05), with post-hoc testing revealing the
ModFO group having greater rates compared to the OO group throughout the
protocol (Table 4-2). The LowFO group also significantly differed from the OO
group in the first twitch of the 5min 2Hz stimulations. There was no difference
between FO groups (all p>0.05) so data was pooled and compared against the OO
group, revealing significantly greater rates of contraction throughout the protocol
(all p<0.05). Pooled analysis also revealed a significantly greater relaxation rate in
FO animals in the first twitch of the 2Hz stimulation period (p=0.03), with a trend
for faster relaxation also evident in the last twitch of the 2Hz stimulation period
(p=0.06) as well as in the first tetanic contraction (p=0.09).

Table 4-2 Effect of diet on maximum contraction and relaxation rates throughout
2Hz continuous twitch stimulation protocol
OO
LowFO
ModFO
Max. contraction rate (dF/dt)
Tetanus 1

97.94 ± 12.17

138.92 ± 17.48

168.18 ± 10.42*#

First twitch

71.89 ± 11.35

148.34 ± 16.59*

163.38 ± 12.78*#

Last twitch

16.78 ± 4.12

49.32 ± 7.38

58.13 ± 7.48*#

Tetanus 2

39.05 ± 5.50

70.00 ± 10.61

79.61 ± 8.82*#

Max. relaxation rate (-dF/dt)
Tetanus 1

106.74 ± 16.92

151.31 ± 21.46

170.27 ± 18.15

First twitch

62.54 ± 8.79

95.83 ± 15.96

111.35 ± 12.72#

Last twitch

10.61 ± 2.56

20.77 ± 3.93

21.61 ± 2.52

Tetanus 2

33.70 ± 6.31

45.22 ± 7.61

50.19 ± 5.67

Values are mean±SEM. *p<0.05 vs. OO diet. #p<0.05 all FO combined vs. OO. n=11-15 per
group.

A greater area under the curve was exhibited in both FO groups (p<0.001). There
was no significant effect of diet on time for twitch decline to 50% of the peak
twitch or the percent decline of force over the 5min period, however FO animals
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tended to decline to a lesser extent over 5min (p=0.144, Table 4-3). Pooled
analysis revealed a significantly less decline in force in the FO animals compared
to OO (p=0.048) but no significant effect of FO on time to 50% (p=0.531).

Table 4-3 2Hz Muscle function parameters
OO
LowFO
Area under the curve
2768 ± 555
7644 ± 977*
Time to 50% (s)
141 ± 28
143 ± 16
% Change in Force over 5min
-80.3 ± 4.5
-70.0 ± 3.7

ModFO
9162 ± 1312*#
173 ± 22
-70.4 ± 3.6#

Values are mean±SEM. *p<0.05 vs. OO diet. #p<0.05 all FO combined vs. OO diet. n=11-15 per
group.

4.3.2.b 5Hz repeated bouts stimulation
In normal muscle the general shape of both the first and last twitch force in
repeated 5Hz bouts was characterised by a maximal force production reached
within the first few bouts of stimulation, followed by a rapid decline in force to a
plateau level maintained over the final minutes of the protocol (Figure 4-6). There
was a significant effect of time on force production in all analyses (Table 4-4, all
p<0.05). Force production (First twitch and Last twitch of each bout) was initially
similar in all dietary groups however the FO rats fatigued at a slower rate (less
drop off of force) in the early stages and maintain a greater force production in the
later stages of the protocol. This observed effect of FO was significantly different
to the OO control group, as indicated by the significant diet*time interaction
(Table 4-4, First twitch p=0.020 and Last twitch p<0.001). Furthermore, there
were no significant differences between LowFO and ModFO groups (First twitch
p=1.000, Last twitch p=0.993) and hence these animals were pooled to reveal a
significant FO effect on force production throughout the protocol compared to the
OO dietary group (First twitch and Last twitch p<0.001).
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In post-fatigue muscle, force production was significantly lower compared to
normal muscle and exhibited a much flatter curve for both the first and last
twitches (Figure 4-7). Compared to the OO group, both FO groups showed greater
force production throughout the protocol, with the effect approaching significance
(First twitch p=0.06 and Last twitch p=0.10. This effect was greater in the ModFO
group in the initial stages of the protocol (2min) compared to the LowFO group
resulting in a significant difference in First twitch between the two FO diets
(p=0.01). Pooled analysis of all FO animals compared to OO animals revealed a
significant dietary effect (First twitch p=0.013, Last twitch p=0.033) but no
significant diet*time interaction (First twitch p=0.989 and Last twitch p=0.630).
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Figure 4-6 Effects of diet on force production during 5Hz repeated bouts stimulation
in normal muscle.
a) and b) force production (N.100g-1 GSP) for first (Ft) and last (Lt) twitch in each bout of
stimulation respectively. *p<0.05 OO vs. FO. †p<0.05 effect of time. n=4-7 per group.
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Figure 4-7 Effects of diet on force production during 5Hz repeated bouts stimulation
in post-fatigue muscle.
a) and b) force production (N.100g-1 GSP) for first (Ft) and last (Lt) twitch in each bout of
stimulation respectively. *p<0.05 OO vs. FO. †p<0.05 effect of time n=6-8 per group.
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Table 4-4 Statistical analyses of 5Hz repeated bouts stimulation force production data

Normal muscle

Ft

Lt

Post-fatigue muscle

diet

time#

int

diet

time#

int

OO, LowFO &
ModFO

0.074

<0.001*

0.020*

0.031*

<0.001*

0.060

OO vs. pooled FO

0.021*

<0.001*

<0.001*

0.013*

<0.001*

0.989

LowFO vs. ModFO

0.855

<0.001*

1.000

0.465

<0.001*

0.010*

OO, LowFO &
ModFO

0.170

<0.001*

<0.001*

0.060

<0.001*

0.104

OO vs. pooled FO

0.054

<0.001*

<0.001*

0.033*

<0.001*

0.630

LowFO vs. ModFO

0.847

<0.001*

0.993

0.559

<0.001*

0.145

a) all 3 diets inclusive. b) OO vs. FO. c) LowFO vs. ModFO. Ft and Lt indicate first and last
twitch in each 5s bout of stimulation. int= diet*time interaction. *p<0.05. #significant effect of
time

There was a significant effect of diet on maximum rate of force development of
the first twitch but no difference in the rate of relaxation of the last twitch of each
5s bout of stimulation in normal muscle (diet*time interaction p=0.016 and
p=0.398 respectively) (Figure 4-8), with the rate of force development being
lower in the OO dietary group. Pooled analysis of all FO animals vs. OO animals
further revealed this effect (p<0.001) of FO on the maximum rate of contraction
and also revealed an effect on the maximum rate of relaxation (p=0.006). In postfatigue muscle, there was no significant effect of diet on the maximum rate of
contraction (p=0.982) but a non-significant trend for FO animals to exhibit a
greater rate of relaxation was evident (p=0.115). Pooled analysis indicated no
effect of fish oil on maximum rate of contraction or relaxation (p=0.993 and 0.891
respectively).
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Figure 4-8 Effect of diet on maximum rates of contraction (dF/dt) of the first and
relaxation (-dF/dt) of the last twitch of each 5s bout of stimulation.
a) normal muscle. n=4-7 per group. b) post-fatigue muscle. *p<0.05 OO vs. FO. †p<0.05
effect of time. n=6-8 per group.

The area under the curve (indicating work performed) was greater in both FO
groups in normal muscle (p=0.004) (Table 4-5). In post-fatigue muscle there was
a similar trend with both FO groups having larger areas compared to the OO
group (p=0.117). The time it took for the first twitch force to decline to 50% of
the peak force was also greater in the fish oil groups (p=0.02 for both normal and
post-fatigue muscle). Although only significant in the ModFO group in the normal
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muscle and LowFO group in the post-fatigue muscle, the trend for the other FO
groups in each condition was in the same direction. There were no significant
differences between dietary groups in the decline of the first twitch force (Ft) over
the 5min period in normal muscle, although there was a trend for the FO groups to
decline less (p=0.132). In post-fatigue muscle, the LowFO group alone exhibited
significantly less decline of first twitch force over the 5min protocol (p= 0.032).

Table 4-5 Effect of diet on muscle function
OO
LowFO

ModFO

Normal muscle
Area under the curve

13681 ± 1586

24406 ± 1459*

25743 ± 2703*#

Time to 50% (s)

73 ± 10

118 ± 14

126 ± 14*#

% Change in Ft force

-79.0 ± 3.2

-67.6 ± 1.8

-68.5 ± 5.0#

Post-fatigue muscle
Area under the curve

2424 ± 764

6817 ± 1719

7944 ± 2210#

Time to 50% (s)

183 ± 39

291 ± 6*

215 ± 28

% Change in Ft force

-64.0 ± 10.9

-37.9 ± 4.6*

-61.7 ± 6.6

Values are mean±SEM. *p<0.05 vs. OO diet. #p<0.05 all FO combined vs. OO. n=4-7 per group
for normal muscle and n=6-8 per group for post-fatigue muscle.

Pooled analysis of FO animals compared to OO group revealed significant FO
effects pertaining to area under the curve (p<0.001), time to 50% (p=0.006) and
force decline (p=0.041) in normal muscle. In post-fatigue muscle there was a
significant effect of FO on area under the curve (p=0.04), a trend of longer time to
fatigue to 50% (p=0.067) but no effect on decline (p=0.189) compared to the OO
dietary group.
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4.3.3 Blood gases and pH
At rest there were no significant differences in hindlimb O2 consumption between
diets, however during the 5Hz repeated bouts stimulation and recovery, the FO
groups consumed more O2 compared to the OO group (all p<0.05)(Figure 4-9).
There was no significant dietary effect observed in carbon dioxide production or
pH however there was a trend for the FO groups to have a lower pH at the end of
the stimulation protocol and during recovery approaching significance at the end
of stimulation (p=0.0613).

No differences between FO groups in any parameter were observed and as such
these animals were pooled and compared to the OO group. This analysis
strengthened the observation of greater O2 consumption during contractile activity
and recovery in FO animals (stim. 60 p=0.061, stim. 5min p<0.01, rec. 4min
p=0.005). The lower pH observed in FO animals was significant at the end of
stimulation (p=0.042) and the trend continues during recovery (p=0.114).
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Figure 4-9 Effect of diet on blood gases and pH at various stages throughout the 5Hz
repeated bouts stimulation protocol (normal muscle).
a) O2 consumption, b) CO2 production and c) pH. stim. 60s = 60 seconds after the
beginning of stimulations, stim. 5min = the end of stimulation protocol, rec 4min=during
recovery, 4 minutes after the end of stimulations. *p<0.05 ModFO vs. OO, **p<0.05
LowFO and ModFO vs. OO. #p<0.05 all FO combined vs. OO. n= 3-6 in each group for
each stage.
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4.3.4. Hindlimb Perfusion Pressure and resistance
4.3.4.a Hindlimb perfusion pressure response to change in flow rate (i.e. FMD 11.5mL.min-1)
In normal muscle, baseline perfusion pressure was similar across all dietary
groups at both 1mL.min-1 and 1.5mL.min-1 flow rates (all p>0.05, Table 4-6).
Perfusion pressure was higher in post-fatigue muscle compared to normal muscle,
in OO dietary group (1mL.min-1 p=0.018 and 1.5mL.min-1 p=0.031).

Table 4-6 Effect of increasing flow rate (from 1mL.min-1 to 1.5mL.min-1) on
perfusion pressure in normal and post-fatigue muscle
OO
LowFO
ModFO
Normal muscle
-1

Pressure (mmHg) at 1mL.min

Pressure (mmHg) at 1.5mL.min-1

73 ± 11

77 ± 2

76 ± 4

106 ± 13*

109 ± 6*

104 ± 5*

Post-fatigue muscle
-1

Pressure (mmHg) at 1mL.min

Pressure (mmHg) at 1.5mL.min

-1

131 ± 14†

83 ± 10

82 ± 10

143 ± 14*†

101 ± 7*

106 ± 8*

-1

Values are mean±SEM. *p<0.05 vs. pressure at 1mL.min within each dietary group. †p<0.05 OO
vs. other dietary groups. n=4-5 per group for normal and n= 4-6 per group for post-fatigue muscle.

When blood flow to the hindlimb was increased, the hindlimb perfusion pressure
rose (Table 4-6) and resistance tended to decrease in response to an increase in
flow rate to the hindlimb (Figure 4-10). The increase in perfusion pressure was
significantly less in combined FO diets (pooled analysis p=0.020) and in LowFO
alone than in the OO group (p=0.029). In post-fatigue muscle, there was less
change in perfusion pressure in response to the increase in flow rate leading to
greater decrease in vascular resistance than that seen in normal muscle. There was
a non-significant trend for each of the FO groups to exhibit less change in
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vascular resistance compared to the OO group (p=0.073). This lesser decrease in
resistance reached statistical significance in the pooled analysis (p=0.036).

Figure 4-10 Effect of increasing flow rate from 1 to 1.5mL.min-1 on hindlimb
perfusion pressure and resistance in normal (a) and post-fatigue muscle (b).
*p=0.029 vs. OO diet. #p<0.05 all FO combined vs. OO. n=4-5 per group for normal
muscle and n=5-7 per group for post-fatigue muscle.
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4.3.4.b Hindlimb perfusion pressure during muscle contraction (at 1.5mL.min-1)
Hindlimb perfusion pressure decreased during muscle contractions induced by
either 2Hz continuous twitch or 5Hz repeated bouts stimulation (Table 4-7). Most
dietary groups showed significant reductions in perfusion pressure (all p<0.05)
and non-significant trends were found in the other groups (OO 5Hz normal
protocol p=0.079, LowFO 5Hz post-fatigue protocol p=0.102). There were no
differences in perfusion pressure between dietary groups at rest or during muscle
activity in the 2Hz continuous twitch protocol or in the 5Hz repeated bouts
stimulation protocol in normal muscle (all p>0.05). In post-fatigue muscle
perfusion pressure was higher at rest in the OO group (p=0.031) compared to the
FO groups and there was a non-significant trend towards higher perfusion
pressure during contractions in post-fatigue muscle (p=0.078).

Table 4-7 Effect of muscle contraction on perfusion pressure at 1.5mL.min-1 flow
rate
OO
LowFO
ModFO
2Hz continuous twitch protocol
Resting Pressure (mmHg)

116 ± 10

115 ± 13

103 ± 7

Contracting Pressure (mmHg)

99 ± 6*

98 ± 12*

92 ± 6*

5Hz repeated bouts protocol-normal
Resting Pressure (mmHg)

106 ± 13

109 ± 6

104 ± 5

Contracting Pressure (mmHg)

92 ± 13

85 ± 3*

88 ± 4*

5Hz repeated bouts protocol- post-fatigue
Resting Pressure (mmHg)

143 ± 14†

101 ± 7

106 ± 8

Contracting Pressure (mmHg)

124 ± 12*

93 ± 5

96 ± 8*

Values are mean±SEM. *p<0.05 vs. resting pressure within each dietary group. †p<0.05 OO vs.
other dietary groups. n= 4-10 per group for 2Hz continuous twitch protocol, n=4-5 per group for
5Hz repeated bouts protocol-normal muscle and n=4-6 per group for 5Hz repeated bouts protocolpost-fatigue muscle.
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The decreases in hindlimb perfusion pressure in response to muscle contractile
activity is reflected in a reduction in resistance (Figure 4-11). There were no
significant differences in this response between dietary groups in the 2Hz
continuous twitch protocol (p=0.457). In the 5Hz repeated bouts stimulation
protocol, responses under each condition were different, with FO showing a
greater percentage fall in resistance than the OO control group in normal muscle
(p=0.031). There were no significant differences between groups in the postfatigue muscle (p=0.331). Pooled analysis further supported the greater FO
response in normal muscle (p=0.010) but failed to reveal a significant difference
in the post-fatigue muscle (p=0.145).

Figure 4-11 Effect of diet on change in resistance in response to activity in each
protocol.
*p<0.05 vs. OO diet. #p<0.05 all FO combined vs. OO by pooled analysis. n= 4-10 per
group for 2Hz continuous twitch protocol, n=4-5 per group for 5Hz repeated bouts
protocol-normal muscle and n=4-6 per group for 5Hz repeated bouts protocol-postfatigue muscle.
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4.3.5 Caffeine
The shape of the curve for each 90s period of 5Hz repeated bouts stimulation was
similar to that of the 5min period, with an initial increase in force production of
the first twitch of each bout, followed by a rapid decline and subsequent
maintenance of force production for the remainder of the protocol. This was
similar across all dietary groups, for each dose of caffeine as well as the saline
injection (see example trace Figure 4-12).

Figure 4-12 Example trace of caffeine extension of protocol.

There was no significant dietary effect on raw force production in response to 0,
2.5, 5 and 10mM caffeine injections (data not shown), however a dietary effect
emerged when expressed as a percentage of the peak force reached during the
initial 5min period of 5Hz repeated bouts stimulation (Figure 4-13). This
calculation of relative force production of the first twitch of each bout of
stimulation represents a better indicator of recovery of force production after each
2min rest period as well as the response to caffeine. The ModFO dietary group
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showed a greater recovery of force after each 2min rest period, both in the absence
and presence of caffeine, as indicated in the first couple of bouts of each 90sec
period. The LowFO response was similar but to a much lower extent.
Furthermore, both FO groups showed a tendency to maintain a higher force
production during the later stages of the 90s period. This resulted in a significant
diet*time interaction regarding relative force production in all of the 90s
stimulation periods (all p>0.01).

Figure 4-13 Effect of diet on force production in the presence of caffeine.
Ft is expressed as a percentage of the peak Ft reached during the 5Hz repeated bouts
stimulation protocol. Time (in seconds) for each dose is from the beginning of the 90s
period of repeated bouts stimulation, following a 2min rest between doses. *p<0.05 OO
vs. FO. †p<0.05 effect of time. n=3-4 for each dietary group for each dose of saline or
caffeine.
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4.3.6. Lipid oxidation
The concentration of malondialdehyde in the soleus muscle was greater than in
the gastrocnemius across all dietary groups (all p<0.05, Figure 4-14). There was
no significant effect of diet on malondialdehyde concentration in either muscle
(all p>0.05).

Figure 4-14 Effect of diet on MDA concentration in the Gastrocnemius and Soleus
muscles of control and perfused limbs.
n=6, 4 & 6 for OO, LowFO and ModFO diets respectively.
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4.4 Discussion
The present study demonstrated that fish oil feeding enhanced contractile function
and promoted fatigue resistance under a wide range of conditions in skeletal
muscle. Specifically, fish oil improved contractile force during high frequency
tetanic contractions, continuous low frequency single twitch contractions and
repeated bouts of low frequency stimulation. The ability of dietary fish oil (5%) to
improve muscle function has been reported previously for single twitch
contractions (Peoples 2004). This study confirmed that preliminary work and
extends it to identify a similar effect of fish oil at low dietary intakes and across a
range of contraction types. The dose of 1.25% (ModFO) was associated with
statistically significant improvements in skeletal muscle contractile function
across a range of measures in both the 2Hz and 5Hz protocols. The analysis of
variance revealed a dose related effect of fish oil, with a significant effect of diet
in most cases. While there were only some significant effects of the 0.31% dose
(LowFO), there was generally a non-significant trend towards an effect in other
measures and increasing the number of observations would increase the power for
statistical analysis. In an attempt to overcome the limitation in power, both FO
groups were pooled (where applicable) for further analysis and comparison
against the OO dietary group. This pooled analysis further strengthened the case
for favourable effects of fish oil in skeletal muscle function.

The characteristics of muscle contraction in both 2Hz single twitch and 5Hz
submaximal repeated bouts protocols in the present study indicate that the decline
in force is representative of low frequency fatigue (Jones 1996; Keeton & BinderMacleod 2006). More specifically, in both protocols, there was an initial
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potentiation or staircase effect prior to the rapid decline in force (Jones 1996) and
the force declined to 50% of peak force or less (Jones 1996; Keeton & BinderMacleod 2006). In addition, the decline in contractile function was long lasting
(Jones 1996; Keeton & Binder-Macleod 2006) and recovery was not immediate,
as evident by the lower force development in post-fatigue muscle stimulation
(20min after the end of the previous stimulation protocol).

4.4.1. Fish oil in muscle contractile function and fatigue
By understanding the physiology behind the different types of contractions, we
can begin to speculate how fish oil may be exerting its favourable effects. The
improved contractile responses of FO muscles can be divided into initial
contractile enhancements, fatigue resistance and improved recovery.

4.4.1.a Initial contractile improvement
Improvements in tetanic force production as well as single twitch force production
suggests that fish oil primes the resting, normal muscle for better performance.
Especially in the first tetanic contraction, but also in the initial stage of the 2Hz
continuous single twitch contractions (first to peak force), when fatigue has not
yet significantly developed and therefore improvements in these contractions are
likely due to optimising processes within the muscle itself, rather than interfering
with fatigue processes. The major muscle contributing to the effects in the GPS
bundle in the current experiment is the gastrocnemius muscle, simply due to its
relative size. Moreover, the gastrocnemius exhibited a greater concentration of
DHA in its membranes, compared to the soleus and left ventricle (Chapter 3). It is
therefore plausible that the improved tetanic and initial twitch contractions may be
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related to the increased incorporation of DHA into gastrocnemius muscle
membranes, especially given the relationship between membrane incorporation of
DHA and physiological function observed in the heart (McLennan et al. 2007)
and the similarities between the heart and skeletal muscle in terms of membrane
DHA incorporation (Chapter 3), O2 consumption (Peoples 2004; Pepe &
McLennan 2002) and recovery from ischaemia or fatiguing contraction
(Abdukeyum et al. 2008; Peoples 2004). In the heart, n-3 PUFA improves various
aspects of Ca2+ homeostasis (Ferrier et al. 2002; Negretti et al. 2000; Pepe et al.
1994). There is preliminary evidence to suggest that n-3 PUFA may also affect
Ca2+ dependent processes in skeletal muscle (Dulloo et al. 1994; Nurnberg et al.
1998). Intracellular Ca2+ plays are large role in skeletal muscle contraction and
relaxation (Berchtold et al. 2000) and increased Ca2+ content and release from the
SR will result in greater force of contraction (Berchtold et al. 2000). Therefore,
improved Ca2+ homeostasis in fish oil fed animals may contribute to the enhanced
contractile force observed in response to both high-frequency tetanic stimulation
and low frequency single twitch stimulation. In myocytes, incubation with DHA
not only prevents digitalis-induced Ca2+ overload, but also prevents the gradual
cellular Ca2+ loss and decline in contractile function that occurs when Ca2+
channels are inhibited (Hallaq et al. 1992).

4.4.1.b Fatigue resistance
The maintenance of higher force production over time suggest that n-3 PUFA, in
addition to enhancing normal muscle contractile function, also may modify the
fatigue processes. The ultimate result is resistance to fatigue. This is evident in
both the 2Hz continuous twitch protocol and the 5Hz repeated bouts stimulation
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protocol by the less overall decline of force and longer time taken for force to fall
to 50% in FO animals. The repeated single twitch protocol substantiates
preliminary work that implicated n-3 PUFA in resistance to fatigue (Peoples
2004). Furthermore, the same observation was made during the intense 5Hz
repeated bouts protocol that is more representative of normal human muscle
activation patterns (Vollestad et al. 1997). There were two distinct phases to the
contractile function in the more intense 5Hz repeated bouts protocol. The first is
rapid fatigue development in the early stages of the protocol, while the second is
maintenance of a steady state of force production in the latter stages of the
protocol.

4.4.1.b.i) Early fatigue resistance
A notable observation in normal muscle was the slower development of fatigue in
the first 1-2min of the protocol in FO animals. During low frequency stimulation,
the early drop in force corresponds to metabolic changes (Baker et al. 1994).
Furthermore, this type of prolonged submaximal activity has a higher O2 and
energy cost due to greater recruitment of type II fibres (Hood et al. 1986;
Vollestad et al. 1997). The intensity of the 5Hz stimulation protocol therefore
stimulates heightened anaerobic metabolism and production of metabolic products
that contribute to fatigue in this protocol, more so than the lower intensity 2Hz
protocol where oxidative metabolism dominates (Fitts 1994). Given the difference
in muscle fibre types, the soleus being slow-twitch oxidative, the gastrocnemius
mixed glycolytic and the plantaris predominantly fast-twitch glycolytic (Delp &
Duan 1996), and the gastrocnemius and plantaris muscles being the largest of the
GSP bundle, the decline in force development in the early part of the protocol is
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likely to be more related to fatigue within the gastrocnemius and plantaris muscles
(McAllister & Terjung 1991). In further support of a greater metabolic effect on
fatigue in the early stages of this protocol, the gastrocnemius and plantaris muscle
exhibit a greater rate of fatigue compared to the soleus (Meyer & Terjung 1979)
and metabolic changes are greater in these fast-twitch fibres (Hintz et al. 1982).
Metabolic alterations such as reduced pH and high energy compounds (PCr and
ATP) and increased lactate, the derived H+ and Pi contribute to fatigue by
interfering with various aspects of Ca2+ handling (Allen et al. 2008b).

The higher membrane DHA in skeletal muscle after FO feeding, especially in the
gastrocnemius (Chapter 3), may contribute to the slower rate of fatigue observed
in FO animals, given the metabolic characteristics of this muscle and its
significant contribution to the force development in the muscle bundle being
investigated. Incorporation of membrane DHA may to affect a range of cellular
processes (Spector & Yorek 1985). One effect of dietary n-3 PUFA that has been
confirmed in the literature is the modification of cardiac intracellular Ca2+
homeostasis (McLennan & Abeywardena 2005). Limited evidence in skeletal
muscle suggests a similar effect in skeletal muscle (Dulloo et al. 1994; Nurnberg
et al. 1998). Therefore, the fatigue resistance effect of fish oil in the early stages
of the 5min protocol in the current study may be related to improved Ca2+
handling due to the higher concentrations of membrane DHA, attenuating the
fatigue associated with metabolic alterations. Furthermore, the increased O2
consumption in FO animals may also be related to the early fatigue resistance.
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The relationship between O2 and muscle contractile function is complex and the
literature not always consistent (Amann & Calbet 2008; Hogan & Welch 1986)
however it is generally accepted that O2 is an important regulator of contractile
function and fatigue resistance in skeletal muscle (Amann & Calbet 2008; Hepple
2002; Hogan et al. 1999a; Hogan et al. 1996; Hogan et al. 1999b; Hogan et al.
1994). Enhanced O2 delivery attenuates the rate of fatigue development while
reduced O2 delivery augments the development of fatigue due to the greater
accumulation of metabolic products (Amann & Calbet 2008; Hogan et al. 1999b).
More specifically, in a similar in vivo hindlimb preparation in the dog, there is a
tight correlation between O2 delivery and contractile force development during
submaximal contractions (Hogan et al. 1996). Delivery of O2 in the current study
was regulated across all groups due to the controlled hindlimb perfusion rate
however the higher O2 extraction in FO animals may also impart a similar effect
on contractile performance as would an increase in O2 delivery via increases in
blood flow. Oxygen availability is required for prevention of fatigue (Hogan et al.
1994) as well as contractile force recovery after ischaemia, independent of blood
flow (Hogan et al. 1999a). Maintenance of O2 consumption during hypoxia via
increased blood flow can also prevent fatigue (Amann & Calbet 2008). It is
therefore plausible that maintenance of a higher O2 consumption under normoxic
conditions, as in the current protocol, would also prevent or attenuate fatigue.
Indeed, exercise training provides a resistance to fatigue and is also associated
with an increase in O2 consumption due to increased O2 extraction (McAllister &
Terjung 1991). The heightened O2 consumption early in the repeated bouts
stimulation in FO animals may contribute to the observed fatigue resistance by
maintaining oxidative metabolism and subsequently preventing the build up of
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metabolic products that interfere with Ca2+ cycling and E-C coupling (Amann &
Calbet 2008). Indeed there was no evidence of a build up of metabolic products in
the FO animals at the 60s time point as indicated by the lack of dietary difference
in pH.

4.4.1.b.ii) Maintenance of steady state contractile function
Following the early fatigue there was little decline in force in the latter stages of
the protocol, with all dietary groups being able to maintain a plateau of steady
state force production. The oxidative, fatigue resistant characteristics of the soleus
muscle, compared to the gastrocnemius and plantaris muscles, suggest that it may
be a significant contributor to this later maintenance of force production in all
dietary groups (McAllister & Terjung 1991; Zhang et al. 2006). Furthermore,
adaptations in the soleus muscle of FO-fed animals may contribute to the higher
maintained plateau of force production (McAllister & Terjung 1991). Despite
lower pH at the end of the protocol in FO animals, indirectly indicating increased
production of metabolic products, the higher force production maintained in the
FO animals suggests that n-3 PUFA may be acting to prevent the detrimental
effects of these by-products on Ca2+ handling and E-C coupling (Allen et al.
2008b), thereby optimising muscle contractile function. As discussed previously,
incorporation of DHA into skeletal muscle membrane phospholipids (Chapter 3)
may be contributing to this improved contractile function, potentially by
interacting with cellular Ca2+ homeostasis (Dulloo et al. 1994; McLennan &
Abeywardena 2005; Nurnberg et al. 1998).
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The maintenance of higher steady state of developed force may also be related to
the increased O2 consumption observed in FO animals in more than one way. That
is O2 consumption drives contraction and contraction drives O2 consumption.
Firstly, there is a close association between O2 and force development, such that a
change in contractile force parallels a change in respiration in order to maintain
the tightly coupled relationship between mitochondrial respiration and force
production (Hogan et al. 1998; Hogan et al. 1996). Although, this O2 conforming
property of skeletal muscle is generally observed as a down-regulation of force
production in response to reduced O2 availability (Hogan et al. 1998; Hogan et al.
1996), it may also allow FO animals to maintain a higher steady state of force
production due to the higher O2 consumption. Secondly, there is also the
possibility that the increased work produced by the muscles of FO animals may
contribute to the heightened O2 consumption towards the latter stages by driving
the need for more O2, especially since the pH at the end of the protocol was lower
in FO animals, indirectly indicating a higher concentration of metabolic products.
It is well established that higher temperature and lower pH is associated with a
right shift in the oxy-haemoglobin dissociation curve that results in greater
unloading of O2 from haemoglobin (Boron 2003). The lower pH, and likely higher
muscle temperature in FO animals due to greater force development may
contribute to the greater O2 consumption. Further suggesting an increased drive
for O2 is the greater active hyperaemic response observed in FO animals, as active
hyperaemia is driven by metabolic by-products (Laughlin et al. 1996). Active
hyperaemia describes an increased blood flow to a region due to dilation of
arteriolar smooth muscle and increased recruitment of capillaries in active
response to an increase in metabolism of that region (as discussed in section 4.4.5
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(Dua et al. 2009)). Although it is not possible to increase total O2 delivery via
vasodilation in the current experimental model due to the controlled hindlimb
perfusion rate, the result indicates that this would occur if blood flow was not
fixed. Changes in distribution of flow are reported in skeletal muscle to redirect
flow between nutritive (active metabolising tissues) and non-nutritive pathways
(Clark et al. 2000). This hindlimb model has been used to verify such distribution
(Hoy et al. 2009). Blood flow redistribution may therefore contribute to the higher
O2 consumption driven by muscle contraction in FO animals. It is likely that a
combination of O2 driving contraction and contraction driving O2 demand are
behind the observed higher contractile force and O2 consumption in FO animals in
the present study.

4.4.1.c Muscle recovery
When the muscle was fatigued by prior activity, recovery was enhanced by FO
feeding with greater force development in subsequent tetanic contractions and
greater force development at the beginning and throughout a subsequent
prolonged period of repeated bout activity. In the current study, the second
tetanic contraction or second period of activity was likely performed when the
muscle was affected by low frequency fatigue, especially given the long time
period of recovery associated with this type of fatigue (Jones 1996; Keeton &
Binder-Macleod 2006). The slow recovery after low frequency stimulation that is
characteristic of low frequency fatigue is associated with disturbances in Ca2+
cycling and E-C coupling (Baker et al. 1993; Bruton et al. 1998; Jones 1996) and
Ca2+ is a target for n-3 PUFA action in the heart (McLennan & Abeywardena
2005; Pepe & McLennan 2002; Pepe et al. 1999) and potentially skeletal muscle

107

(Dulloo et al. 1994; Nurnberg et al. 1998). It is therefore likely that if fish oil is
acting to enhance Ca2+ handling during contraction to prevent fatigue, it is also
acting to improve function after muscle activity so that the muscle responds better
to subsequent stimuli (another bout of activity). Improved force recovery has been
observed previously in repeated bouts of single twitch stimulation (Peoples 2004).
Our results are in agreement with this, further validating the earlier observations
as an effect that is potentially important across a range of contraction modalities.
Recovery of repeated bouts of contraction was the only aspect of muscle function
and fatigue where a significant dose difference was evident in the effects of FO
feeding. While both FO doses sustained greater contractile force than the OO
group, the ModFO dose was associated with a significant increase in recovery of
the initial twitch force in the early phase which fatigued to be not different to the
LowFO group in the second phase. The differences can explain the results
pertaining to calculations of muscle function and fatigue resistance. These results
suggest that, within the range of human dietary intake, doses of FO within the
upper range may be required for enhancing recovery from fatiguing muscle
activity.

Of further interest in terms of a fish oil effect on muscle recovery is the pattern of
O2 consumption during recovery. While O2 consumption remained higher in the
FO than the OO groups during recovery, it was returning towards resting levels
four minutes after contraction had ceased, whereas O2 consumption was still
rising during recovery in the OO group. This improved recovery is in line with
previous work indicating quicker return to baseline O2 consumption during
recovery in fish oil-fed animals (Peoples 2004). This suggests a greater reserve in
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FO animals for increasing O2 consumption in a subsequent bout of muscle
activity. Direct comparisons between recovery O2 consumption and contractile
function cannot be made in the present study, as the measurements of recovery O2
consumption were taken in different animals to those where recovery contractile
performance was assessed. However, given the complex relationship between O2
consumption and muscle contractile function (Hogan et al. 1998; Hogan et al.
1996; Hogan et al. 1994), it is plausible that these effects may be related and thus
may offer, at least in part, an explanation for the improved contractile recovery in
FO animals after muscle stimulation.

4.4.2. Fish oil and O2 consumption
The higher O2 consumption observed in FO animals in this study is in contrast to
previous studies. In rats, dietary fish oil is associated with reduced O2
consumption in both cardiac (Pepe & McLennan 2002) and skeletal muscle
(Peoples 2004). Also, in humans during exercise, whole body O2 consumption
largely representing contracting muscle, was reduced by dietary fish oil
supplementation (Peoples et al. 2008). All of those differences are associated with
maintained or enhanced contraction. A possible explanation for the discrepancies
regarding skeletal muscle O2 consumption in the rat may lie in the different
stimulation protocols used. A more demanding 5Hz repeated bouts stimulation
protocol was used in the present study, as opposed to the 1Hz and 2Hz continuous
twitch protocols used in the earlier study. With a more intense protocol,
metabolism would likely be more glycolytic with a higher energy cost (Vollestad
et al. 1997), especially since the majority of fibres in the GSP bundle are
glycolytic (Delp & Duan 1996). This is evident from the lower pH observed in the
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current study in FO animals, whereas no reduction in pH was observed in that
preliminary study (Peoples 2004). The greater O2 consumption in the present
study is therefore indicative of the greater intensity of the stimulation protocol.
Maintaining oxidative metabolism is more efficient at generating ATP (Nadel
2003). Therefore, being able to extract more O2 in this more vigorous protocol
will delay the change from predominately oxidative to glycolytic metabolism and
prevent early build up of lactate and high-energy metabolites that contribute to
fatigue (Allen et al. 2008b; Fitts 1994), especially since the muscle types within
the GSP bundle are more prone to the generation of metabolic products (Hintz et
al. 1982)

Higher O2 consumption in the present study in FO animals was linked to
improved contractile performance and fatigue resistance and this effect was
independent of blood flow, as hindlimb perfusion was maintained at a constant
rate. This means that the heightened O2 consumption represents higher O2
extraction, rather than improved O2 delivery. Determining the mechanisms behind
higher O2 extraction in FO animals is beyond the scope of this study however, it
can be speculated that a number of factors might be involved. In exercise training,
where improved contractile performance is also associated with higher O2
consumption, possible contributors to the elevated O2 extraction are capillary
density and cellular myoglobin and mitochondrial content (McAllister & Terjung
1991). There is no direct evidence for an effect of fish oil on capillary density,
myoglobin or mitochondrial content in skeletal muscle, however, in the heart,
modified

mitochondrial

function,

and

particularly

protection

against

mitochondrial damage, may contribute to the cardioprotective effect of n-3 PUFA
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(Demaison et al. 1994; McLennan & Abeywardena 2005; Pepe et al. 1999).
Furthermore, effects of n-3 PUFA on red blood cell composition and deformity
may also improve O2 extraction by enhancing O2 unloading (Mills et al. 1993;
Poschl et al. 1996; van Bommel et al. 2001). Further research is necessary to
identify the exact mechanisms behind the greater O2 extraction in FO animals and
how this might more specifically relate to muscle contraction.

4.4.3. Mechanisms of fatigue and potential targets for fish oil action
This study is one of the first to identify a role of n-3 PUFA in skeletal muscle
function and fatigue resistance. It is therefore difficult to speculate on the exact
mechanisms that contribute to the fish oil effect. The results presented so far,
representing low frequency fatigue, and extrapolation from the associated
literature, especially cardiac studies, suggest that the main mechanism by which
n-3 PUFA may be improving muscle function is through modifications of cellular
Ca2+ homeostasis. Indeed disturbed Ca2+ cycling is one of the major mechanisms
of low frequency fatigue (Jones 1996; Keeton & Binder-Macleod 2006). Another
major mechanism of fatigue that may be associated with a fish oil effect is
modification of cellular redox balance (Allen et al. 2008b; Bruton et al. 1998).
The results of the present study, although inconclusive, provide preliminary
evidence that n-3 PUFA act via interfering with Ca2+ homeostasis and ROS.
Indeed, these mechanisms have also been implicated as a target for n-3 PUFA
action in the heart, with potentially parallel effects in skeletal muscle, given the
similarities in membrane composition (chapter 3) (Andersson et al. 2002; Ayre &
Hulbert 1997; McLennan 1993; McLennan et al. 1993; Peoples 2004) and
function (Wasserstrom 1997) in the heart and skeletal muscle.
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4.4.3.a. Caffeine and Ca2+ handling
Alterations in Ca2+ handling are implicated in the fatigue process (Allen et al.
2008b) and fish oil is linked to improved Ca2+ handling in both the heart and
skeletal muscle (Dulloo et al. 1994; McLennan & Abeywardena 2005; Nurnberg
et al. 1998). In light of this, and in order to investigate Ca2+ handling as a possible
mechanism in fish oil-mediated improved contractile function and fatigue
resistance, we injected caffeine into the perfusate supplying the hindlimb at the
end of the 5Hz repeated bouts stimulation protocol. Caffeine causes the release of
Ca2+ from the SR (Allen et al. 2008a). There was a non-significant trend for the
response to caffeine to be greater in FO animals, especially when expressed as a
percentage of peak force produced in the 5min 5Hz protocol. There are two
schools of thought of how fish oil may influence the caffeine response in this
protocol. Firstly, fish oil improves Ca2+ handling so the caffeine response may be
greater in FO than OO animals because of less Ca2+ depletion of the SR (Negretti
et al. 2000). Secondly, the improved Ca2+ handling with fish oil may obscure or
prevent any major effect of caffeine, as the muscle is working at an optimal level.
Thus the effect of caffeine may not be as great in FO animals as in OO animals as
caffeine may bring function of the OO group up to the level of FO group. Our
results of a trend towards higher caffeine responses in FO animals point toward
the former case. This is in agreement with another study that has used caffeine to
examine the effect of fish oil in low frequency continuous twitch stimulation.
Dietary fish oil in that case promoted a heightened contractile response to caffeine
in the form of improved recovery as a percent of peak twitch force (Peoples
2004). The improved contractile response to caffeine in the current study, in
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addition to the higher force development in FO animals in the absence of caffeine,
strengthens the case for a role of Ca2+ in the effect of n-3 PUFA.

It is therefore evident that improved Ca2+ homeostasis is one potential mechanism
behind the effect of fish oil in skeletal muscle. The exact alterations that occur
pertaining to the specific aspects of Ca2+ handling that may be targeted by n-3
PUFA in skeletal muscle are not well known. However, work in other tissues
suggests an overall effect of n-3 PUFA in improving function related to Ca2+
handling. In the heart, fish oil prevents Ca2+ overload (Leaf et al. 2005;
McLennan & Abeywardena 2005; Xiao et al. 2005) by inhibiting spontaneous
release of SR Ca2+ (Honen et al. 2003) and the L-type Ca2+ channel and increasing
SR Ca2+ content (Negretti et al. 2000; Pepe et al. 1994) as well as improving
mitochondrial metabolic processes that are disrupted by elevated Ca2+ (Pepe et al.
1999). Furthermore, contractility is maintained via voltage-sensitive release of SR
Ca2+ (Ferrier et al. 2002) when Ca2+-induced- Ca2+-release is inhibited (via the Ltype Ca2+ channel). Fish oil has also been shown to modulate Ca2+ homeostasis in
platelets (Podczasy et al. 1995) and smooth muscle cells (Nyby et al. 2003).
Obviously the physiology is different in different tissues and direct comparisons
cannot be made but the literature and the results of our study suggest that Ca2+
homeostasis may be a target for the action of n-3 PUFA in skeletal muscle. These
properties, especially the increased SR Ca2+ content and voltage-sensitive SR Ca2+
release, may be transferred to skeletal muscle, resulting in improved initial
contractile force and maintenance of contractile force over a given time period.
Indeed, there is preliminary evidence to suggest that n-3 PUFA may modify
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skeletal muscle Ca2+ homeostasis by modulating SR Ca2+ uptake however results
are limited and inconclusive and may be species specific (Nurnberg et al. 1998).

It must be noted that there were some limitations in the present study that may
have reduced our ability to definitively determine a significant effect of fish oil in
response to caffeine. The 2min rest period between the previous stimulation
period and the addition of caffeine may have interfered with the effect of the
caffeine injection on muscle force production. This rest period was due to
physical obstacles in procedure, not being able to inject caffeine and maintain
constant stimulation of the muscles at the desired rate. As such, the results of
caffeine may be overshadowed by the recovery of muscles that occurred during
these short (unstimulated) rest periods. And as observed previously in post-fatigue
muscles, this recovery is likely to be greater in FO animals.

Also, these experiments were only conducted on a few animals per dietary group.
This combined with the variation within groups limited the ability to identify any
effects statistically. In the future, it would be advantageous to perform these
experiments on a larger number of animals per group, as well and improving the
protocol so that the confounding effect of the rest period is reduced or abolished.

4.4.3.b. MDA and oxidative stress
Muscle fatigue is associated with disturbances in oxidation status (Allen et al.
2008b; Ferreira & Reid 2008; Powers & Jackson 2008) and fish oil has also been
widely implicated in the oxidative stress literature (Javouhey-Donzel et al. 1993;
Kubo et al. 1998; Richard et al. 2008; Saito 2000; Saito & Kubo 2003;
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Venkatraman et al. 1994). MDA was measured in both control and perfused
muscles, in an attempt to identify if changes in oxidative stress may contribute to
the fish oil effect observed in muscle contraction and fatigue resistance. In the
current study there were inconclusive results with no significant effect of n-3
PUFA on MDA concentration observed in the gastrocnemius or soleus under
these conditions in control or perfused muscles. It was expected that FO animals
might show elevated control MDA concentrations due to the higher
peroxidisability of n-3 PUFA in the cell membranes (Javouhey-Donzel et al.
1993), as confirmed in Chapter 3. The higher level of baseline oxidative stress
would stimulate the upregulation of antioxidant enzymes, which would protect the
muscles in times of increased oxidative stress (such as during muscle activity).
There are a couple of possible explanations for the inconclusive results.

Firstly, in control muscles, it is possible that there was an initial increase in lipid
peroxidation (Adler et al. 2003; Calviello et al. 1997; Javouhey-Donzel et al.
1993; Leibovitz et al. 1990; Saito & Kubo 2002; 2003; Song et al. 2000; Song &
Miyazawa 2001) but, because fish oil was fed for at least 4 weeks prior to
euthanasia, tissues had already begun to compensate for the enhanced lipid
peroxidation by the upregulation of antioxidant defence systems (Aguilera et al.
2003; Atalay et al. 2000; Hsu et al. 2001; Jahangiri et al. 2006; Leonardi et al.
2007; Ruiz-Gutierrez et al. 1999; Ruiz-Gutierrez et al. 2001; Venkatraman et al.
1994; Wang et al. 2004). Therefore, under control baseline conditions, any effect
of n-3 PUFA may be masked by the upregulated antioxidant defences.
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Secondly, the lack of effect of fish oil on MDA in stimulated, perfused muscles
may be related to a potential greater ability to cope with the excessive ROS
produced by muscle activity. It could be argued that in FO animals, the
heightened O2 consumption and therefore maintenance of oxidative metabolism
could increase the generation of ROS, another major contributor to muscle fatigue
(Allen et al. 2008b; Ferreira & Reid 2008). The results, however, suggest that this
is not the case, as there was no evidence of excessive oxidative lipid damage in
FO animals in active muscles. Furthermore, the increased O2 consumption was
not associated with heightened fatigue in FO animals. A similar situation is
observed with exercise training, where improved contractile function is also
associated with heightened O2 consumption (McAllister & Terjung 1991) and
potentially excessive ROS generation. The physiological mechanisms behind the
paradoxical effects of both fish oil and exercise training may be similar, namely
preconditioning, involving chronic protection against the increased oxidative
stress associated with an acute elevation of O2 consumption and potentially ROS.
Although not measured in this study, it is possible that, similar to exercise training
induced upregulation of antioxidant defences (Ji 2008; Sen 1995), fish oil feeding
stimulated the upregulation of antioxidant defence systems (Venkatraman &
Pinnavaia 1998) that allowed these animals to better cope with the potentially
heightened oxidative stress associated with the elevated O2 consumption in this
stimulation protocol (Ferreira & Reid 2008). Indeed fish oil has been found to
produce nutritional preconditioning in the heart, protecting against the oxidative
stress associated with ischaemia and reperfusion (Abdukeyum et al. 2008) as well
as upregulate various antioxidant defences in skeletal muscle, liver and plasma
(Aguilera et al. 2003; Atalay et al. 2000; Hsu et al. 2001; Jahangiri et al. 2006;
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Leonardi et al. 2007; Ruiz-Gutierrez et al. 1999; Ruiz-Gutierrez et al. 2001;
Venkatraman et al. 1994; Wang et al. 2004).

Finally, there was a relatively large amount of variation within each group, which
may have contributed to the lack of statistical significance. Increasing the number
of observations would increase the power for statistical analysis and reduce the
variation. Also contributing to the larger variation within each group is the
potential difference in oxidative status, depending on where in the lipid
peroxidation cascade the tissue is captured in. Malondialdehyde is just one
product of the lipid peroxidation cascade (De Zwart 1999). It is therefore difficult
to definitively determine the role of oxidative stress in the fish oil-induced
improvements in muscle function without also measuring other markers of
oxidative stress and antioxidant defence (De Zwart 1999). Because the results of
the present study regarding MDA were inconclusive, analysis of other products in
the lipid peroxidation cascade, as well as antioxidant defence systems, would help
to further elucidate the complex relationship between n-3 PUFA, fatigue and
oxidative stress.

The purpose of measuring MDA was to get a general, overall view of lipid
peroxidation in the muscles. Other measures of oxidative stress including
antioxidant enzyme concentration and activity, are beyond the scope of this thesis.
MDA is a widely accepted method for measuring oxidative stress (Ristow et al.
2009). Although it is commonly criticised in the literature due to its lack of
specificity, which may lead to inaccurate results regarding the exact amount of
MDA in tissues (Grotto et al. 2009), this is not such an issue in the present study
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as we have used the same commercially available assay kit for analysis of all
samples. The kit attempts to improve specificity by limiting any potential
interferences by other compounds and using the same method for analysis of all
tissue samples allows reasonable comparison between tissues and dietary groups.

4.4.4. Human significance
The present study shows a universal effect of n-3 PUFA in skeletal muscle, as
improvements were observed across a range of contraction types and stimulation
conditions. Despite this however, the results pertaining to improved function
during the 5Hz repeated bouts stimulation protocol are particularly important and
potentially most relevant as this stimulation protocol is representative of human
sub-maximal activity and thus is more applicable to normal everyday life than the
continuous twitch or high frequency situations (Allen et al. 2008b; BiglandRitchie et al. 1986; Jones 1996; Vollestad et al. 1997). The protocol in the present
study was based on that used previously in rats (Lunde et al. 2002; Verburg et al.
2001) which is similar to that used in humans to assess fatigue in situations more
closely related to normal muscle activation patterns (Bigland-Ritchie et al. 1986;
Vollestad et al. 1997). The isolation of the hindlimb from central input and output
in the present study by direct stimulation of the sciatic nerve, also more closely
represents the human situation, where this type of protocol in humans is
associated with alterations within the muscle itself, as opposed to central factors
(Bigland-Ritchie et al. 1986).

Improved function in normal muscle has potential implications for the average
person in terms of being better able to deal with activities of daily living.
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Furthermore, the results in post-fatigue muscle may have potential consequences
in both elite athletes and patients with muscular fatigue and dysfunction. Indeed in
humans, fish oil has been studied as a successful intervention to improve exercise
performance in patients with impairments such as chronic obstructive pulmonary
disease (Broekhuizen et al. 2005) or paraplegia (Javierre et al. 2006). A fish oil
effect may also be potentially beneficial in alleviating the fatigue associated with
heart failure.

The novel aspects of this study not only included identifying an effect of fish oil
on skeletal muscle function and fatigue across a range of conditions, but also
identifying these effects using extremely low doses of fish oil that are equivalent
to those achievable in the human diet. The preliminary work that foreshadowed
this study used a 5% fish oil diet (Peoples 2004). The current study thus validates
this earlier work, providing further evidence for a role of fish oil in skeletal
muscle function, indicating that significant changes in membrane composition of
skeletal muscle with fish oil feeding are associated with significant physiological
effects in terms of improved function. The low doses used in the present study
provide the crucial link between improved muscle function and human equivalent
doses of fish oil.

4.4.5. Vascular function
In addition to the changes in muscle contractile function, dietary FO altered
vascular function and this may be related to the improved ability to supply blood
and O2 to working muscles. Although not a major focus of the present study, the
effects of diet on hindlimb perfusion pressure and vascular resistance allowed
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some important observations regarding fish oil and endothelial function. Vascular
resistance is an important parameter determining blood flow to active tissues
(Boulpaep 2003a; Laughlin et al. 1996). It is a function of both perfusion pressure
and flow rate and is an important indicator of endothelial function. Vasodilation
reduces vascular resistance, while vasoconstriction increases resistance (Boulpaep
2003a; b). Generally, changes in blood flow are used to assess vascular resistance.
Although blood flow was tightly controlled in this study, fluctuations in hindlimb
pressure can be interpreted as changes in vascular resistance.

Endothelial function is commonly assessed by observing the response to a change
in conditions, such as a change in flow or tissue O2 demand, such as that during
muscle activity. An increase in hindlimb flow results in an immediate increase in
hindlimb pressure and a subsequent reduction in vascular resistance in a
phenomenon known as flow-mediated vasodilatation (FMD), an important
determinant of endothelial function (Korkmaz & Onalan 2008). In response to the
sheer-stress associated with an increase in flow, vasodilators are released from the
endothelium, including nitric oxide and prostaglandins (Pyke & Tschakovsky
2005). Alternatively, muscle activity or exercise, induces blood vessels in the
active muscles to dilate in order to increase blood flow to the working muscles.
This phenomenon is termed active hyperaemia and this too is an indicator of
endothelial function. Generally, the more strenuous the activity, the greater the
response (Dua et al. 2009). Both FMD and active hyperaemia responses were
observed in the present study and there was a general trend towards improved
vasodilation in FO-fed animals.
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In normal muscle, a greater FMD in response to an increase in hindlimb flow in
FO animals supports the improved endothelial function and brachial artery FMD
in humans, associated with fish oil supplementation (Goodfellow et al. 2000; Hall
2009; Hill et al. 2007; Khan et al. 2003; Shah et al. 2007). There was also better
recovery of vascular tone after the first contraction protocol in FO animals, with
resistance returning to baseline levels after 20min rest, while in the OO group,
resistance remained high despite both the cessation of exercise and the controlled
reduction of blood flow. While the FMD in post-fatigue muscle was greater than
in normal muscle across all dietary groups, the greater vasodilation and improved
recovery of vascular tone in FO animals further supports improved endothelial
function and a general vasodilatory effect of fish oil (Goodfellow et al. 2000;
Leeson et al. 2002), resulting in a greater ability to supply the muscles with blood
and O2 during recovery. With blood flow tightly controlled in the present study,
improved vascular function could only contribute to improved contractile function
in post-fatigue muscle by redistribution of blood flow between nutritive and nonnutritive pathways (Clark et al. 2000) as greater muscle perfusion reduces the rate
of fatigue development (Barclay 1986). Such effects may be more evident when
blood flow is not held constant.

Muscle activity stimulates active hyperaemia which is, under constant flow
conditions, expressed as a reduction in vascular resistance in response to increased
metabolic activity. Active hyperaemia was observed in the current study during all
stimulation protocols and conditions. There were no dietary differences in the
active hyperaemia observed during the lower intensity 2Hz continuous twitch
protocol, however a greater active hyperaemia in FO animals emerged during the
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higher intensity 5Hz repeated bouts stimulation protocol. The differences are
probably related to the intensities of the protocols, as a greater hyperaemia would
be expected at higher stimulation frequencies (Dua et al. 2009). This was
observed in FO animals, but not OO-fed animals, suggesting a greater reserve in
FO animals resulting in an improved ability to meet the demand of the working
muscles at higher intensities. This effect would further enhance muscle function in
circumstances where blood flow is not controlled, as increased blood flow
attenuates the rate of fatigue development by improving O2 delivery and removal
of metabolites (Amann & Calbet 2008; Barclay 1986). It is suggested that the
greater response to higher stimulation frequencies is related to Ca2+-dependent
enzymes such as nitric oxide synthase (Berchtold et al. 2000; Dua et al. 2009) and
fish oil affects other Ca2+-dependent processes in the heart and skeletal muscle
(Dulloo et al. 1994; McLennan & Abeywardena 2005; Nurnberg et al. 1998).
Increased generation of metabolic products from more active muscles in the
higher intensity protocol may also drive the active hyperaemic response (Dua et
al. 2009). Indeed, the fall in pH, an indirect measure of muscle metabolism, was
greater in FO animals in the 5Hz protocol while a similar 2Hz protocol in the
same model did not affect pH (Peoples 2004). The greater response in FO animals
to the higher stimulation frequency may therefore be related to these intracellular
signalling effects. These results are in line with previous observations in humans,
where a greater active hyperaemia in the brachial artery was attributed to fish oil
supplementation, as represented by a larger drop in systemic vascular resistance in
response to both low and moderate intensity workloads (Walser & Stebbins 2008)
or increased blood flow (Walser et al. 2006).
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In contrast to the results in normal muscle, active hyperaemia in post-fatigue
muscle was not significantly different between groups however both FO groups
tended to have a lower response, which approached significance in the pooled
analysis. The reason for the potentially lower active hyperaemia in FO animals is
the lower starting vascular resistance, as indicated by the lower resting hindlimb
pressure. The FO animals also dropped to lower resistance values during this
stimulation protocol. So although the active hyperaemic response (% change) was
less, the FO hindlimbs were always in a more dilated state. This vasodilatory
effect of fish oil is well documented in humans and animals (Goodfellow et al.
2000; Hall 2009; Hill et al. 2007; Khan et al. 2003; Leeson et al. 2002; Shah et al.
2007).

All of the results under various conditions in the present study suggest an
improved vasodilatory effect of n-3 PUFA that serves to improve nutrient delivery
to the muscles in different situations, including during activity and recovery. This
represents an additional mechanism by which fish oil may act to improve muscle
contractile function and fatigue resistance in models where blood flow is not held
constant.

Given the general vasodilatory role of n-3 PUFA confirmed in the present study,
the likely mechanisms for fish oil-mediated improved endothelial function are
related to the vasodilatory mediators released from endothelial cells. An increase
in blood flow, whether it be induced by activity or otherwise, results in the release
of vasodilators in response to an increase in sheer-stress (Pyke & Tschakovsky
2005). These vasodilators, namely nitric oxide (NO) and prostaglandins,
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significantly contribute to (mediate) smooth muscle relaxation in response to
increased flow and/or activity (Grange et al. 2001; King-Vanvlack et al. 2002;
Pyke & Tschakovsky 2005) and both of these vasodilators have been linked to
fish oil effects on endothelial function with prostaglandins directly derived from
20 carbon PUFA including EPA.

Chronic treatment of isolated human coronary artery endothelial cells with DHA
increases endothelial nitric oxide synthase (eNOS) and heat shock protein
(HSP90) expression as well as Akt activity, all of which contribute to the
synthesis of NO (Stebbins et al. 2008). Both EPA and DHA induce heightened
eNOS activity in human umbilical vein endothelial cells (Li et al. 2007a; Li et al.
2007b). In addition, the effect of n-3 PUFA on Ca2+ handling observed in the
heart (McLennan & Abeywardena 2005) and potentially also in skeletal muscle
(Dulloo et al. 1994; Nurnberg et al. 1998) may further strengthen a case for a fish
oil effect on eNOS, which is also Ca2+-dependent (Berchtold et al. 2000).
Improved Ca2+ handling in fish oil animals therefore has the potential to maintain
a better vasodilatory response by maintaining eNOS activity.

The n-3 PUFA from fish oil stimulate an increased production of the vasodilatory
prostaglandins PGI3, whilst producing the less active vasoconstrictor TXA3,
which may also contribute to the improved endothelial function (Hishinuma et al.
1999). Studies of direct mechanistic links between n-3 PUFA and NO and
prostaglandins in relation to improved endothelial function are restricted to
isolated cells and are yet to be validated in in vivo models. However the evidence
points towards these mechanisms being involved, at least in part, in the fish oil
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effect on endothelial function. Despite the limited knowledge regarding the
mechanism of action, our results are in support of previous work concerning fish
oil and endothelial function that show improvements in both FMD and active
hyperaemia in humans supplemented with fish oil (Goodfellow et al. 2000; Hall
2009; Hill et al. 2007; Khan et al. 2003; Leeson et al. 2002; Shah et al. 2007;
Walser et al. 2006; Walser & Stebbins 2008), further strengthening the case for
fish oil-mediated improved endothelial function. This effect has important
implications, not only in relation to muscle function and fatigue but broader
implications for the use of fish oil in pathophysiological conditions where
vascular and endothelial function may be impaired such as in heart failure
(Devaux et al. 2004; Fischer et al. 2005).

4.4.6. Overall conclusions and limitations
The major findings of the present study were that low dose dietary FO improved
muscle contractile function and fatigue resistance across a range of contraction
conditions. This was associated with heightened O2 consumption, which is likely
to be multi-factorial involving both O2 driving contraction and contraction driving
O2 demand. In addition, muscle endothelial function may also be enhanced,
representing an additional mechanism behind improved muscle function relating
to nutritive and non-nutritive blood flow distribution that may further contribute
to an effect of fish oil in situations where blood flow is not fixed. To our
knowledge, despite numerous substances being used to acutely enhance
performance, no other previously tested chronic intervention, aside from exercise
training, has exhibited direct effects on skeletal muscle contraction and fatigue
resistance as dietary fish oil has in the present study (Rodriguez et al. 2009). In
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this respect, exercise and fish oil may precondition the skeletal muscle in much
the same way that ischaemic preconditioning and fish oil prepare the heart to
resist the harmful effects of a major ischaemic insult (Abdukeyum et al. 2008).

The effect on muscle contractile function is likely due to the incorporation of
DHA (and reduction in AA) into muscle membranes, reported in Chapter 3.
Further investigation into how this might relate to the improved function (caffeine
and MDA) was inconclusive however, when interpreted in light of previous
literature regarding low frequency fatigue, as well as the fish oil effect in the heart
where more extensive data is available, our results suggest that an effect on Ca2+
handling and cellular oxidative stress may be involved.

Perhaps the most important aspect of these findings is not just that they suggest a
role of n-3 PUFA in improved skeletal muscle function but that the doses used are
representative of those that could easily be achieved in the human diet (see Table
1-1)(Slee et al. 2010). Furthermore, the auto-perfused hindlimb model and low
frequency repeated bouts stimulation protocols also reliably model human
physiology for the assessment of muscle function and fatigue (Hoy et al. 2009;
Peoples 2004; Verburg et al. 2001; Vollestad et al. 1997). Therefore our results
provide a link between animal and human studies and more specifically, make it
possible to relate these findings to humans and validate the limited evidence
available regarding fish oil and skeletal muscle function. As mentioned
previously, those studies reporting skeletal muscle improvements with fish oil
feeding have used high doses and those pertaining to vascular function are
generally in humans. Therefore the present study links the previous studies to
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support general beneficial effects of dietary fish oil on skeletal muscle contractile
function, skeletal muscle vascular function and a role for n-3 PUFA in fatigue
resistance.

The present study was limited by lack of statistical power in a few aspects,
particularly regarding the mechanistic extensions of the main study, namely
caffeine and MDA. Future directions would include extensions of the mechanistic
investigations into the effects of fish oil on skeletal muscle function.
Improvements in the caffeine protocol are required to more closely observe the
effect of caffeine that is not obscured by the rest intervals between each dose.
Furthermore, other measures of Ca2+ handling could also be assessed (Allen et al.
2008b; Berchtold et al. 2000). In regards to oxidative stress, there are many
different aspects that could be measured to gain a wider understanding of tissue
oxidative stress. These include antioxidant enzyme concentration and activity,
non-enzymatic antioxidant concentrations and other products in the lipid
peroxidation cascade, as well as products of protein and DNA oxidative damage
(De Zwart 1999).

There were some limitations to the blood gas measurements in the current study
that should also be noted. Firstly, the CO2 and, to a lesser extent, pH
measurements were affected by low resolution of the blood gas analyser to detect
minor alterations throughout the protocol. The production of CO2 did not appear
to change throughout the protocol although the increase in H+ (decrease in pH)
indicates successful buffering by the carbonic anhydrase system in red blood cells.
Similarly, although it was obvious that venous pH dropped during the stimulation
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protocol and FO animals tended to drop more than the OO animals, this was only
significant in the pooled FO analysis, again likely due to this limitation in
sensitivity of the blood gas analyser. Further investigation may involve using
more sensitive equipment. Considerable time and effort was made to obtain
continuous in-line O2, CO2 and pH recordings which are not reported here. Slow
electrode response times and significant baseline drift without the capacity for
recalibration during each experiment impaired data interpretation. Future studies
may include evaluating O2 consumption across a range of different stimulation
protocols (for example the 2Hz continuous twitch protocol and during the 5Hz
repeated bouts protocol in post-fatigue muscle), taking more frequent
measurements or using improved in-line O2 electrodes to more closely relate O2
consumption to specific events during the protocol, as well as extending studies to
include longer recovery periods.
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Chapter 5 SKELETAL MUSCLE FUNCTION – CLAUDICATION
5.1 Introduction
The results of Chapter 4 established a role for n-3 PUFA in improving skeletal
muscle function, fatigue resistance and contractile force recovery in normal and
fatigued muscle. It was therefore proposed that dietary fish oil intervention might
be applied to a clinical situation that may benefit from this improved function.
Claudication refers to exercise-induced pain in the lower extremities as a result of
ischaemia caused by obstructed arterial blood flow (Cassar 2006; Meru et al.
2006; Sommerfield et al. 2007). It is a common symptom of peripheral arterial
disease, where atherosclerosis of limb vessels causes inadequate blood flow to the
muscles, especially during the increased demand of exercise. In addition to
atherosclerosis, it is also thought that endothelial dysfunction may further
contribute to claudication (Brevetti et al. 2008). Furthermore, there is increasing
evidence to suggest that claudication is associated with oxidative stress and tissue
damage (Judge & Dodd 2003). The consequence of reduced blood flow during
exercise is that the muscle reverts to anaerobic metabolism and the subsequent
build up of metabolites such as lactic acid causes pain (Meru et al. 2006). While
cessation of exercise and muscle activity relieves claudication, the inability to use
the lower limbs without pain can severely influence a patient’s ability to perform
everyday tasks and as such, quality of life is adversely affected. Furthermore,
claudication is also associated with an increased risk of cardiovascular morbidity
and mortality (Cassar 2006). Thus, its rising prevalence, especially in the aging
population (Meru et al. 2006), highlights the need for investigation into easily
accessible treatments and therapies.
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The use of fish oil in alleviating claudication is plausible, given the favourable
effects on both skeletal muscle and vascular endothelial function established in
Chapter 4. Moreover, fish oil has been previously investigated for the
management of claudication and improving quality of life (Carrero & Grimble
2006; Carrero et al. 2006; Madden et al. 2007; Sommerfield et al. 2007). This
idea of using fish oil to treat peripheral vascular disease is not new. Since the
benefits of fish oil in coronary heart disease have emerged, it has been suggested
that it may also improve peripheral vascular disease, given the similarities in
aetiology of the two diseases (Carrero & Grimble 2006; Sommerfield et al. 2007;
Woodcock et al. 1984). Many aspects of peripheral vascular disease are affected
by n-3 PUFA, including blood viscosity (Woodcock et al. 1984) and endothelial
function (Schiano et al. 2008). However, the literature pertaining to claudication
and the transfer of these fish oil-induced physiological improvements to clinical
outcomes is limited and inconclusive. Studies in humans have revealed either
improvements or no change in walking distance and other measures of
claudication (Carrero et al. 2006; Conway et al. 2005; Leng et al. 1998; Madden
et al. 2007). Differences in methodology exist between these studies and as such
further research is essential in establishing an effect, if any, of fish oil in
alleviating claudication.

Further to the potential effects on skeletal muscle and vascular endothelial
function, fish oil may also manage claudication by reducing tissue oxidative
damage. It is well established that claudication causes significant oxidative stress
and tissue damage, as shown by increases in lipid peroxidation products in human
and rat skeletal muscle (Grisotto et al. 2000; Judge & Dodd 2003; 2004; Pipinos
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et al. 2006). Furthermore, antioxidants have been shown to attenuate the oxidative
damage associated with claudication both in humans (Wijnen et al. 2001) and in
rats (Judge et al. 2008). While an effect of fish oil on oxidative stress was not
apparent in normal muscle, it is possible that it may help the tissues cope in a
more stressful situation such as claudication, where oxidative stress may be
heightened.

Animal models of claudication have been developed to mimic the human situation
in an attempt to elucidate mechanisms and treatments for claudication. Because
rodents are not susceptible to developing atherosclerosis (Turner et al. 1990),
other mechanisms are used to induce or mimic claudication. The standard model
of claudication in rodents is the femoral artery ligation method involving surgical
severing of the femoral artery (Angersbach et al. 1988; Dodd et al. 1998; Judge &
Dodd 2003). Following surgery, collateral vessels develop, which at rest can
maintain sufficient blood flow to the muscles but a greater demand during
exercise cannot be met. Claudication occurs as a result of 60% reduction in
exercising muscle blood flow (Dodd et al. 1998). The model used in the present
study is a non-surgical adaptation of the femoral artery ligation method allowing
acute application of claudication conditions to the auto-perfused hindlimb set-up.
Instead of cutting the femoral artery, blood flow during the muscle stimulation
protocol was controlled at a lower flow, equivalent to a 60% reduction in normal
active muscle flow rate.

The purpose of the present study was to extend the observations made in normal
muscle (Chapter 4) and determine whether the favourable effects of dietary fish
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oil are applicable to the pathophysiological condition of claudication. The clinical
implications of a positive effect of fish oil in this situation are improved quality of
life for sufferers of claudication.

It was hypothesised that
a) reduced blood flow in the perfused hindlimb would restrict O2
consumption and exacerbate contractile dysfunction and fatigue during
muscle contraction.
b) FO animals would perform better during stimulation, with improved
contractile force and resistance to fatigue associated with higher O2
consumption throughout the 5Hz repeated bouts stimulation protocol.
This protocol was chosen, as it is most representative of human skeletal
muscle activity.
c) FO animals would be protected against the heightened oxidative stress
associated with claudication, as represented by a lower MDA
concentration in the stimulated muscles.

5.2 Methods
5.2.1 Animals and diets
Procedures for animal care and dietary intervention are outlined in Chapter 2.1
and 2.2. Briefly, animals were assigned to one of three dietary groups: Olive oil
(OO) control; LowFO (0.31%) and ModFO (1.25%), fed for at least four weeks
prior to muscle function experimentation and euthanasia. Rat age at time of
experimentation ranged from 16-17 weeks.
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Animals were prepared for surgery and set up for experiments as indicated in
section 2.3. Rats were anaesthetised (pentobarbitone sodium, 60mg/kg i.p.) and
maintained throughout the experiment with supplementary injections of 20mg/kg
i.p. pentobarbitone sodium. The rat auto-perfused hindlimb was set up in a heated
perspex chamber for assessment of skeletal muscle function. Animals were
ventilated at 60 breaths per minute and blood pressure was monitored via a
cannula, attached to a pressure transducer, inserted in to the carotid artery. The
sciatic nerve was isolated for electrical stimulation of the hindlimb and the GSP
muscle bundle was attached to a force transducer at the Achilles tendon. Once all
cannulations were made and blood flowed passively throughout the system, the
pump was switched on to perfuse the experimental leg at 1mL.min-1. Hindlimb
perfusion pressure was monitored via a pressure transducer linked to a t-connector
situated in-line after the pump. The hindlimb was perfused for 20-30min before
the stimulation protocols began.

5.2.2 Stimulation protocol (5Hz repeated bouts)
Following the initial 20-30min of equilibration the peristaltic pump speed was
decreased to 0.6mL.min-1, based on surgical models of claudication which reduce
blood supply by 60% of normal exercising blood flow (Dodd et al. 1998).
Immediately prior to and 5min after reducing the perfusion pump flow rate from
1mL.min-1 to 0.6mL.min-1, a short bout of stimulation was performed (2Hz, 5s).
This was to assess that the muscle was able to respond to a short period of
stimulation similarly at both flow rates, indicating sufficient blood flow at rest.
After 10min at the low flow rate, the experimental stimulation protocol
commenced. The protocol was the same 5Hz repeated bouts stimulation used in
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4.2.3 (Figure 4-2) consisting of 5s trains of 5Hz stimulation followed by 5s rest
for a period of 5min. At the end of the stimulation period animals were allowed to
recover for 30min prior to euthanasia.

5.2.3 Data analysis and calculations
Force data and twitch characteristics were analysed using LabView for Windows
display/analyse software. Area under the curve was calculated as the total area
under all twitches over the 5min period. The decline in force over the 5min period
was calculated as (peak twitch force-last twitch force)/peak twitch force*100
using the first twitch of the 5s bout. The time to 50% was calculated as the time
(in seconds) for first force of the 5s bout to decline to 50% of peak first twitch
force.

5.2.4 Sample collection and analysis
Blood and tissue samples were collected as outlined in section 2.3.4. Briefly,
blood samples were taken at intervals throughout the protocol for blood gas
analysis. Resting samples were taken at both pump speeds (1mL.min-1 and
0.6mL.min-1) prior to the stimulation protocol. Blood samples were taken 60s into
and at the end of the 5min contraction protocol. Recovery samples were taken 5
and 30min after the contraction protocol. Tissue samples were snap frozen and
stored for later analysis of MDA.

5.2.5 Malondialdehyde
Tissue malondialdehyde was measured in the gastrocnemius and soleus muscles
from control and perfused hindlimbs as described in section 4.2.5, using a
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Thiobarbituric Acid Reactive Substances (TBARS) assay kit (Cayman Chemical
Company, USA).

5.2.6 Statistical Analysis
Results are expressed as mean ± standard error of the mean (SEM). One-way
ANOVA with Tukey post-hoc comparison of means was used to analyse any
effect of diet on muscle function parameters and hindlimb pressure and resistance
as well as blood gases and electrolytes. Statistix for Windows (Analytical
Software, USA) was used to perform all ANOVA. To assess any dietary effect on
force production over the 5min period of 5Hz repeated bouts stimulation, linear
mixed models analysis was employed (SPSS Version 15). Where trends for a FO
effect were evident and there were no significant differences between FO diets,
these two diets were pooled and compared against the OO control group. p<0.05
was accepted as statistically significant.

5.3 Results
5.3.1 Rat age and weight
All animals were of similar age and body weight at time of experimentation and
euthanasia (p=0.45 and p=0.32 for age and body weight respectively) (Table 5-1).
Muscle weight (expressed as GSP/tibia length ratio) was significantly less in the
ModFO group compared to the OO control group (p=0.03).
Table 5-1 Effect of diet on baseline rat parameters at euthanasia
OO
LowFO
ModFO
Age (weeks)
17 ± 0
16 ± 0
16 ± 0
BW (g)

392 ± 5

406 ± 13

376 ± 18

GSP/TL

6.75 ± 0.30

6.38 ± 0.12

5.90 ± 0.15*

Values are mean±SEM. p<0.05 vs. OO diet. n=6 per group. BW=body weight, GSP/TL=
gastrocnemius/soleus/plantaris weight to tibia length ratio
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5.3.2 Force characteristics
The force response to the 2Hz, 5s stimulation at the low flow rate of 0.6mL.min-1
was not different to that observed at the normal flow rate of 1mL.min-1 (data not
shown). Force production under low flow conditions over the 5min repeated bouts
stimulation period (Figure 5-1) showed a similar pattern to that observed under
normal flow conditions (Chapter 4), with an initial rise within the first couple of
bouts followed by decline in the middle stages. The difference being that the force
towards the end of the protocol continued to gradually decline (significant effect
of time both Ft and Lt p<0.001), with little plateau effect and the force
development in all groups at this stage was less compared to the same time in
normal flow conditions.

While FO animals tended to maintain a higher force production and exhibit a
slower rate of fatigue development in the early stages of the current protocol,
there were no significant differences between dietary groups by the last half of the
protocol, resulting in no significant diet*time interaction (Ft p=0.77 and Lt
p=0.35). Comparison of both FO diets revealed no significant difference between
them (diet*time both Ft and Lt p=0.98) so these diets were pooled and compared
to the OO control diet. This pooled analysis revealed a trend for both the first and
last force to be greater in fish oil animals compared to controls (diet*time Ft
p=0.15 and Lt p=0.05).
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Figure 5-1 Effects of diet on force production during 5Hz repeated bouts stimulation
in low flow conditions.
a) and b) force production (N.100g-1 GSP) for first (Ft) and last (Lt) twitch in each bout of
stimulation respectively. †p<0.05 effect of time. n=6 for each dietary group.

A notable difference in force production between the present study and that
observed in Chapter 4 was the characteristics of each 5s bout of stimulation. In
Chapter 4, relaxation of each twitch in a 5s bout of stimulation occurred such that
force returned to baseline values between twitches. In the present low flow
situation, there was a tendency for slower relaxation and therefore resting tension
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remained high resulting in unfused trains of contraction (Figure 5-2). To further
examine an effect of fish oil in this case, another measure was derived, Ltmin
(Verburg et al. 2001). This is the resting tension at the beginning of the last twitch
of each 5s bout of stimulation. The difference between Lt and Ltmin was expressed
as a percentage of Lt such that a lower value indicates greater fusion of
contractions within each bout of stimulation (Figure 5-3). There was a significant
effect of time on Ltmin (p<0.01) however this was not different between dietary
groups (p=0.679 diet* time interaction). Pooled analysis further indicated no
effect of fish oil on Ltmin (p=0.675).

Figure 5-2 Example trace of one 5s bout of 5Hz stimulation during normal (left) and
low flow (right) conditions indicating Ft, Lt and Ltmin
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Figure 5-3 Effect of diet on fusion of twitches within each 5s bout of 5Hz stimulation
under low flow conditions.
n=6 per dietary group.

Across all diets there was a significant effect of time on the maximum rates of
contraction of the first and relaxation of the last twitches of 5s stimulation (both
p<0.01, Figure 5-4). There was no significant effect of diet over time (p=0.834
and 0.998 for contraction and relaxation rates respectively, diet*time interaction).
Pooled analysis revealed a trend towards a higher rate of force development in
fish oil animals (p=0.072) but not in the rate of relaxation (p=0.641).
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Figure 5-4 Effect of diet on maximum rates of contraction (dF/dt) of the first and relaxation
(-dF/dt) of the last twitch of each 5s bout of stimulation under low flow conditions.

†p<0.05 effect of time. n=6 for each dietary group.

There was no significant effect of fish oil on area under the curve (p=0.78), the
change in Ft (%) during the protocol (p=0.52) or in the time for Ft to reach 50% of
the peak Ft (p=0.54, Table 5-2). Pooled analysis did not reveal any further effects
of fish oil (all p>0.05).

Table 5-2 Effect of diet on muscle function under low flow conditions
OO
LowFO
ModFO
Area under the curve
16736 ± 2291
16273 ± 2060
18475 ± 2517
Time to 50% (s)

99 ± 9

117 ± 8

113 ± 13

% Change in Ft force

-86.0 ±1.6

-89.0 ± 0.8

-87.4 ± 2.6

Values are mean±SEM. *p<0.05 vs. OO diet. n=6 per dietary groups.

5.3.4 Blood Gases and pH
In all diets, O2 consumption remained similar at rest and 60s into the protocol
(Figure 5-5). There was a rise in O2 consumption at the end of the contraction
protocol (stim. 5min) before it began to decline during recovery and return to
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baseline levels by 30min post-stimulation. There were some dietary differences in
O2 consumption throughout the protocol. In general the FO diets had higher O2
consumption at rest and during the stimulation protocol, although this was not
significant at all sample time points. At rest, the LowFO group exhibited higher
O2 consumption compared to the OO group (p=0.055 at 1mL.min-1 and p=0.049 at
0.6mL.min-1). Both FO groups had significantly higher O2 consumption at the end
of muscle activity (p=0.027) and this trend remained during recovery but was only
significant in the ModFO group (p=0.026 at rec. 5min and p=0.060 at rec. 30min).
There were no significant differences between FO diets throughout the protocol so
these data were pooled and compared to the OO control group. This pooled
analysis strengthened an effect of FO, with significantly higher O2 consumption at
the end of stimulation (p=0.006) and during recovery (rec. 5min p=0.009 and rec.
30min p=0.016) and approaching significance at rest (0.6mL.min-1 p=0.050) and
at the beginning of stimulation (stim. 60s p=0.078).

There were no significant differences between diets in CO2 production and pH
was only significantly higher in the ModFO group at rest (1mL.min-1 p=0.020 and
0.6mL.min-1 p=0.010) but not during stimulation or recovery (all p>0.05). Pooled
analysis did not reveal any further effects of FO on CO2 production or pH (all
p>0.05).
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Figure 5-5 Effect of diet on blood gases and pH at various stages throughout the
stimulation protocol under low flow conditions.
a) O2 consumption, b) CO2 production and c) pH. stim. 60s = 60 seconds after the
beginning of stimulations, stim. 5min = the end of stimulation protocol, rec 5min and rec
30min=during recovery, 4 and 30 minutes after the end of stimulations, respectively.
*p<0.05 LowFO vs. OO, **p<0.05 ModFO vs. OO, ***p<0.05 both FO vs. OO. #p<0.05
all FO combined vs. OO. n= 3-6 in each group for each stage.
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5.3.4 Hindlimb perfusion pressure and resistance
Baseline hindlimb perfusion pressure was not significantly different between
dietary groups (Table 5-3). The reduction in flow rate from 1mL.min-1 to
0.6mL.min-1 resulted in a significant decrease in hindlimb perfusion pressure in
all dietary groups (all p<0.05). Contracting muscle further reduced hindlimb
pressure but this was only significant in the FO groups (p=0.09, p=0.04 and
p=0.03 for OO, LowFO and ModFO diets respectively).

Table 5-3 Effect of decreasing flow rate (from 1mL.min-1 to 0.6mL.min-1) on
perfusion pressure.
OO
LowFO
ModFO
Resting Pressure
-1

Pressure (mmHg) at 1mL.min

88 ± 7

87 ± 9

95 ± 10

Pressure (mmHg) at 0.6mL.min-1

52 ± 7*

55 ± 8*

56 ± 6*

Contracting pressure
Pressure (mmHg) at 0.6mL.min

-1

46 ± 4

49 ± 6†

49 ± 4†

-1

Values are mean±SEM. *p<0.05 vs. pressure at 1mL.min within each dietary group. †p<0.05 vs.
resting pressure at 0.6mL.min-1 within each dietary group. n=6 per dietary groups.

Reducing the flow rate resulted in an increase in resistance in the OO group
(Figure 5-6). The response was similar in the LowFO group but to a lesser extent
and the ModFO showed a slight decrease in resistance. Despite these trends
however, the observations were not significantly different between dietary groups
(p=0.49). The change in resistance in response to activity at the low flow rate was
similar across all dietary groups (p=0.85). Pooled analysis was also not significant
(all p>0.05).
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Figure 5-6 Effect of decreasing flow rate from 1mL.min-1 to 0.6mL.min-1 on
hindlimb perfusion pressure and resistance.
n=6 per dietary group.

5.3.5 Lipid oxidation
MDA concentration was greater in the soleus compared to the gastrocnemius in
all dietary groups (all p<0.05, Figure 5-7). There were no significant differences
in MDA concentration between dietary groups in control muscles (both
gastrocnemius p=0.85 and soleus p=0.61). In perfused muscles, FO animals had
lower MDA concentrations. This effect was significant in the soleus (p=0.002)
and approached significance in the gastrocnemius (p=0.14). Pooled analysis
revealed no effect of FO in the control muscles (both p>0.05) but the effect in
perfused muscle was significant in both the gastrocnemius (p=0.04) and soleus
(p<0.01).
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Figure 5-7 Effect of diet on MDA concentration in the Gastrocnemius and soleus
muscles of control and low flow perfused limbs.
*p<0.05 vs. OO group. #p<0.05 all FO combined vs. OO. n=6 per dietary group.
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5.4 Discussion
5.4.1. Animal models of claudication
The contractile response to 5Hz stimulation under low flow conditions, including
initial potentiation of force and decline of peak force by more than 50% is
characteristic of low frequency fatigue (Jones 1996; Keeton & Binder-Macleod
2006). Furthermore, the low flow conditions exacerbated fatigue and muscle
dysfunction with a more rapid decline in force development to a lower steady
state in all dietary groups. This greater decline in force is characteristic of skeletal
muscle ischaemia and given the tight relationship between force production and
O2 availability, is associated with the reduced O2 availability during muscle
activity (Hogan et al. 1998; Hogan et al. 1996; Hogan et al. 1994). The rise in
baseline force development within each contraction bout also represents increased
demand on the muscle under these conditions. The rise reflects incomplete
relaxation and represents Ca2+ overload at the cellular level, likely due to a slowed
rate of SR Ca2+ uptake or slowed cross bridge detachment (Lunde et al. 2002;
Verburg et al. 2001). In the current situation of low flow and limited O2
availability, the Ca2+ dysfunction is probably related to the effects of by-products
of anaerobic metabolism as increased H+ and Pi can adversely affect SR Ca2+
uptake, Ca2+ sensitivity and cross-bridge interactions (Allen et al. 2008b; Fitts
2008).

The present study is the first of its kind to assess the effects of fish oil on
claudication in an animal model. The model used in the current study was adapted
from the commonly used femoral artery ligation model. The characteristics of the
model itself, as well as the similar observations regarding force development and
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fatigue, suggest that the current model is representative of what occurs following
femoral artery ligation. Specifically, the reduction of blood flow to 0.6mL.min-1
represents the 60% reduction of active blood flow observed with femoral artery
ligation (Dodd et al. 1998; Hickey et al. 1992). Similar resting O2 consumption
and pH at both flow rates indicate that blood flow was sufficient to meet the
demands of inactive tissues, a characteristic of human claudication that is also
mimicked in the rat femoral artery ligation model (Cassar 2006; Dodd et al.
1998). Similarities between the current model and the femoral artery ligation
model were also observed in regards to force development. There was no effect of
the low flow conditions on peak force development and there was a higher
percentage of force decline over the 5min period, reflecting more pronounced
fatigue during these conditions compared to normal flow conditions. Both of these
are characteristic of the femoral artery ligation model of claudication (Angersbach
et al. 1988; Dodd et al. 1998). These results suggest that the current model may be
a non-surgical alternative for assessing acute claudication in animals. Chronic
claudication would still require the femoral artery ligation model to encompass
the adaptive mechanisms that may be involved (Angersbach et al. 1988; Hickey et
al. 1992).

To our knowledge, this is the first use of such a model of claudication. While the
data suggests that it was successful in mimicking the femoral artery ligation
model of claudication, as well as certain aspects of the human condition, more
research would help to refine the model and validate its use as a non-surgical
animal model of acute claudication. Furthermore, although the doses of fish oil
used in the present study are relevant to human intakes, allowing us to more
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closely relate the effects observed in animals to humans, it must be noted that
other factors associated with the animal models of claudication limit the ability to
directly translate our results in animals to the clinical condition in humans.
Claudication in humans is associated with pain during exercise (Cassar 2006), an
effect which cannot be assessed in animal models. In addition, claudication in
humans is caused by atherosclerosis of the limb vasculature that limits blood flow
to muscles during activity when demand is increased (Cassar 2006). Rodents
however, are not susceptible to atherosclerosis even with high saturated fat intake
(Turner et al. 1990). Therefore, animal models of claudication focus on other
ways to limit blood flow to muscles during activity. The femoral artery ligation
model is generally accepted as a valid model of claudication (Dodd et al. 1998;
Judge & Dodd 2003) and our model closely represents what is observed acutely
with that model. Although care must be taken in the interpretation of results due
to the different aetiologies in humans and animal models, the advantage in using
rodents to assess therapies or treatments for claudication is the ability to isolate
effects observed directly on muscle and vascular function rather than the
atherosclerotic plaque (Hickey et al. 1992). Obviously, reducing the
atherosclerotic plaque would relieve claudication and reduce the associated risk of
cardiovascular mortality however therapies that act via other pathways may be
just as important in relieving claudication associated with peripheral artery disease
and improving quality of life (Cassar 2006).

5.4.2 Fish oil and claudication
The present study has proposed a role for fish oil in an animal model of the
debilitating human condition, claudication. Compared to that observed under
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normal conditions in FO animals, dietary differences in contractile performance
and fatigue resistance under these low flow conditions were modest. The fatigue
resistance in the early stages of the protocol in FO animals was less pronounced
during low flow conditions and force development fell to the same low level in all
dietary groups in the latter stages of the protocol. Despite this, O2 consumption
was higher in FO hindlimbs and muscles from FO animals seemed to be protected
from exercise-induced oxidative stress.

Similarly to the normal flow situation, the short delay in the rapid decline in force
in the early stages of the protocol in FO animals was associated with to the higher
concentration of DHA in skeletal muscle membranes (Chapter 3). The early drop
in force in low frequency stimulation is due to metabolic changes (Baker et al.
1994) and the major contributors to contractile function are the gastrocnemius and
plantaris muscles, due to their size and metabolic characteristics (Delp & Duan
1996; Meyer & Terjung 1979). As well as fatiguing faster under normal
conditions (Hintz et al. 1982; Meyer & Terjung 1979), the gastrocnemius and
plantaris muscles are more susceptible than the soleus to fatigue during hypoxia
due to greater cellular metabolic disturbances (Howlett & Hogan 2007; Walker et
al. 1982). Thus the higher DHA concentration in the gastrocnemius may have, to
some extent, contributed to the improved contractile function in the early stage of
this protocol under conditions of reduced blood flow by modifying intracellular
Ca2+ handling (Dulloo et al. 1994; McLennan & Abeywardena 2005; Nurnberg et
al. 1998) and reducing the fatigue associated with metabolic alterations (Allen et
al. 2008b). This effect however may have been limited under these conditions by
the heightened anaerobic metabolism that contributes to slower relaxation and
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faster development of fatigue under these conditions. The higher O2 consumption
is also likely to have contributed to the FO response in the early stages of the
protocol under low flow conditions. The relationship between O2 availability and
contractile performance is well established, especially regarding ischaemic or
hypoxic conditions (Hogan et al. 1999a; Hogan et al. 1996; Hogan et al. 1994),
where reduced O2 availability is related to the initial decline in force during
ischaemia (Hogan et al. 1994) and further reductions are tightly coupled to further
decline in force development (Hogan et al. 1996). Given the tight coupling
between O2 and contraction, known as O2 conforming, it is plausible that in OO
animals, the reduced O2 consumption contributed to a quicker downregulation of
force compared to FO animals that, sensing greater O2 consumption, were able to
initially resist fatigue (Hogan et al. 1998; Hogan et al. 1996). In addition, the
initial higher O2 consumption would preserve oxidative metabolism and
contribute to the fatigue resistance by maintaining more efficient generation of
ATP and preventing the build up of metabolic by-products that may interfere with
Ca2+ and E-C coupling (Amann & Calbet 2008; Nadel 2003). However, despite
the greater O2 consumption in FO animals, it was less in all groups compared to
normal flow situations. As such, this lesser O2 consumption under these
conditions may contribute to the less pronounced effect of FO on fatigue
resistance.

In the latter stages of the protocol, the dietary differences in contractile
performance were abolished and force development in all groups dropped to a
level lower than that observed in normal conditions. The limitation of reduced O2
availability under these low flow conditions accelerates fatigue (Amann & Calbet
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2008). As discussed previously, under normal conditions the soleus is likely to be
a major contributor to the maintenance of force production in the latter stages of
the protocol as the gastrocnemius and plantaris fatigue (McAllister & Terjung
1991). The soleus is more resistant to hypoxia than the gastrocnemius and
plantaris (Howlett & Hogan 2007), however it is still to some extent adversely
affected by reduced O2 consumption (Zhang et al. 2006) and therefore it may have
contributed to the lower steady state force production observed in these low flow
conditions. In addition, the contribution of the soleus to overall force development
may have been overshadowed by the effects of low flow on the gastrocnemius and
plantaris, where the restricted blood flow would not only reduce O2 availability
but contribute to a build up of metabolic waste products from these muscles
(Hogan et al. 1998). Specifically, despite the higher O2 consumption in FO
hindlimbs compared to OO hindlimbs, it was lower under these low flow
conditions than under normal conditions in Chapter 4. As such, O2 delivery may
not have been enough to maintain higher contractile force development in the
latter stages of the protocol (Hogan et al. 1998; Hogan et al. 1996). There was
also likely a greater production of metabolic by-products (including H+) from the
enhanced work performed in the early stages of the protocol under ischaemic
conditions in FO animals, as indicated by the reduced venous pH. This would
affect contraction via interactions between these products and Ca2+ handling and
E-C coupling (Amann & Calbet 2008; Harris et al. 1986). Although FO has been
previously associated with improved cellular Ca2+ handling (Dulloo et al. 1994;
McLennan & Abeywardena 2005; Nurnberg et al. 1998), the results of the present
study suggest that these more severe conditions at the end of the protocol may
diminish this effect. Therefore, lower overall O2 consumption in these low flow
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conditions as well as greater build up of H+ (reduced pH) may have severely
affected muscle performance and prevented an effect of n-3 PUFA in these
conditions.

Despite only modest effects of FO on muscle contractile performance under low
flow conditions, fish oil may be associated with protection of the muscle from
oxidative damage associated with exercise. An acute bout of exercise increases
ROS and potential damage to lipids, proteins and DNA (Reid et al. 1992a; Reid et
al. 1993; Reid et al. 1992b), an effect which is enhanced in claudication or muscle
ischaemia (Harris et al. 1986; Judge & Dodd 2003). In the present study, this
stress could be expected to be more pronounced in FO animals due to the greater
O2 consumption. However MDA was reduced in FO hindlimbs subjected to
contraction during low flow, an effect not apparent in normal muscle (Chapter 4).
It may be that the current protocol under low flow conditions was more
demanding, as indicated by the rising resting tension within each 5s bout of
stimulation, enhancing oxidative stress and stimulating the activity of antioxidant
enzymes that protect the muscle from damage associated with activity (Radak
2000). In the heart, fish oil exerts a nutritional preconditioning effect, mimicking
ischaemic preconditioning in reducing tissue damage caused by ischaemia
(Abdukeyum et al. 2008). A similar nutritional preconditioning effect may be
involved in skeletal muscle whereby the upregulation of antioxidants in response
to fish oil consumption (Venkatraman & Pinnavaia 1998) or the action of fish oil
as an antioxidant (Richard et al. 2008) allows the tissues to better cope with
oxidative stress insults and prevents tissue damage from ischaemic injury. Indeed,
it is well documented that fish oil increases the activity and amounts of
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antioxidant enzymes in various tissues including the liver, heart, skeletal muscle
and plasma (Aguilera et al. 2003; Atalay et al. 2000; Hsu et al. 2001; Jahangiri et
al. 2006; Leonardi et al. 2007; Ruiz-Gutierrez et al. 1999; Ruiz-Gutierrez et al.
2001; Venkatraman et al. 1994; Venkatraman & Pinnavaia 1998; Wang et al.
2004). As ROS are implicated in the fatigue process (Ferreira & Reid 2008), it is
also likely that the protection from oxidative damage may have contributed, to
some extent, to the improved contractile response to stimulation. MDA is just one
player in the complex tissue redox system (De Zwart 1999). Further
investigations, including analysis of antioxidant enzyme concentrations and
activities, as well as other markers of oxidative damage, are warranted to
determine the full extent of the fish oil effect on oxidative stress and its
subsequent relationship to muscle fatigue.

The effects of FO on vascular function were also less pronounced under low flow
conditions. A reduction in flow from normal resting 1mL.min-1 to the
experimental flow rate of 0.6mL.min-1 resulted in an increase in resistance, the
opposite effect to flow mediated dilatation. Although not significant, this effect in
FO animals was less pronounced, indicating a reduced vasoconstrictor response.
This is in line with effects observed in humans where fish oil promotes
vasodilatation (Goodfellow et al. 2000; Hall 2009; Hill et al. 2007; Khan et al.
2003; Leeson et al. 2002; Shah et al. 2007). In response to muscle activity, vessels
vasodilate in order to enhance O2 delivery to tissues, resulting in a decrease in
vascular resistance (active hyperaemia)(Dua et al. 2009). This response was not
different between dietary groups under these conditions, in contrast to the greater
active hyperaemic response observed in FO animals under normal flow conditions
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in normal muscle (Chapter 4). Blood flow to exercising muscles is enhanced
during hypoxic conditions (Casey et al. 2009). It is likely that in the current
situation, vessels were already dilated in response to the low flow conditions,
leaving less vasodilatory reserve. As the vessels are maximally dilated during
muscle activity there is little potential for dietary differences in vasodilatory
response.

5.4.3. Conclusions and future recommendations
The present study has identified a potential role of n-3 PUFA in treatment or
prevention of claudication. While there was only a modest effect of FO on
contractile function, the O2 consumption and lipid oxidation results indicate that
these animals may be coping better with the stress of muscle activity at a low flow
rate. These results reflect that seen in human claudication where fish oil improves
pain-free and maximal walking distances (Madden et al. 2007; Sommerfield et al.
2007). The results of the present study are far from conclusive, however combined
with the positive outcomes observed in some human studies, further investigation
into the effects of fish oil on claudication is warranted. It would be of interest to
further explore the modest improvements in contractile function and how this may
translate to the human condition. Furthermore, the likelihood of oxidative stress
being implicated in the fish oil effect highlights the importance of analysing other
biomarkers of oxidative stress including antioxidants and other markers of
oxidative damage that have previously been linked to n-3 PUFA (Aguilera et al.
2003; Atalay et al. 2000; Calviello et al. 1997; Cho & Choi 1994; Hsu et al. 2001;
Jahangiri et al. 2006; Javouhey-Donzel et al. 1993; Kaasgaard et al. 1992;
Leonardi et al. 2007; Ruiz-Gutierrez et al. 1999; Ruiz-Gutierrez et al. 2001;
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Venkatraman et al. 1994; Venkatraman & Pinnavaia 1998; Wang et al. 2004).
Further exploration of the model used in the current study would also help to
validate the current model as a non-surgical alternative for mimicking the human
condition of claudication.
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Chapter 6 HEART FAILURE
6.1 Introduction
The effects of fish oil pertaining to contractile function and fatigue resistance in
skeletal muscle (Chapter 4) may have application in the treatment and/or
management of the muscle dysfunction and fatigue associated with heart failure.
With fish oil exerting similar effects on cardiac and skeletal muscle membrane
composition and potentially similar effects on muscle physiology, the
investigation into a role for fish oil intervention in heart failure and its associated
muscle function is warranted.

6.1.1 Cardiac Hypertrophy and Heart Failure
Heart failure (HF) refers to the heart’s inability to pump blood around the body to
meet the metabolic demands of the tissues (Dyer & Fifer 2003). It is defined
clinically by features of ascites, pleural effusion, and tachypnoea and confirmed,
according to ESC guidelines by echocardiography identification of slowed wall
motion and changes in morphology and ejection fraction. It is a major cause of
morbidity and mortality, with an estimated 300,000 Australians affected and
30,000

new

cases

diagnosed

each

year

(Heart_Foundation

&

Cardiac_Society_of_Australia_and_New_Zealand 2002). Some common causes
of heart failure include myocardial ischaemia/infarction, chronic pressure
overload due to hypertension or aortic stenosis and chronic volume overload
(Dyer & Fifer 2003). However, almost any form of heart disease has the potential
to lead to failure (Francis et al. 2004). Cardiac hypertrophy (enlargement of the
heart) is a compensatory response mechanism that appears early in the
development of HF. This increase in myocardial cell size is initiated by the
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increased cardiac work resulting from a number of mechanical, haemodynamic,
hormonal and pathological stimuli (Hunter & Chien 1999). The hypertrophied
heart is initially in a compensated state, however chronic prolonged stimulation
results in this compensation being no longer sufficient to meet the body’s
metabolic requirements and the heart progresses to contractile dysfunction and
decompensated HF (Walsh 2004). There are a number of intrinsic abnormalities
of heart function that are associated with cardiac hypertrophy and HF. Calcium
cycling is altered significantly (Hasenfuss & Pieske 2002) and may contribute to
the observed contractile dysfunction in HF.

6.1.2 Skeletal muscle function in heart failure
The New York Heart Association classifies HF into four classes based on the
patient’s ability to perform physical activity and the symptoms that may present.
These classes are Class 1: no limitation of physical activity, Class 2: Slight
limitation of physical activity – dyspnea and fatigue present during moderate
activity, Class 3: marked limitation of physical activity – dyspnea and fatigue with
minimal activity, and Class 4: Severe limitation of activity – dyspnea and fatigue
present at rest (Dyer & Fifer 2003). These classifications touch on an important
aspect of HF, exercise intolerance and skeletal muscle fatigue (Coats 1996) that,
in addition to low cardiac output leading to shortness of breath, may also be partly
brought about by an underlying skeletal muscle dysfunction (Lunde et al. 2001b).
It has been shown that although skeletal muscle underperfusion may be present in
HF (Sullivan et al. 1991; Sullivan & Hawthorne 1995; Sullivan et al. 1989;
Weber et al. 1982; Wilson et al. 1984) it does not always exist even though
muscle fatigue may be present (Massie et al. 1987; Thorud et al. 2004; Wiener et
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al. 1986) and underlying skeletal muscle dysfunction plays a role in fatigue and
exercise intolerance. Although the exact mechanisms involved in this skeletal
muscle dysfunction are unknown, it is likely that a number of intrinsic alterations
are involved, including morphological, metabolic and functional abnormalities
(Lunde et al. 2001b).

Evidence suggests that the changes in skeletal muscle involving Ca2+ handling are
similar to those observed in the heart in HF (Lunde et al. 2001a; Perreault et al.
1993; Ward et al. 2003). These intracellular abnormalities, similar in both cardiac
and skeletal muscle, may represent a novel target for preventing and/or treating
HF or its symptoms.

6.1.3 Fish Oil and Cardiac Hypertrophy/Heart Failure
Extending from their effects on coronary heart disease, sudden cardiac death and
arrhythmias, there is emerging evidence for a role of n-3 PUFA in the setting of
HF. The risk of developing congestive heart failure in humans is reduced in
association with eating fish (Mozaffarian et al. 2005a) and supplementation with
n-3 PUFA reduces mortality and admission to hospital for cardiovascular reasons
(Tavazzi et al. 2008). One point that must be considered when looking at
prevention of HF with n-3 PUFA treatment is that there are different ways in
which n-3 PUFA may attenuate or prevent HF. The n-3 PUFA may either act to
prevent hypertrophy and subsequent HF by interfering with hypertrophic
signalling pathways initiated by a stressful stimulus such as myocardial infarction
and pressure overload (Nair et al. 2001) or alternatively, they may act to prevent
the stimulus for hypertrophy altogether. They may also act on ion channels and

158

pumps involved in Ca2+ handling (McLennan & Abeywardena 2005) to improve
myocardial functioning and halt the progression of myocardial dysfunction
associated with HF. One general mechanism by which fish oil may achieve these
effects is the incorporation of n-3 PUFA into the cell membrane. As described in
Chapter 3, even low doses of FO have the capacity to significantly modify
membrane FA composition and such modification (no matter what the dose) is
accepted as a major way in which n-3 PUFA exert their effects on cell function
(McLennan 2004; McLennan & Abeywardena 2005). Further to this dietary
manipulation, membrane composition can be altered in pathophysiological states,
as is the case in cardiac hypertrophy and HF where changes in membrane
composition are associated with poor heart function (Reibel et al. 1986). Whether
these modifications in the absence of dietary manipulation are the cause or the
consequence of the pathological stimulus is not known, however if the latter is the
case, there is the potential for dietary modifications involving n-3 PUFA to help to
restore an optimal membrane composition and ultimately improve function.

A more specific example of how fish oil may be beneficial in hypertrophy and
heart failure is through interaction with protein kinase C (PKC). As βadrenoreceptors become desensitised in HF (Petrashevskaya et al. 2002; Schwarz
et al. 2003), the role of alpha adrenoceptors becomes more prominent.
Angiotensin II and endothelin I receptors may also play a greater role in Ca2+
regulation under these conditions (Molkentin & Dorn 2001). These three receptor
types activate the phospholipase C pathway, which has been implicated in the
development of cardiac hypertrophy via the downstream PKC. As well as
reducing the activity of SERCA, responsible for removing Ca2+ from the cytosol
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during relaxation, PKC has been shown to be involved in gene transcription
pathways which regulate cardiac hypertrophy (Molkentin & Dorn 2001).
Inhibition of PKC by n-3 PUFA may be beneficial in HF by increasing SERCA
activity and/or by interfering with hypertrophic gene transcription (Siddiqui et al.
2008). There are several other ion channels, pumps and signalling pathways that
may also be influenced by n-3 PUFA (Bordoni et al. 2007; McLennan 2004;
Siddiqui et al. 2008; Siddiqui et al. 2000) and thus potentially could contribute to
any beneficial role of fish oil in HF, however our focus is on membrane
incorporation of n-3 PUFA.

Only few animal studies have dealt with the idea of n-3 PUFA in the setting of
cardiac hypertrophy and HF, with most of these being focused on the process of
cardiac hypertrophy. Generally, it seems that when n-3 PUFA are present before
the hypertrophic stimulus, hypertrophy or HF is attenuated (Mozaffarian et al.
2005a; Siddiqui et al. 2004; Takahashi et al. 2005) however they do not appear to
reverse hypertrophy when given after the initial stimulus (Fischer et al. 2008;
McLennan et al. unpublished; Rousseau et al. 2001).

In regards to skeletal muscle function, n-3 PUFA may act to prevent fatigue and
slow the progression of skeletal muscle dysfunction in HF. The results presented
in Chapter 4 indicate that n-3 PUFA improve muscle function and reduce fatigue
induced under different contractile conditions in otherwise normal physiological
circumstances. Fish oil feeding has some similar effects in cardiac and skeletal
muscle in terms of membrane n-3 PUFA incorporation (Chapter 3) (Andersson et
al. 2002; Ayre & Hulbert 1996a; b; McLennan 1993; McLennan et al. 1993) and
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physiological function (Peoples 2004; Pepe & McLennan 2002). Furthermore,
changes in skeletal muscle in HF reflect those seen in the heart with respect to
metabolism and intracellular Ca2+ handling (Hasenfuss & Pieske 2002; Lunde et
al. 2001b; Ventura-Clapier et al. 2004). It is therefore feasible that in the setting
of HF, n-3 PUFA will have similar effects on skeletal muscle as in the heart. First
though, we must determine if the aortic banding model of heart failure results in
skeletal muscle dysfunction. This chapter represents the preliminary extension of
earlier findings in skeletal muscle (Chapter 4) into a model of HF.

6.1.4 Aims and Hypotheses
The purpose of this study was to examine the effects of fish oil on cardiac and
skeletal muscle in the aortic banding model of cardiac hypertrophy and heart
failure. Specifically, this study aimed to determine:
a) the extent to which aortic banding causes cardiac hypertrophy and
membrane fatty acid modifications after 1, 5 and 15 week post-surgery,
b) the effect of low dose fish oil on cardiac hypertrophy and membrane fatty
acid composition when FO is introduced to the diet either before or after
the hypertrophic stimulus (aortic banding surgery),
c) if the aortic banding model causes skeletal muscle dysfunction after 15
weeks post-surgery
d) the role of n-3 PUFA in improving muscle function in heart failure
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It was hypothesised that aortic banding would result in
a) significant cardiac hypertrophy and changes in membrane fatty acid
composition after 5 weeks that will continue to be evident at 15 weeks
post-surgery.
b) skeletal muscle dysfunction in association with clinical signs of HF by
15 weeks post surgery

In addition, it was hypothesised that fish oil would:
a) prevent or attenuate the development of cardiac hypertrophy when given
before but not after the hypertrophic stimulus
b) alter membrane fatty acid composition by increasing n-3 PUFA
incorporation, especially in banded animals
c) exert beneficial effects on muscle function in the context of cardiac
hypertrophy and heart failure

6.2 Methods
6.2.1 Cardiac Hypertrophy
6.2.1.a Animals and diets
Male Sprague Dawley rats (5-6 weeks old) were assigned to one of two diets (OO
or lowFO) as described in 2.1. The LowFO group was split in to two sub groups,
differing only in the timing of the fish oil intervention. This is illustrated in Figure
6-1. Briefly, the LowFO (before) group was maintained on the LowFO diet for the
duration of the experiment. The LowFO (after) group was maintained on the OO
diet for the period before and 1 week following aortic banding surgery, at which
time the diet was switched to the LowFO for the remainder of the experiment.
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Figure 6-1 Dietary groups and timing of intervention.
Light (yellow) shading indicates OO diet. Dark, (green) shading indicates LowFO diet.
║indicates time of aortic banding.

Animals were euthanased 5 weeks following aortic banding surgery by rapid
removal of the heart and exsanguination under anaesthesia (pentobarbitone
sodium 60mg/kg i.p.). A subset of the OO dietary group were euthanased 1 week
following surgery to evaluate the skeletal muscle fatty acid composition just prior
to the LowFO intervention. Heart and skeletal muscle tissues were excised,
weighed, snap frozen in liquid nitrogen and stored at –80ºC for later fatty acid
analysis. Tibia length was also measured to normalise heart to body size, as it is a
more reliable control than body weight which may be subject to acute fluctuations
such as body wasting or oedema and weight gain in disease states (Yin et al.
1982).

6.2.1.b Aortic banding surgery
All surgical instruments were autoclaved prior to surgery (Siltex, Australia) and
then sterilised before use during surgery at 450ºC in a portable glass bead
steriliser (Fine Science Tools Inc., Canada). Animals (9-10 weeks old) were
anaesthetised with Fluothane (in oxygen). Depth of anaesthesia was monitored by
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respiratory rate (maintained at 60 breaths per minute) and the absence of the foot
withdrawal reflex. Once the animal was under anaesthetic (as determined by
stable respiratory rate and absence of the foot withdrawal reflex), the abdominal
region was shaved and swabbed with iodine solution.

An incision was made through the skin and underlying muscles of the left flank.
The underlying tissue was moved aside to expose the aorta, below the level of the
diaphragm and above the level of the renal artery braches. A blunted 23-gauge
needle was laid along the exposed aorta and a silk suture was passed around both
the aorta and the needle and tied tightly. Successful tying of the band was
confirmed by observing the loss of colour of the left kidney. The needle was
immediately removed, leaving a restriction to flow that was consistent in all
animals. Colour restoration of the kidneys indicates successful re-flow of blood
through the restrictive tie. A topical antibiotic (clavulox) was applied to the
wound prior to closure following swabbing with iodine solution. The inner wound
(muscle layer) was closed using sutures and the outer wound (skin) was closed
with stainless steel clips that were left in place until naturally falling off during the
healing process.

Fluid replacement was provided by an intraperitoneal injection of sterile saline
(5mL) immediately following and four hours after surgery. Ketoprofen (5mg/kg
s.c) was given to animals following surgery for post-operative analgesia. Animals
were kept in a warm soft-bedded environment following surgery until recovery of
wakefulness and mobility at which point they were returned to their cages.
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Animals were housed singly until their wound healed to prevent damage to the
wound by their cage mate.

Sham operated animals underwent the same surgical procedure outlined above
except that the suture was removed from around the aorta and needle without
completing the restrictive tie.

6.2.2 Skeletal muscle function/fatigue
6.2.2.a Animals and diets
Male Sprague-Dawley rats (5-6 weeks old) were maintained on olive oil diets
(See section 2.2) for the duration of the experiment. Aortic banding surgery was
performed at 9-10 weeks of age. In the weeks following surgery, rats were
monitored for signs of stress and HF including laboured breathing, immobility,
spiky fur, reduced food intake and weight loss. Rats were euthanased 15 weeks
following surgery at the end of muscle function tests by rapid removal of the heart
and exsanguination. Heart and muscle tissue were weighed upon excision, snap
frozen in liquid nitrogen and stored at -80ºC for later analysis. Tibia length was
also measured.

6.2.2.b Skeletal Muscle fatigue protocols
Skeletal muscle function was assessed 15 weeks following aortic banding surgery
using the auto-perfused hindlimb set up outlined in 2.3. The fatigue protocols used
to assess muscle function (Figure 6-2) are described in 4.2.2 and 4.2.3. In the
current experiment they were conducted in the same animal, separated by a 20min
rest period.
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Figure 6-2 Muscle stimulation protocols

6.2.2.c Data analysis and calculations
Force data and twitch characteristics were analysed using LabView for Windows
display/analyse software. Area under the curve for both the 2Hz and 5Hz 5min
stimulation bouts was calculated as the total area under all twitches over the 5min
period. The decline in force over the 5min period of 2Hz stimulation was
calculated as (peak twitch force-last twitch force)/peak twitch force*100. The
same equation was used for calculating decline over the 5min of 5Hz stimulation
but in this case, the decline of the first twitch of each 5s bout was measured. The
time to 50% was calculated as the time (in seconds) for the twitch force (in the
2Hz protocol) or the first force of the 5s bout (in the 5Hz protocol) to decline to
50% of peak twitch force.

6.2.3 Fatty Acid Analysis
Membrane fatty acid composition was determined in cardiac and skeletal muscle
for each group of animals in 6.2.1.a and 6.2.2.a to a) determine the effect of
hypertrophy on FA composition in the OO control diet at 1, 5 and 15 weeks
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following surgery and b) determine the effect of low dose (0.31%) fish oil on FA
incorporation 5 weeks after surgery in cardiac hypertrophy/HF.

Left ventricle, gastrocnemius and soleus samples were analysed with gas
chromatography for membrane fatty acid composition as outlined in Section 3.2.2.

6.2.4 Statistical Analysis
Two-way analysis of variance was used to assess any effect of aortic banding and
the effect of diet. For analysing the effect of banding over time in the 5Hz
repeated bouts protocol, linear mixed models was employed. One-way ANOVA
was used for analysis of hindlimb pressure and resistance change during each
protocol within each group.

6.3 Results
6.3.1 Animal weights
There were no significant differences in body weight at time of surgery or at time
of euthanasia (all p>0.05, data not shown). Across all groups however, there was a
significant effect of aortic banding on the change in body weight from surgery to
euthanasia, with banded animals gaining less weight (p=0.033, Figure 6-3). The
weight gain was significantly greater in all animals at 5wk after surgery compared
to 1wk after, with the LowFO (after) animals having the greatest weight gain after
surgery (p=0.01).
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Figure 6-3 Effect of aortic banding on body weight gain from surgery to euthanasia.
*p=0.033 sham vs. banded. #p<0.01 5wk vs OO 1wk. †p<0.01 LowFO after vs. other
dietary groups. n=4-6 per group.

6.3.2 Membrane Fatty Acid Composition
In the left ventricle (Table 6-1), there were significant effects of aortic banding on
membrane fatty acid composition in the control (OO diet), 15, but not 1 or 5,
weeks after surgery. These include an increase in 18:0, 22:4n-6, 22:5n-6 and
22:5n-3 and a reduction in 18:2n-6. These changes resulted in a rise in total
saturated fatty acids and a reduction in total PUFA and total n-6 PUFA. Across all
time points there was a non-significant trend towards increased 22:6n-3 and total
n-3 PUFA however these changes were not significant (p=0.19-0.30).

When initiated before aortic banding surgery, dietary FO resulted in a large,
significant incorporation of 22:6n-3 and a marked reduction in incorporation of
20:4n-6 (p<0.001). Small but significant increases were seen in 20:5n-3 and
20:3n-6 together with small decreases in incorporation of 18:1n-9, 18:2n-6, 22:4n6, 22:5n-6 and 22:5n-3 (all p<0.05 FO sham vs. OO sham at 5wk). The result was
an increase in total n-3 PUFA and peroxidation index and a decrease in total
168

MUFA, total n-6 PUFA and the n-6/n-3 ratio (all p<0.05). These effects of the FO
diet obscured or prevented all effects of aortic banding on membrane composition,
with no significant differences observed between banded and sham animals with
this dietary intervention (all p>0.05).

Similar changes were observed when the FO intervention began after the aortic
banding surgery, with marked increases in 22:6n-3, total n-3 PUFA and the
peroxidation index and marked decreases in 20:4n-6, total n-6 PUFA and the n6/n-3 ratio (all p<0.05 FO sham vs. OO sham at 5wk) with other small changes in
the same fatty acid species described above.

In the gastrocnemius (Table 6-2), aortic banding was associated with significantly
increased 20:4n-6 and 22:5n-6 and decreased 22:4n-6 and 22:6n-3 resulting in a
lower total n-3 PUFA and higher n-6/n-3 ratio (all p<0.05 sham vs. banded) by 15
weeks after surgery. Dietary fish oil intervention, either before or after surgery
resulted in a marked rise in 22:6n-3 and reduction in 20:4n-6. Small but
significant changes in other fatty acids were also observed, with increased 20:5n-3
and decreased 18:0, 18:2n-6, 22:4n-6, 22:5-6 and 22:5n-3. These effects resulted
in an overall increase in total n-3 PUFA and the peroxidation index and a
reduction in total n-6 PUFA and the n-6/n-3 PUFA ratio in both sham and banded
groups (all p<0.05 FO vs. OO diets), obscuring the effect of hypertrophy observed
in OO control animals (all p>0.05 sham vs. banded within dietary FO group).

In the soleus muscle (Table 6-3), there was no significant effect of hypertrophy on
any aspect of membrane composition. Dietary FO resulted in the similar changes
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in membrane composition as observed in the gastrocnemius. These changes
included a marked increase in 22:6n-3 and concomitant reduction in 20:4n-6,
along with small increases in 20:5n-3 and decreases in 18:1n-9, 18:2n-6, 22:4n-6,
22:5n-6 and 22:5n-3, resulting in higher total n-3 PUFA and peroxidation index
and lower total n-6 PUFA and n-6/n-3 PUFA ratio (all p<0.05 FO vs. OO diets).
These effects were more prominent in the FO intervention that began before aortic
banding surgery.

170

Table 6-1 Fatty acid composition of the Left Ventricle
OO

OO

OO

LowFO (before)

1wk sham

1wk banded

5wk sham

5wk banded

15wk sham

15wk
banded

9.22 ± 0.32

9.22 ± 0.30

8.56 + 0.22

8.64 ± 0.32

9.59 ± 0.18

0.10 + 0.10

0.06 ± 0.06

0.04 ± 0.04

0.00 ± 0.00

0.36 ± 0.02

21.45 ± 0.63

21.66 ± 0.21

22.27 ± 0.31

22.32 ± 0.25

8.77 ± 0.31

8.86 ± 0.40

8.50 ± 0.44

9.32 ± 0.49

18:2n-6
20:3n-6
20:4n-6
20:5n-3
22:4n-6
22:5n-6
22:5n-3
22:6n-3

20.22 ± 1.02

18.22 ± 1.31

19.33 ± 0.96

0.59 ± 0.04

0.58 ± 0.02

0.53 ± 0.03

22.48 ± 0.52

23.62 ± 0.43

ND

ND

0.95 ± 0.06
3.56 ± 0.46

5wk sham

5wk banded

10.03 ± 0.22

9.74 ± 0.32

0.31 ± 0.03

0.06 ± 0.06

20.49 ± 0.13

20.97 ± 0.11*

9.58 ± 0.27

9.12 ± 0.37

17.80 ± 0.67

21.17 ± 0.39

0.45 ± 0.03

0.55 ± 0.02

24.87 ± 0.02

23.73 ± 0.52

ND

ND

0.91 ± 0.04

0.93 ± 0.08

3.29 ± 0.31

3.01 ± 0.34

0.71 ± 0.04

0.65 ± 0.08

7.20 ± 0.47

8.15 ± 0.72

Σ Sat
Σ MUFA
Σ PUFA

31.21 ± 0.46

Σ n-6
Σ n-3
n-6/n-3
PI

16:0
16:1
18:0
18:1n-9

LowFO (after)
5wk sham

5wk banded

9.87 ± 0.30

10.01 ± 0.32

9.91 ± 0.31

0.00 ± 0.00

0.056 ± 0.06

0.00 ± 0.00

21.53 ± 0.29

21.55 ± 0.23

21.59 ± 0.13

22.23 ± 0.19*

7.43 ± 0.37

8.03 ± 0.37

7.12 ± 0.29

6.99 ± 0.41

17.06 ± 0.39*

17.66 ± 0.43

17.14 ± 1.10

17.81 ± 0.87

17.50 ± 0.82

0.48 ± 0.03

0.63 ± 0.02

0.62 ± 0.04

0.56 ± 0.01

0.53 ± 0.02

24.04 ± 0.37

25.22 ± 0.52

18.03 ± 0.52

17.64 ± 0.45

18.34 ± 0.50

17.92 ± 0.14

ND

ND

0.12 ± 0.03

0.15 ± 0.03

0.10 ± 0.03

0.13 ± 0.01

0.88 ± 0.03

0.71 ± 0.04

0.86 ± 0.03*

0.31 ± 0.03

0.36 ± 0.02

0.43 ± 0.03

0.41 ± 0.03

3.50 ± 0.15

2.07 ± 0.10

2.94 ± 0.27*

0.75 ± 0.05

0.73 ± 0.06

1.11 ± 0.14

1.06 ± 0.10

0.65 ± 0.04

0.52 ± 0.03

0.68 ± 0.04

0.84 ± 0.05*

0.66 ± 0.04

0.63 ± 0.07

0.75 ± 0.07

0.73 ± 0.06

6.95 ± 0.48

7.96 ± 0.48

6.62 ± 0.34

7.29 ± 0.61

18.80 ± 0.85

18.35 ± 0.55

17.93 ± 0.47

17.94 ± 0.80

31.34 ± 0.30

31.25 ± 0.36

31.49 ± 0.32

30.11 ± 0.12

31.00 ± 0.19*

31.34 ± 0.29

31.90 ± 0.24

31.92 ± 0.22

32.60 ± 0.19

13.01 ± 0.44

13.19 ± 0.26

12.41 ± 0.50

13.68 ± 0.61

13.79 ± 0.20

14.07 ± 0.41

11.66 ± 0.36

12.49 ± 0.26

11.06 ± 0.29

11.19 ± 0.39

55.79 ± 0.18

55.47 ± 0.23

56.34 ± 0.32

54.83 ± 0.38

56.10 ± 0.15

54.93 ± 0.47*

57.00 ± 0.31

55.62 ± 0.40

57.02 ± 0.23

56.22 ± 0.48

47.79 ± 0.51

46.61 ± 0.75

48.67 ± 0.73

46.35 ± 0.36

48.54 ± 0.23

46.57 ± 0.71*

37.39 ± 0.69

36.49 ± 0.69

38.25 ± 0.55

37.42 ± 0.88

7.91 ± 0.46

8.80 ± 0.72

7.60 ± 0.46

8.48 ± 0.46

7.30 ± 0.34

8.13 ± 0.60

19.58 ± 0.90

19.13 ± 0.50

18.77 ± 0.47

18.80 ± 0.86

6.13 ± 0.39

5.46 ± 0.50

6.52 ± 0.48

5.52 ± 0.33

6.73 ± 0.34

5.86 ± 0.45

1.93 ± 0.11

1.91 ± 0.08

2.05 ± 0.08

2.01 ± 0.13

137.60 ± 0.92

139.94 ± 3.80

136.91 ± 2.52

138.91 ± 2.91

133.80 ± 1.79

138.69 ± 1.91

161.24 ± 2.97

157.33 ± 2.87

159.52 ± 1.55

158.13 ± 3.14

Values are mean ± SEM. n= 5-6 per group. *p<0.05 vs. sham. Σ Sat = sum of saturated fatty acids. Σ MUFA = sum of monounsaturated fatty acids. Σ Poly = sum of
polyunsaturated fatty acids. Σ n-3 PUFA = sum of n-6 polyunsaturated fatty acids. Σ n-6 = sum of n-6 polyunsaturated fatty acids. PI = Peroxidation Index. ND = not detected.
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Table 6-2 Fatty acid composition of the Gastrocnemius
OO

OO

OO

LowFO (before)

LowFO (after)

1wk sham

1wk banded

5wk sham

5wk banded

15wk sham

15wk
banded

5wk sham

5wk banded

5wk sham

5wk banded

16:0
16:1
18:0
18:1n-9

18.18 ± 1.78

18.86 ± 0.90

18.52 ± 2.12

19.52 ± 1.61

15.70 ± 0.83

15.26 ± 1.07

18.31 ± 1.17

16.88 ± 1.61

19.76 ± 1.64

19.69 ± 1.44

0.61 ± 0.07

0.54 ± 0.01

0.59 ± 0.04

0.48 ± 0.18

0.63 ± 0.04

1.01 ± 0.46

0.54 ± 0.03

0.60 ± 0.07

1.44 ± 0.88

0.78 ± 0.02

16.06 ± 0.24

16.50 ± 0.29

15.94 ± 0.18

16.19 ± 0.79

16.15 ± 0.76

14.80 ± 0.33

15.15 ± 0.43

15.59 ± 0.30

14.51 ± 1.26

16.07 ± 0.36

10.29 ± 1.10

9.80 ± 0.20

11.54 ± 1.07

12.69 ± 1.14

6.59 ± 1.05

7.87 ± 1.36

9.46 ± 0.18

10.71 ± 0.69

10.83 ± 0.60

10.74 ± 1.06

18:2n-6
20:3n-6
20:4n-6
20:5n-3
22:4n-6
22:5n-6
22:5n-3
22:6n-3

18.32 ± 0.69

17.27 ± 0.31

18.30 ± 1.15

17.07 ± 2.10

19.66 ± 0.85

18.24 ± 0.37

14.25 ± 0.76

16.11 ± 0.42

17.05 ± 0.79

18.22 ± 0.44

0.80 ± 0.06

0.78 ± 0.02

0.73 ± 0.04

0.60 ± 0.07

0.47 ± 0.10

0.71 ± 0.05

0.73 ± 0.01

0.68 ± 0.03

0.60 ± 0.04

0.63 ± 0.05

16.09 ± 0.66

16.58 ± 0.33

15.25 ± 1.52

16.36 ± 1.45

15.85 ± 0.53

18.64 ± 0.39*

11.53 ± 0.60

10.83 ± 0.31

11.12 ± 1.25

11.79 ± 0.38

ND

ND

ND

ND

ND

ND

0.18 ± 0.07

0.14 ± 0.08

0.15 ± 0.06

ND

0.74 ± 0.02

0.72 ± 0.05

0.67 ± 0.18

0.61 ± 0.24

0.94 ± 0.09

0.66 ± 0.05*

0.19 ± 0.08

0.05 ± 0.05

0.20 ± 0.06

0.24 ± 0.08

2.50 ± 0.13

2.33 ± 0.17

1.84 ± 0.31

2.34 ± 0.16

1.39 ± 0.11

2.05 ± 0.14*

0.68 ± 0.05

0.60 ± 0.03

1.01 ± 0.20

1.14 ± 0.11

1.41 ± 0.10

1.20 ± 0.09

1.12 ± 0.09

1.04 ± 0.02

0.87 ± 0.06

0.99 ± 0.08

0.94 ± 0.05

0.91 ± 0.12

1.17 ± 0.13

1.27 ± 0.11

9.33 ± 0.31

8.70 ± 0.47

10.20 ± 2.47

8.40 ± 0.28

9.26 ± 0.74

6.74 ± 0.35*

20.04 ± 0.12

20.27 ± 0.70

14.41 ± 1.27

16.37 ± 0.59

Σ Sat
Σ MUFA
Σ PUFA

37.34 ± 1.03

38.96 ± 0.83

37.74 ± 2.07

38.59 ± 1.65

37.40 ± 1.16

35.26 ± 0.73

37.81 ± 0.94

36.09 ± 1.18

38.05 ± 0.83

38.37 ± 1.37

14.33 ± 1.10

13.78 ± 0.36

15.22 ± 1.15

16.13 ± 1.39

11.15 ± 0.95

13.15 ± 1.02

14.06 ± 0.37

15.04 ± 0.85

16.73 ± 2.38

14.17 ± 1.13

48.34 ± 0.31

47.26 ±0.61

17.04 ± 1.42

45.28 ± 0.28

51.45 ± 0.89

51.59 ± 1.64

48.14 ± 0.62

48.88 ± 0.55

45.22 ± 3.06

47.64 ± 0.26

Σ n-6
Σ n-3
n-6/n-3
PI

38.20 ± 0.21

38.78 ± 0.54

36.59 ± 2.7

36.39 ± 0.35

41.23 ± 0.94

43.40 ± 1.41

28.35 ± 0.35

29.13 ± 0.43

30.59 ± 2.04

31.64 ± 0.26

9.57 ± 0.34

8.90 ± 0.45

10.00 ± 2.06

8.32 ± 0.19

9.75 ± 0.63

7.47 ± 0.40*

19.51 ± 0.31

19.45 ± 0.70

14.20 ±1.16

15.46 ± 0.46

4.01 ± 0.15

4.29 ± 0.24

4.27 ± 0.78

4.38 ± 0.13

4.33 ± 0.34

5.86 ± 0.28*

1.45 ± 0.02

1.51 ± 0.07

2.18 ± 0.10

2.05 ± 0.07

136.33 ± 1.10

133.08 ± 2.51

134.40 ± 4.96

130.37 ± 3.87

135.85 ± 2.85

136.67 ± 2.78

161.42 ± 3.09

161.11 ± 2.94

137.91 ± 9.90

145.56 ± 2.16

Values are mean ± SEM. n= 5-6 per group. *p<0.05 vs. OO diet. Σ Sat = sum of saturated fatty acids. Σ MUFA = sum of monounsaturated fatty acids. Σ Poly = sum of
polyunsaturated fatty acids. Σ n-3 PUFA = sum of n-6 polyunsaturated fatty acids. Σ n-6 = sum of n-6 polyunsaturated fatty acids. PI = Peroxidation Index. ND = not detected.
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Table 6-3 Fatty acid composition of the Soleus
OO

OO

1wk sham

1wk banded

16:0
16:1
18:0
18:1n-9

13.22 ± 1.18
0.71 ± 0.17

OO

LowFO (before)

LowFO (after)

15wk
banded

5wk sham

5wk banded

5wk sham

5wk banded

9.83 ± 0.56

8.79 ± 0.36

12.88 ±1.08

12.71 ± 2.08

12.95 ± 0.96

11.13 ± 0.40

0.75 ± 0.09

0.45 ± 0.03

0.45 ± 0.05

0.53 ± 0.11

0.48 ± 0.03

0.50 ± 0.07

5wk sham

5wk banded

15wk sham

13.46 ± 0.94

9.34 ± 0.66

13.35 ± 1.12*

0.66 ± 0.07

0.42 ± 0.11

0.45 ± 0.08

18.26 ± 0.33

18.33 ± 0.27

18.98 ± 0.24

18.59 ± 0.23

18.77 ± 0.45

18.73 ± 0.42

18.54 ± 0.16

18.45 ± 0.39

18.96 ± 0.27

18.52 ± 0.37

14.34 ± 0.74

15.37 ± 0.90

15.32 ± 1.00

15.82 + 1.01

12.35 ± 1.02

11.75 ± 0.89

12.67 ± 0.86

13.35 ± 1.18

12.75 ± 1.09

14.63 ± 1.17

18:2n-6
20:3n-6
20:4n-6
20:5n-3
22:4n-6
22:5n-6
22:5n-3
22:6n-3

19.82 ± 0.40

18.26 ± 0.77

18.48 ± 0.50

17.61 ± 0.46

20.68 ± 0.55

21.12 ± 0.74

17.05 ± 0.32

17.94 ± 0.77

16.43 ± 0.52

17.65 ± 0.27

0.77 ± 0.06

0.76 ± 0.03

0.66 ± 0.04

0.57 ± 0.04

0.80 ± 0.02

0.73 ± 0.05

0.88 ± 0.02

0.83 ± 0.01

0.73 ± 0.02

0.76 ± 0.02

15.83 ± 0.61

15.61 ± 0.40

17.16 ± 0.12

17.27 ± 0.35

16.37 ± 0.42

17.48 ± 0.45

13.05 ± 0.38

11.08 ± 0.84

12.65 ± 0.72

13.04 ± 0.46

ND

ND

ND

ND

ND

ND

0.10 ± 0.06

ND

ND

0.13 ± 0.13

0.86 ± 0.02

0.81 ± 0.03

0.91 ± 0.06

0.78 ± 0.05

0.66 ± 0.06

0.69 ± 0.05

0.27 ± 0.07

0.17 ± 0.10

0.28 ± 0.09

0.46 ± 0.07

2.51 ± 0.21

2.29 ± 0.14

1.85 ± 0.78

2.25 ± 0.11

1.24 ± 0.08

1.71 ± 0.20

0.59 ± 0.02

0.46 ± 0.05

0.76 ± 0.09

0.77 ± 0.04

1.22 ± 0.06

0.93 ± 0.08

0.92 ± 0.06

0.84 ± 0.04

0.71 ± 0.03

0.77 ± 0.04

0.94 ± 0.07

0.91 ± 0.09

1.06 ± 0.08

1.04 ± 0.07

8.68 ± 0.64

8.40 ± 0.58

5.89 ± 0.42

7.27 ± 0.36

5.14 ± 0.23

4.77 ± 0.44

15.21 ± 0.69

15.73 ± 0.57

14.51 ± 0.39

14.49 ± 0.07

Σ Sat
Σ MUFA
Σ PUFA

33.37 ± 1.21

34.14 ± 1.00

31.82 ± 0.69

34.30 ± 1.28

32.94 ± 0.73

31.78 ± 0.78

34.78 ± 0.77

34.39 ± 2.00

35.86 ± 1.40

32.73 ± 0.30

18.22 ± 0.91

19.36 ± 0.80

20.04 ± 0.86

19.66 ± 1.25

17.72 ± 1.29

16.74 ± 0.86

17.05 ± 1.06

17.64 ± 1.67

16.94 ± 1.07

18.77 ± 0.94

48.41 ± 0.43

46.50 ± 1.24

48.14 ± 0.76

46.04 ± 0.21

49.34 ± 1.07

51.48 ± 0.84

48.17 ± 0.46

47.98 ± 0.67

47.20 ± 0.67

48.49 ± 0.65

Σ n-6
Σ n-3
n-6/n-3
PI

39.03 ± 0.56

37.47 ± 1.07

40.98 ± 0.84

38.07 ± 0.10*

42.92 ± 1.10

45.21 ± 0.86

32.84 ± 0.50

32.31 ± 0.45

32.21 ± 0.48

33.63 ± 0.48

8.68 ± 0.58

8.27 ± 0.49

6.38 ± 0.32

7.19 + 0.21

5.62 ± 0.21

5.34 ± 0.40

14.85 ± 0.51

15.21 ± 0.52

14.44 ± 0.34

14.32 ± 0.26

4.62 ± 0.45

4.59 ± 0.31

6.50 ± 0.39

5.31 ± 0.15*

7.71 ± 0.43

8.71 ± 0.82

2.23 ± 0.11

2.13 ± 0.08

2.23 ± 0.05

2.35 ± 0.03

136.17 ± 1.76

133.57 ± 2.38

132.61 ± 1.61

132.13 ± 1.38

125.37 ± 1.38

129.66 ± 1.93

149.37 ± 0.82

148.41 ± 2.21

146.91 ± 3.86

150.17 ± 0.63

Values are mean ± SEM. n= 5-6 per group. *p<0.05 vs. OO diet. Σ Sat = sum of saturated fatty acids. Σ MUFA = sum of monounsaturated fatty acids. Σ Poly = sum of
polyunsaturated fatty acids. Σ n-3 PUFA = sum of n-6 polyunsaturated fatty acids. Σ n-6 = sum of n-6 polyunsaturated fatty acids. PI = Peroxidation Index. ND = not detected.
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6.3.3 Cardiac hypertrophy
Aortic banding was associated with significantly increased heart size (as measured
by heart weight to tibia length ratio) after 5wk (p=0.001) and 15wk (p=0.018) of
aortic banding (Table 6-4). This hypertrophy was not evident at 1wk after surgery
(p=0.807).

Table 6-4 Effect of aortic banding on heart size in control (OO diet) rats.
Time after Surgery
Sham
Banded
Difference
2%
1 wk
2.41 ± 0.15
2.46 ± 0.15
*
20%
5 wk
2.31 ± 0.07
2.78 ± 0.07
23%
15 wk
2.82 ± 0.08
3.47 ± 0.26*
Heart weight to tibia length ratio in OO diet. Values are mean±SEM. *p<0.05 sham vs. banded.

In rats fed FO prior to the surgical hypertrophic stimulus, there was no significant
cardiac hypertrophy at 5wk (2% increase; sham, n=6, 2.760±0.119 vs. banded
n=5, 2.812±0.159, p=0.797, Figure 6-4). A significant hypertrophic response
(15% increase) was observed in those animals that began their LowFO
intervention after the surgery (sham, n=6, 2.058±0.035 vs. banded, n=4,
2.373±0.154, p=0.041), however it was less than the OO response.
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Figure 6-4 Percent change in heart size, 5wk after aortic banding.
HW/TL ratio = ratio of heart weight to tibia length.

6.3.4 Skeletal muscle function
6.3.4.a Heart and muscle weight
Heart weight was significantly greater in aortic banded animals at 15wk compared
to the sham operated animals (Table 6-4). Skeletal muscle weight was measured
as the weight of the gastrocnemius/soleus/plantaris muscle bundle in relation to
tibia length. There was no significant effect of banding on skeletal muscle weight
at 5wk after surgery however at 15wk, muscle weight was significantly less in
banded animals (Figure 6-5).
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Figure 6-5 Effect of banding on muscle weight.
GSP/TL= ratio of GSP muscle bundle weight to tibia length. *p=0.004. n=5-6 per group.

6.3.4.b 2Hz continuous twitch stimulation
Force production in response to 50Hz tetanic stimulation conducted after the 5min
of 2Hz stimulation was significantly less than that achieved at the beginning of
the protocol (Figure 6-6), however the tetanic contraction was not different
between sham and banded groups (T1 p=0.715 and T2 p=0.786). During the 2Hz
stimulation period, the force production rose to a peak within the first 60 seconds
before falling gradually throughout the rest of the protocol. There was no
significant effect of aortic banding on this pattern of response to 2Hz stimulation,
represented by the first (p=0.769), peak (p=0.213) and last (p=0.174) twitch forces
(Figure 6-6). There were also no significant differences between sham and banded
groups in measures of twitch characteristics such as rise and fall times and
maximum rates of contraction and relaxation (data not shown, all p>0.05)
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Figure 6-6 Effect of diet on force production throughout 2Hz continuous twitch
stimulation protocol.
Force production in N.100g-1 of GSP tissue. Tetanus 1 and Tetanus 2 represent the tetanic
50Hz, 1 sec contractions 60s. First twitch, Peak twitch and Last twitch represent the force
generated in the first, peak and last twitches of the 2Hz stimulation. n=5-6 per group.

There were no significant differences in area under the tension curve or time to
50% between sham and banded animals (p=1.00 and p=0.81 respectively)(Table
6-5). The banded animals showed a non-significant trend (p=0.09) towards greater
decline in twitch tension over the 5min, from a combination of slightly higher
peak force and lower last force however this effect was not significantly different
(Figure 6-6).
Table 6-5 Muscle function parameters (2Hz Continuous twitch stimulation).

Sham
3363 ± 765
153 ± 46
-73.5 ± 5.9

Area under the curve
Time to 50% (s)
% Change in Force over 5min

Values are mean±SEM. n=5-6 per group.
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Banded
3359 ± 388
140 ± 19
-88.2 ± 4.5

6.3.4.c 5Hz repeated bouts stimulation
The force produced by the first (a) and last (b) twitches in each 5s bout of 5Hz
stimulation over the 5min protocol is illustrated in Figure 6-7. Although there was
a significant effect of time (p<0.01), no significant differences between sham and
banded animals were observed in either the first or last forces of each bout of
stimulation (FF treatment p=0.804 and treatment*time interaction p=0.912, FL
treatment p=0.985 and interaction p=0.951). Additionally, twitch characteristics
(of the first and last twitch in each bout) such as rise and fall times and maximum
rates of contraction and relaxation were not significantly different between groups
(all p>0.05, data not shown)

There was no significant effect of banding on other parameters of muscle function
including the area under the curve (p=0.968), time for FF to reach 50% of peak
force (p=0.856) or decline of FF over the 5min period (p=0.550, Table 6-6).
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Figure 6-7 Effect of banding on force production throughout 5Hz repeated bouts
stimulation protocol.
a) force production of the first twitch (Ft) in each 5s bout of 5Hz stimulation. b) force
production of the last twitch (Lt). n= 5-6 per group.
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Table 6-6 Muscle function parameters (5Hz repeated bouts stimulation).
Sham
Banded
Area under the curve
2380 ± 737
2426 ± 794
Time to 50% (s)
174 ± 29
183 ± 39
% Change in Ft force
-66 ± 9
-73 ± 6
Values are mean+SEM. n=5-6 per group.

6.3.4.d Hindlimb Pressure and resistance
Hindlimb pressure rose slightly upon increasing flow rate in both groups however
this increase was only significant in the sham group (Table 6-7). There was also a
significant reduction in vascular resistance with the increase in flow (sham
p=0.0002 and banded p=0.0017). The initial perfusion pressure and the responses
to a change in flow rate were not different between the sham and banded groups
(p=0.260). A significant drop in hindlimb perfusion pressure was observed in
association with muscle contraction during each stimulation protocol (a and b, all
p<0.05, Figure 6-8). This drop was not significantly different between sham and
banded groups (c, p>0.05). There was a significant decrease in vascular resistance
in association with muscle contraction in both protocols (all p<0.05) but no effect
of banding on this response (data not shown, p=0.25 and p=0.59 for 2Hz and 5Hz
protocols respectively).

Table 6-7 Perfusion pressure response to an increase in resting flow rate.
Sham
Banded
-1
Pressure (mmHg) at 1mL.min
105.92 ± 5.92
107.74 ± 6.82
Pressure (mmHg) at 1.5mL.min-1
116.42 ± 9.66*
114.40 ± 7.76
Δ resistance (%)
-25.90 ± 1.93
-29.22 ± 1.82
Values are mean±SEM. n=3-5 per group. *p=0.025 vs. 1mL.min-1.
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Figure 6-8 Hindlimb Pressure at rest and in response to muscle activity.
a) resting HP prior to and lowest HP during 2 Hz continuous twitch stimulation protocol,
b) resting HP prior to and lowest HP during 5Hz repeated bouts stimulation protocol, c)
maximal drop in HP in response to stimulation and contraction. *p<0.05 muscle activity
compared to corresponding group baseline. n=3-5 per group.
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6.4 Discussion
6.4.1. Aortic banding and membrane fatty acid composition
Our study is one of the first to show the changes in membrane fatty acid
composition associated with aortic banding. While this has been examined to
some extent in cardiac muscle (Duda et al. 2009; Reibel et al. 1986; Shah et al.
2009), it has not previously been examined in skeletal muscle.

The major effects of aortic banding on myocardial membrane composition are a
significant reduction in 18:2n-6 and an increase in 22:6n-3 concentration (Duda et
al. 2009; Reibel et al. 1986; Shah et al. 2009). Our results, although not
significant in all cases, support these earlier findings and extend them to include a
wider range of fatty acid analysis. Extending our analysis to include more fatty
acids has indicated that some remodelling pertaining to n-6 PUFA has occurred,
where some of the reduced 18:2n-6 may have been converted to longer chain n-6
PUFA such as 22:4n-6 and 22:5n-6. In contrast to previous work, (Duda et al.
2009; Reibel et al. 1986; Shah et al. 2009), we did not find a significant rise in
22:6n-3, however the rise in 22:5n-3 was significant in our study. This result can
be explained by the relationship between n-6 PUFA and n-3 PUFA in their
respective biosynthetic pathways. In our study there was a greater initial amount
of n-6 PUFA and less n-3 PUFA in the tissues. Because of this and the
competition between n-6 PUFA and n-3 PUFA for the enzymes involved in the
biosynthetic pathways (Geiger et al. 1993; Sprecher 2000; Tran et al. 2001), it is
likely that the n-6 PUFA pathway was more active in the present study, thus
potentially contributing to the lack of significant rise in 22:6n-3 but the significant
rise in it’s precursor 22:5n-3. In addition, the current study used purified diets
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with only OO provided as the control. This is different to the studies that showed
a significant rise in DHA with aortic banding, where chow diets (Reibel et al.
1986) or other pre-fabricated diets (Duda et al. 2009; Shah et al. 2009)were used.
The chow diet is likely to have contained significant 18:3n-3, the precursor to
DHA found in grain sources, as well as traces of DHA in meat or even fish meal
(Howe et al. 2007). The other pre-fabricated diets contained a small amount of
soybean oil as a source of fat (Duda et al. 2009; Shah et al. 2009). This oil is rich
in 18:n-3 and although the conversion of 18:3n-3 to EPA, and subsequently DHA,
is relatively slow (Wallis et al. 2002), it is likely that the dietary compositions of
those studies may have contributed to the significant incorporation of DHA with
aortic banding in those studies. In the model used in the present study, it is
probable that the increase in 22:6n-3 would become significant over a longer
period of time after aortic banding.

Despite the lack of statistical significance at 1wk and 5wk post-surgery the
observed trends represent a progressive change in membrane fatty acid
composition as cardiac hypertrophy develops. Furthermore, although not
significant, there was a general trend for n-3 PUFA to increase in banded animals.
This may represent an adaptive response of the cardiac muscle to the
pathophysiological states to optimise membrane composition and improve or
restore function. In support of an adaptive mechanism, the concentration of DHA
is increased after exposure to catecholamine stress (Emilsson & Gudbjarnason
1983; Gudbjarnason 1989; Gudbjarnason & Benediktsdottir 1995; 1996) and
furthermore, a higher DHA concentration is evident in animals with high heart
rates (Gudbjarnason et al. 1978) and metabolic rates (Hulbert 2008). In contrast,
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dietary manipulation of DHA concentrations reduces heart rate (Pepe &
McLennan 1996) and catecholamine-induced arrhythmias (Gudbjarnason 1989)

Of particular interest in the left ventricle is the effect of low doses of fish oil
supplied in the diet either before or after the hypertrophic stimulus. As n-3 PUFA
were increased in banded animals on a control diet, it was hypothesised that
supplying very low doses of fish oil in the diet would increase the incorporation of
n-3 PUFA into cardiac membranes in banded animals more so than in sham
animals, as new membrane is produced for cells as they hypertrophy. Our results
however show similar incorporation of n-3 PUFA in both sham and banded
animals. While this is not as hypothesised, the vastly higher amounts of n-3 PUFA
in FO fed animals compared to OO animals (when fed either before or after the
surgery) indicates that even at this low dose (0.31%), cardiac membranes
preferentially incorporate as much n-3 PUFA as is available in the diet, with the
increased DHA concentration from 8% to 18% of total fatty acids obscuring any
subtle changes due to the banding. Preferential incorporation of n-3 PUFA in
banded animals may be exposed if even smaller amounts than the 0.31% is
supplied in the diet. Indeed, this was probably the case in earlier studies of cardiac
membrane composition changes with aortic banding where trace amounts of n-3
PUFA were likely present in the diet from grain, red meat or soybean oil sources
resulting in increased DHA incorporation in banded animals (Duda et al. 2009;
Reibel et al. 1986; Shah et al. 2009).

It is noteworthy that the animals fed FO only after the aortic banding surgery had
very similar membrane DHA incorporation compared to those given FO before

184

the surgery (9weeks feeding), corresponding to a 5 week difference in FO feeding
time. This confirms that dietary modification of membrane fatty acids occurs
relatively quickly, with near maximal changes observed after 4 weeks of FO
feeding (Owen et al. 2004).

Cardiac hypertrophy was also associated with small changes in skeletal muscle
membrane composition. Although the soleus muscle fatty acid composition
remained relatively unaffected by aortic banding, there were significant changes
in the gastrocnemius muscle, with the major effect being a reduction in n-3 PUFA
after 15wk. This represents a different pattern of membrane composition
compared to the cardiac changes and could potentially contribute to altered
skeletal muscle function in heart failure. As in many other tissues, the membrane
fatty acid profile of skeletal muscle has the potential to change and respond to
different circumstances however in general, changes have been directly associated
with the muscle itself. For example, chronic exercise modifies membrane fatty
acid composition (Helge et al. 1999), with adaptive increases in DHA as seen in
the heart under stress (Emilsson & Gudbjarnason 1983; Gudbjarnason &
Benediktsdottir 1995; 1996). In the present study, the changes (trend to reduction
in DHA) were stimulated by the external effects of aortic banding, which in
contrast to exercise, does not imply any increase in skeletal muscle load. In the
absence of any dietary intervention (the OO control diet), the changes observed in
the gastrocnemius may suggest a pool from which cardiac muscle draws its n-3
PUFA. Obviously further investigation into this area is required to determine the
relationship between these changes in skeletal muscle and those observed in the
heart.
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6.4.2 Fish oil effects on cardiac hypertrophy
The present study is the first to show that low doses of dietary fish oil
significantly halts the development of cardiac hypertrophy in the aortic banding
rat model of cardiac hypertrophy and HF. This was especially obvious when the
FO supplementation was given prior to the hypertrophic stimulus. These results
support previous animal studies with higher fish oil doses that show a similar
preventative effect of fish oil on cardiac hypertrophy (Huggins et al. 2009;
Siddiqui et al. 2004; Takahashi et al. 2005). Specifically, in mice genetically bred
to have enlarged hearts (Takahashi et al. 2005) and in neonatal cardiomyocytes
(Siddiqui et al. 2004) hypertrophy was attenuated by n-3 PUFA when given prior
to the hypertrophic stimulus. Studies using spontaneously hypertensive rats as a
hypertrophic model are contradictory, showing a reduction (von Au et al. 1988) or
no change (Brandle & Jacob 1990) in hypertrophy after dietary fish oil
supplementation.

The finding of a lesser hypertrophic effect in response to banding when FO was
supplied after the hypertrophic stimulus is also of interest, as this is one of the first
observations of its kind. Only one prior study has demonstrated a similar effect of
fish oil on cardiac hypertrophy with an intervention after the hypertrophic
stimulus, in this case beginning at 30 weeks of age in female transgenic mice,
bred to develop normotensive cardiac hypertrophy (Huggins et al. 2009). The
majority of evidence regarding fish oil supplementation after a hypertrophic
stimulus suggests no antihypertrophic effect of fish oil when n-3 PUFA are
provided after the initial stimulus, whether it is renovascular hypertension
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(Rousseau et al. 2001), aortic banding (McLennan et al. unpublished) or in a
genetic model of hypertension, hypertrophy and myocardial infarction (transgenic
rats expressing human renin and angiotensinogen genes, (Fischer et al. 2008)). n-3
PUFA do however preserve heart function in the case of aortic banding in the
presence of cardiac hypertrophy and therefore may halt disease progression to
decompensated HF (McLennan et al. unpublished).

One likely mechanism for the effect of fish oil on cardiac hypertrophy is the
incorporation of n-3 PUFA into cardiac cell membranes. Even at the low dose of
0.31%, there were significant modifications in membrane composition in favour
of n-3 PUFA. Indeed the similar incorporation of n-3 PUFA observed with FO
feeding both before and after the hypertrophic stimulus may be a major factor in
explaining both the prevention and attenuation of cardiac hypertrophy observed in
the present study. Incorporation of n-3 PUFA has previously been suggested as a
mechanism for a fish oil effect in abdominal aortic banding (Duda et al. 2009;
Shah et al. 2009). Furthermore, the greater effect observed when fish oil was
provided prior to aortic banding suggests an influence of n-3 PUFA in
hypertrophic cell signalling pathways. Indeed, interaction of n-3 PUFA with
signalling pathways, for example involving PKC, is proposed as a mechanism
behind the anti-hypertrophic effect (Siddiqui et al. 2008; Siddiqui et al. 2000).

The important point to note in the present study pertaining to the antihypertrophic
effect of fish oil is that we have observed beneficial effects using extremely low
doses of dietary fish oil that are equivalent to human intakes. Previous studies
with n-3 PUFA have used 10 fold higher doses or more of fish oil within the range
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of 3-10%. Such doses represent intake well above what could be achieved in the
human diet. Reproducing the effects using very low doses establishes the
relevance of the higher dose animal studies in regards to their translation to the
human form. In humans, eating fish 1-2 times per week or n-3 PUFA
supplementation (1g/day) is associated with reduced risk of HF and reduced
mortality in HF patients respectively (Mozaffarian et al. 2005a; Tavazzi et al.
2008). To a certain extent, the present study represents the two different
circumstances surrounding the human studies. In one study (Mozaffarian et al.
2005a), fish intake acts to prevent the development of heart failure, similar to our
FO dietary intervention initiated prior to the hypertrophic stimulus, aortic
banding. In the other human study (Tavazzi et al. 2008), fish oil supplementation
was provided in patients diagnosed with HF, similar to our dietary intervention
initiated after aortic banding surgery. The beneficial findings in our study
regarding a fish oil cardioprotective effect both before and after aortic banding
surgery, combined with that observed in humans, further supports a common
mechanism of action, likely the incorporation of n-3 PUFA into cardiac
membranes, regardless of when the dietary intervention was initiated. Therefore,
the use of low doses of fish oil and subsequent observations in the present study
provides the basis for linking the animal and cellular studies to human physiology
and pathophysiology.

The numerous different animal models used to look at the effect of n-3 PUFA on
cardiac hypertrophy make it difficult to draw any clear conclusions pertaining to
the exact effect of n-3 PUFA in HF. Obviously, further research following the
progression of the development of cardiac hypertrophy and heart failure over a
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longer period of time is pertinent to support and extend our current results and
further the knowledge in this area. However, the implications of the results of the
current study are clinically relevant in that a beneficial role for fish oil has been
identified, not only in the prevention of cardiac hypertrophy but also in the
treatment and management of cardiac health after an initial hypertrophic stimulus
such as acute myocardial infarction or chronic high blood pressure. This is
particularly important since all forms of cardiovascular disease have the potential
to eventually lead to cardiac hypertrophy and HF (Francis et al. 2004).

6.4.3 Aortic banding and skeletal muscle function
Muscle atrophy, observed in the present study 15wk following aortic banding, is a
common finding in both human HF (Mancini et al. 1992; Massie et al. 1987) and
in different animal models of HF, including spontaneously hypertensive heart
failure in rats (Peters et al. 1997), supraventricular tachycardia-induced HF
(Howell et al. 1995), myocardial infarction-induced HF (Simonini et al. 1999;
Simonini et al. 1996a; Simonini et al. 1996b) and monocrotaline-induced HF
(Vescovo et al. 1998). However, it is not always evident, with some studies
showing no atrophy associated with HF in Dahl salt sensitive rats (Toth et al.
2006) and in myocardial infarction-induced HF (Spangenburg et al. 2002; Thorud
et al. 2004; Williams & Ward 1998). Further research on the cause and
significance of muscle atrophy in HF is required as the inconsistencies in the
literature do not seem to be related to severity or duration of HF or to muscle type
(Lunde et al. 2001b).
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In contrast to previous reports, our study did not show any skeletal muscle
contractile dysfunction under any of the contraction conditions tested. Both twitch
(Howell et al. 1995; Perreault et al. 1993; Ward et al. 2003; Williams & Ward
1998) and tetanic (MacFarlane et al. 2000; Perreault et al. 1993; Williams &
Ward 1998) force has been shown to be reduced in HF. Heart failure is also
associated with prolonged time course of the twitch and tetanic force (Lunde et al.
2001a; Perreault et al. 1993; Ward et al. 2003). These changes are associated with
Ca2+ cycling within the cell with reduction of the intracellular Ca2+ transient (Ca2+
inside the cell during each contraction) amplitude (Perreault et al. 1993; Ward et
al. 2003) and prolonged Ca2+ transient rise (Perreault et al. 1993; Ward et al.
2003) and decay (Lunde et al. 2001a; Perreault et al. 1993; Ward et al. 2003)
time. In relation to the repeated bouts of 5Hz stimulation protocol, our results are
similar to what was observed in the soleus muscle with a similar stimulation
protocol of 5Hz (6s on/4s off) (Thorud et al. 2004). This protocol failed to find
any significant differences in force between sham and HF rats over 30 minutes
duration. There was however evidence of dysfunction with significantly lower
maximal rates of force development in the HF group, which was not observed in
the current study.

The difference between these studies that have shown some aspects of muscle
dysfunction and the current one is the model of HF. They have all used
myocardial infarction-induced model where the current study used aortic banding.
The myocardial infarction model is a more severe model that typically has a low
survival rate. It is also less suitable for use in studies of n-3 PUFA effects since
fish oil feeding would likely reduce the degree of infarction (Abdukeyum et al.
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2008) and hence alter the development of HF in that group compared to controls.
Dietary intervention would need to be delayed until after the myocardial
infarction is established, as shown here for aortic banding. Further development of
the current model of aortic banding to increase the severity of cardiac hypertrophy
or to extend the study duration until overt expression of HF may help to elucidate
the effects of banding on skeletal muscle function and furthermore, the effects of
dietary fish oil intervention on this associated dysfunction.

Skeletal muscle dysfunction in heart failure was long thought to be related to
reduced muscle blood flow and disuse but changes in function have been observed
in the absence of atrophy and lower blood flow (Thorud et al. 2004) and with
atrophy but no changes in activity in rats (Simonini et al. 1996a). These
observations suggest a mechanism intrinsic to the muscle that contributes to the
observed dysfunction and exercise intolerance. In the present study, blood flow
was acutely controlled by the perfusion pump and thus not directly measured in
vivo, however there were no significant effects of aortic banding on flowmediated dilatation or active hyperaemia responses, as assessed by changes in
vascular resistance with increased flow rate and muscle activity respectively.
These indicators of endothelial function have been assessed in heart failure in both
humans and animals, showing reductions in flow-mediated dilatation (Chong et
al. 2004; Katz et al. 2005; Kovacs et al. 2006; Varin et al. 1999; Vercauteren et
al. 2006) and active hyperaemia (Haitsma et al. 2002) indicating endothelial
dysfunction (Tousoulis et al. 2005). This dysfunction is also supported by low
levels of markers of endothelial function such as NO (Varin et al. 1999), although
this is not always observed (Haitsma et al. 2002). The lack of differences in flow-
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mediated dilatation and active hyperaemia in the present study between banded
and sham groups suggests that the observed muscle atrophy is unlikely to be
caused by reduced blood flow. Furthermore, it suggests that this model was not
severe enough to induce endothelial dysfunction and thus may contribute to the
explanation regarding the absence of skeletal muscle dysfunction observed in
banded animals.

6.4.4 Conclusions, limitations and future recommendations.
This study is the first to relate the changes in skeletal muscle membrane
composition to muscle function in cardiac hypertrophy. The changes in skeletal
muscle membrane composition, especially in the gastrocnemius, have the
potential to contribute to muscle dysfunction. As n-3 PUFA are associated with
improved function (Chapter 4), the reduction in n-3 PUFA and increase in n-6
PUFA may affect optimal muscle functioning in this setting. This however was
not the case in the present study, as no dysfunction was observed. It is likely that
the modifications in membrane composition were not great enough to affect
muscle function, as they were only found in one muscle group, yet muscle
function was assessed using a bundle of muscles (the GSP muscle bundle).

Although there were some significant changes in membrane phospholipid fatty
acid composition and muscle atrophy, the aortic banding model was not severe
enough in this instance to induce significant changes in skeletal muscle function
after 15wk. Combined with the lack of symptoms or signs of HF, these findings
suggest that the animals were in a state of compensated hypertrophy, i.e. the
enlargement of the heart was sufficient to maintain daily activity in response to
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the stimulus. This therefore offers a potential explanation for the lack of effect of
banding in producing skeletal muscle dysfunction.

A limitation in the current study is that we were not initially equipped to track the
cardiac changes associated with the development of cardiac hypertrophy and HF.
Future recommendations would be to follow the progression of the condition
within each animal. This may be done with echocardiography. As well as the
benefit of monitoring disease progression over a lengthy period of time in the
same animal, this technique would also permit identification of HF as an endpoint
for determination of muscle function, which may reduce variation related to the
different degrees of hypertrophy and extent of HF seen in animals examined at a
fixed time point. In addition, the number of animals required for an experiment
such as the present one would be less as it would eliminate the need to euthanase
animals at different time points.

Our initial purpose for assessing skeletal muscle function in HF using the current
model was to develop this model for assessment of the effects of dietary fish oil.
Because there was no effect of this aortic banding model on muscle function, the
study was not extended to assess the effect of fish oil on muscle dysfunction.
Future studies may involve extending the time for heart failure and subsequent
muscle dysfunction to develop or increasing the degree of aortic restriction to
speed up the process of hypertrophy and progression to heart failure. Moreover,
the use of echocardiography would allow regular assessment of the progression of
heart failure and thus enable the examination of muscle function at a particular
stage of heart failure rather than at a specific time point.
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Chapter 7 NORMAL HEART FUNCTION
7.1 Introduction
The ability to more closely track changes in the heart during the development of
cardiac hypertrophy and heart failure and thus assess skeletal muscle function at a
desired degree of heart failure, rather than a fixed point in time, would be a
valuable improvement to the current model used in Chapter 6. Echocardiography
is a non-invasive tool that can serve this purpose of regular assessment of the
development of heart failure. This study is a preliminary extension of Chapter 6.
While examining the effects of fish oil on normal rat heart function, this study
also assessed the use of echocardiography to determine it’s potential suitability for
future dietary studies using the abdominal aortic banding model of cardiac
hypertrophy and heart failure.

7.1.1 Fish oils and cardiac function
The cardioprotective role of n-3 PUFA from fish is well established. From the
early work of Bang and Dyerberg (Bang & Dyerberg 1972) to more recent and
comprehensive epidemiology studies, a strong case has developed for a beneficial
role of fish oil in many aspects of cardiovascular health and protection. Regular
fish consumption has been associated with a reduced risk of coronary heart
disease death and sudden cardiac death (Mozaffarian 2008), atrial fibrillation
(Mozaffarian 2007), heart failure (Mozaffarian et al. 2005a) and stroke
(Mozaffarian et al. 2005b). Fish oils have been shown to have anti-arrhythmic,
anti-atherogenic and anti-thrombotic properties (De Caterina & Zampolli 2007;
Leaf 2007; Lombardi & Terranova 2007; Robinson & Stone 2006).
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While fish oils have been shown to be protective in stress or pathophysiological
situations, the underlying normal physiological functions that may contribute have
been less extensively studied. There is the potential that fish oil may positively
affect normal heart function and provide a basis for the observed reduced risk and
incidence of cardiovascular diseases and death in pathophysiological conditions.
In humans, fish intake of three or more meals per week is associated with lower
heart rate and blood pressure as well as a higher cardiac stroke volume
(Mozaffarian et al. 2006). The HR lowering effect has also been observed in
animals however as with most early studies, these studies used high doses of fish
oil (5%) (Pepe & McLennan 1996).

When studying the effects of fish oil on cardiovascular disease, it is important to
understand the underlying physiological changes pertaining to normal heart
structure and function that occur even in the absence of disease. Human studies
show reduced mortality in patients with existing coronary artery disease without
any difference in new cardiac events (Burr et al. 1989; Marchioli et al. 2001).
This suggests a mechanism intrinsic to the heart, such as the incorporation of n-3
PUFA into myocardial membranes rather than effects on coronary artery
atherosclerosis or thrombosis. In the rat, the idea of change to inherent properties
of the heart is strengthened and by the lack of susceptibility of rats to
atherosclerosis and coronary heart disease (Turner et al. 1990). Therefore, if the
presence of n-3 PUFA in the heart prior to an event protects the heart under
pathophysiological circumstances, it is likely to be evident in normal heart
function. Furthermore, knowing the effects in the normal heart can provide
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valuable insight in elucidating the mechanisms by which fish oil may be exerting
their effects in relation to heart disease.

7.1.2 Aims and Hypotheses
This study serves as a preliminary extension of the fish oil and heart failure study
to a) assess the effect of low doses of dietary fish oil on normal heart structure
and function and b) to identify the potential for using the non-invasive technique
of echocardiography in future studies in pathophysiological conditions (for
example to follow the progression of cardiac hypertrophy and heart failure noninvasively within individual animals in order to evaluate muscle fatigue
associated with a common degree of HF).

In Chapter 3 it was established that the low doses of fish oil markedly increased
the n-3 PUFA concentration of myocardial membranes. Based on the association
between cardiac n-3 PUFA and heart rate (Pepe & McLennan 1996), it was
hypothesised that fish oil would reduce heart rate with corresponding changes in
heart function (stroke volume and end diastolic volume) without differences in
cardiac structure (ventricular diameters, septal and wall thickness). Furthermore,
by being able to use this technique to determine dietary differences in function,
echocardiography will be identified as a potentially useful tool for analysing heart
structure and function under different circumstances.
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7.2 Methods
7.2.1 Animals
Male Sprague Dawley rats were assigned to dietary groups as described in
Chapter 2.1. All rats were maintained on diets for a minimum of 4 weeks prior to
assessment of heart structure and function by echocardiography. Two groups of
rats, varying only in their age, were used in this study. The first group of animals
were assessed at 8-10wks of age and the second group were assessed at 15-20wks
of age. The animals assessed at 15-20wks of age were some of the animals that
underwent muscle function assessment in Chapters 4 and 5. In these animals,
echocardiography was performed immediately prior to auto-perfused hindlimb
experiments. Animals were anaesthetised with pentobarbitone sodium (40mg/kg
i.p.) for the procedure. The chest area was shaved and the animal was secured to a
heat pad in a supine position, tilted slightly to the left with the aid of a support
behind its back that propped up the right side of the animal. This was to allow
ideal positioning of the heart for assessment without obstruction by the sternum.
Following echocardiographic assessment, rats were allowed to either wake up or
they were used immediately for skeletal muscle function studies.

7.2.2 Echocardiography
7.2.2.a Background
Echocardiography is a diagnostic tool that uses ultrasound to produce images of
the heart. It was one of the first clinical uses of diagnostic ultrasound, with the
first patient echocardiogram performed in 1953 (Elder & Lindstrom 2004). These
days echocardiography is a vital tool in the everyday diagnosis of many heart
conditions and it has also been used extensively for research purposes (Brown et
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al. 2002; Coatney 2001; Pawlush et al. 1993; Sanzen et al. 2006; Watson et al.
2004). Amongst the benefits of echocardiography in research are: it is noninvasive; it can measure heart parameters in vivo; and it can also be used to
monitor changes in heart function over time within an individual animal.

The underlying concept of echocardiography/ultrasound is based upon the
interaction between the tissues and ultrasound waves. Ultrasound waves, when
applied to tissue will act in one of four ways. They will be reflected, refracted,
attenuated or scattered. Echocardiography focuses on the reflected and scattered
ultrasound waves in generating 2-dimensional and m-mode images and doppler
recordings, respectively (Lawrence 2007).

7.2.2.a.i) 2-Dimensional echocardiography
2-Dimensional echocardiography is the mode of ultrasound that generates real
time 2-D images of the heart (figures 7-1 and 7-2). It is the preferred mode due to
its ease of visualisation of the heart and its function (Coatney 2001; Lawrence
2007). 2-D images can be generated from many angles of the heart. The most
common view being in the long axis, which produces visualisation of the heart
from the aorta and base of the heart to the apex. The short axis view generates
cross sectional circular images. Apical images are difficult to achieve in rodents
due to their small size (Pawlush et al. 1993).

7.2.2.a.ii) M-Mode echocardiography
M-Mode echocardiography, also called time-motion display, was the original
mode of echocardiography. A single ultrasound beam is transmitted through the
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heart, resulting in an image of a section of the heart (on the y-axis) displayed over
time (on the x-axis, Figure 7-2)(Coatney 2001). Although useful in accurately
measuring many aspects of ventricular structure, many individuals in the early
days found it difficult to understand its relationship to heart function and as such
2-D echocardiography was developed (Krishnamoorthy et al. 2007; Lawrence
2007).

Today, the importance of m-mode echocardiography is accepted and it is used in
conjunction with 2-D echocardiography with the 2-D images used to guide the
position of the cursor/ultrasound beam for more accurate measurements
(Lawrence 2007).

7.2.2.a.iii) Doppler echocardiography
Ultrasound waves are scattered when the target is smaller than the transmitted
wave. The principle of Doppler echocardiography is base upon the scattering of
ultrasound waves by moving red blood cells. Doppler echocardiography can be
used to measure direction and flow of blood throughout the heart and vessels
(Lawrence 2007) (Figure 7-3).

7.2.2.b. Echocardiographic methods
Echocardiography was performed using a Philips ATL HDI3000 ultrasound
system with a linear array (hockey stick) transducer (10-5MHZ). Images were
obtained at a depth of 3-4cm with a high frame rate (temporal resolution-2025Hz). The quality of the image was optimised by applying generous amounts of
ultrasound transducer gel to the animal and adjusting the system for dynamic
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range and gain (power of the ultrasound beam and the visual display of the
image). Data was measured and recorded from images in 4 different modes: 2-D
long axis; 2-D short axis; m-mode and Doppler (Figures 7-1-7-3). 2-D long axis
images were obtained by gently placing the probe on the left parasternal region,
directed towards the head and aligning with the long axis of the heart. The probe
was rotated 90º from the long axis position to obtain short axis images. M-mode
images of a single point of the heart over time were then obtained with the
guidance of 2-D short axis images. Doppler recordings of the Aorta were obtained
under the guidance of 2-D long axis view.

Figure 7-1 Two-dimensional long axis image of the rat heart.
An example image obtained during echocardiographic assessment of heart structure and
function in the present study. Image shows cross section of the aorta (right) and the left
ventricle (right).
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Figure 7-2 Two-dimensional short axis (top) and m-mode (bottom) images of the rat
heart.
Example images obtained in the present study. The m-mode image represents the change
in heart dimensions over time at the point where the line intersects the short axis view.

Figure 7-3 Doppler recording of the rat aorta
An example recording obtained during the present study, recorded from the aorta in the
long axis view. Each peak represents the velocity of blood flow with each beat.
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Measurements of heart structure and function were made on-screen at the time of
imaging. Each echocardiographic assessment was recorded on to a VHS video
tape. Structural measurements such as wall thicknesses (posterior wall and
interventricular septum), left ventricle internal diameters and aortic diameter were
obtained from 2-D long and short axis views, as well as m-mode images (Brown
et al. 2002; Pawlush et al. 1993; Watson et al. 2004). Pulmonary artery diameter
was measured in the 2-D short axis view. Heart rate (HR) was obtained from
Doppler examination of the aorta and pulmonary artery and from m-mode images
and an average was calculated from the three sites. Within each view, HR was
calculated as the average beat-beat interval over 10 beats. Other functional
measurements were calculated from measures already obtained. End diastolic
volume (EDV) and end systolic volume (ESV) were calculated using the left
ventricular internal diameter (LVID) in either diastole or systole (EDV or ESV=
LVID3(d or s) (Pawlush et al. 1993). The stroke volume (SV) was calculated as
the difference between end diastolic volume and end systolic volume. Cardiac
output was calculated as HR*SV. Each parameter was measured in three cardiac
cycles and averaged.

7.2.3 Statistics
Differences between the age groups (8-10wk and 15-20wk) as well as any dietary
effects were assessed using one-way ANOVA with Tukey post hoc comparisons.
p<0.05 was accepted as statistically significant.
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7.3 Results
Rat weight at time of echocardiographic assessment was significantly greater at
15-20wks compared to 8-10wks (Table 7-1). There were no dietary differences in
body weight.
Table 7-1 Body weight at echocardiographic assessment
8-10wks
15-20wks
OO
270 ±08
424 ± 15*
LowFO
273 ± 4
440 ± 15*
ModFO
277 ± 8
421 ± 15*
Data is mean±SEM. *p<0.001 vs. 8-10wks group. n=14-16 per group.

7.3.1 Heart structure
Regardless of diet, there were significant differences in heart and great vessel
structural measurements at 15-20wks compared to 8-10 weeks (Table 7-2). These
consisted of a general increase in septal thickness, as measured in 2-D long axis,
2-D short axis and m-mode scans during both diastole and systole, as well as
increased left ventricular internal diameter (diastole) and aortic and pulmonary
diameters and decreased left ventricular internal diameter (systole) (all p< 0.05, 810wk vs. 15-20wk).

The dietary effects on the structural characteristics of the heart were minimal
(Table 7-2). Across all modes of measurement, FO animals had larger left
ventricular internal diameter (all p<0.05). There were no significant effects of diet
on wall thicknesses (interventricular septum and posterior wall) or vessel
diameters (aorta and pulmonary artery). Pooled analyses of all FO animals against
the OO group strengthened the effect of larger left ventricular internal diameter
(all p<0.01) but did not reveal any further effect of FO on heart structure (all
p>0.05).
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Table 7-2 Structural characteristics of the rat heart at 8-10 and 15-20 weeks of age.
8-10 weeks
15-20 weeks
Parameter
LowFO
ModFO
OO
LowFO
ModFO
OO
(cm)
IVSd†

0.18 ± 0.01

0.16 ± 0.00

0.17 ± 0.00

0.19 ± 0.00

0.18 ± 0.00

0.18 ± 0.01

0.49 ± 0.02

0.55 ±0.02

0.54 ± 0.02

0.55 ± 0.01

0.58 ± 0.02

0.58 ± 0.01

PWd

0.19 ± 0.01

0.19 ± 0.01

0.17 ± 0.00

0.17 ± 0.00

0.18 ± 0.01

0.18 ± 0.01

IVSs†

0.24 ± 0.00

0.24 ± 0.00

0.25 ± 0.01

0.29 ± 0.00

0.30 ± 0.00

0.29 ± 0.01

LVIDs†

0.31 ±0.01

0.36 ± 0.01

0.33 ± 0.01

0.29 ± 0.01

0.30 ± 0.02

0.31 ± 0.01

PWs†

0.27 ± 0.01

0.26 ± 0.01

0.25 ± 0.00

0.28 ± 0.00

0.29 ± 0.01

0.29 ± 0.01

AoD†

0.25 ± 0.00

0.25 ± 0.00

0.25 ± 0.00

0.26 ± 0.00

0.26 ± 0.00

0.26 ± 0.00

0.18 ± 0.00

0.17 ± 0.00

0.17 ± 0.00

0.18 ± 0.00

0.19 ± 0.01

0.19 ± 0.00

0.45 ± 0.02

0.54 ± 0.03*

0.54 ± 0.02*

0.57 ± 0.01

0.58 ± 0.02

0.60 ± 0.02

PWd†

0.19 ± 0.01

0.18 ± 0.01

0.17 ± 0.00

0.16 ± 0.01

0.17 ± 0.00

0.16 ± 0.01

IVSs†

0.24 ± 0.00

0.25 ± 0.01

0.26 ± 0.01

0.29 ± 0.01

0.30 ± 0.01

0.30 ± 0.01

LVIDs†

0.27 ± 0.01

0.32 ± 0.01*

0.30 ± 0.01

0.25 ± 0.01

0.26 ± 0.02

0.27 ± 0.01

PWs†

0.27 ± 0.01

0.27 ± 0.01

0.26 ± 0.01

0.30 ± 0.01

0.30 ± 0.01

0.28 ± 0.01

AoD†

0.24 ± 0.00

0.25 ± 0.00

0.25 ± 0.00

0.26 ± 0.00

0.26 ± 0.00

0.26 ± 0.00

†

PAD

0.21 ± 0.00

0.21 ± 0.00

0.21 ± 0.00

0.22 ± 0.00

0.22 ± 0.01

0.22 ± 0.00

IVSd†

0.14 ± 0.00

0.14 ± 0.00

0.13 ± 0.00

0.15 ± 0.00

0.17 ± 0.00

0.15 ± 0.00

LVIDd†

0.53 ± 0.01

0.59 ± 0.02*

0.58 ± 0.01

0.60 ± 0.02

0.63 ± 0.02

0.62 ± 0.02

PWd

0.14 ± 0.01

0.14 ± 0.00

0.14 ± 0.00

0.14 ± 0.00

0.14 ± 0.00

0.14 ± 0.00

IVSs†

0.22 ± 0.01

0.22 ± 0.01

0.24 ± 0.01

0.28 ± 0.01

0.30 ± 0.01

0.28 ± 0.01

LVIDs†

2-D long axis

LVIDd

IVSd

†

2-D short axis

LVIDd

m-mode

†

†

0.29 ± 0.01

0.32 ± 0.01

0.30 ± 0.01

0.26 ± 0.01

0.26 ± 0.02

0.28 ± 0.02

†

0.24 ± 0.01

0.26 ± 0.01

0.26 ± 0.01

0.28 ± 0.01

0.29 ± 0.01

0.28 ± 0.01

Ao
diam†

0.25 ± 0.00

0.24 ± 0.00

0.24 ± 0.00

0.26 ± 0.00

0.26 ± 0.00

0.26 ± 0.00

PWs

Values are mean±SEM. *p<0.05 vs. OO diet. †p<0.05 difference in parameter between 8-10wk
and 15-20wk. IVS=interventricular septum, LVID=left ventricle internal diameter, PW=posterior
wall, AoD =aortic diameter, PAD=pulmonary artery diameter, d=diastole, s=systole. n=14-16 per
group.
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7.3.2 Heart function
Differences in heart function were observed between age groups (Figure 7-4).
Older rats (15-20wk) had significantly lower heart rate and end systolic volume
and higher end diastolic volume resulting in higher stroke volume (all p≤ 0.001).
Cardiac output was significantly greater in older animals, despite lower HR
(p<0.01).

Fish oil fed animals exhibited significant lower heart rates compared to the OO
control diet (p<0.001). This was accompanied by a greater stroke volume
(p=0.003) and end diastolic volume (p=0.004) in fish oil fed rats. There was a
trend for FO animals to also have a higher cardiac output (p=0.110). Pooled
analysis further revealed an effect of FO compared to the OO group, with
increased ESV (p=0.022) and CO (p=0.034) in addition to the lower HR and
increased EDV and SV (all p<0.001).
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Figure 7-4 Functional aspects of the heart.
a) Heart rate, b) Heart volumes, c) Cardiac Output. SV=stroke volume, EDV=end
diastolic volume, ESV=end systolic volume. ■ OO, LowFO, □ ModFO. *p<0.05 vs.
OO diet. #p<0.05 all FO pooled vs. OO diet. †p<0.05 15-20wk vs. 8-10wk. n=14-16 per
group.
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7.4 Discussion
7.4.1 Dietary effects
The finding of a heart rate lowering effect in the fish oil animals in the present
study is particularly important as high heart rate is an independent risk factor for
cardiovascular disease mortality (Fox et al. 2007; Kannel et al. 1987). These
results support both human and animal studies that have demonstrated that fish oil
is associated with lower heart rates. In human trials, n-3 PUFA lower resting heart
rate by up to 5 beats per minute (Dallongeville et al. 2003; Mori et al. 1999; Shah
et al. 2007; Vandongen et al. 1993). This is further supported by a meta-analysis
of randomised control trials that identified an average reduction of up to 2.5 beats
per minute with fish oil supplementation (Mozaffarian et al. 2005b). Furthermore,
heart rate during exercise across a range of workloads is less in humans
supplemented with fish oil (Peoples et al. 2008). The lower heart rate associated
with fish oil has also been observed in several animal species including horses
(O'Connor et al. 2004), pigs (Montfoort et al. 1986), dogs (Billman et al. 1997)
and marmoset monkeys (McLennan et al. 1992a). In addition to these whole
animal studies, a lower heart rate has been observed in isolated working hearts
(Pepe & McLennan 1996) and isolated spontaneous beating atria (personal
observations (Henry et al. unpublished) from fish oil fed rats, as well as in
isolated myocytes exposed to EPA and DHA (Courtois et al. 2005; Leaf et al.
2003). These studies support a direct heart rate lowering effect of fish oil. The
most important consideration of the current study is that HR was lowered by very
low doses of fish oil, an observation never made before in animal studies due to
the uniform use of high fish oil concentrations in the experimental diets.
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The mechanisms behind this heart rate lowering property of fish oil have yet to be
elucidated. While it has been postulated that fish oil may act through neural
pathways(Christensen & Schmidt 2007), there is emerging evidence that supports
a role of fish oils acting directly on the heart, in particular, pacemaker cells of the
right atria. Suggestions of neural mechanisms have stemmed from heart rate
variability studies. Heart rate variability is an indicator of vagal and sympathetic
nervous system activity and n-3 PUFA have been shown to increase heart rate
variability (Christensen & Schmidt 2007; Mozaffarian et al. 2008). It is possible
that the fish oil-induced reduction in heart rate may involve changes in
parasympathetic activity. However there is also a strong case for a direct action of
fish oils on the heart with the heart rate lowering effect of fish oil evident in both
human and animal models where neural influences are excluded (Harris et al.
2006b; Henry et al. unpublished). For example, a study in cardiac transplant
patients showed a 5 beat per minute reduction with fish consumption (Harris et al.
2006b) which is comparable to non-transplant patients (O'Keefe et al. 2006).
Isolated hearts (Abdukeyum et al. 2008; Pepe & McLennan 1996) and even
isolated right atria from fish oil fed rats exhibited a significantly lower
spontaneous beating rate compared to the control saturated fat dietary group
(personal observations (Henry et al. unpublished)).

In addition to the effect on heart rate, the present study has demonstrated other
effects of fish oil on normal heart function. All of these observed dietary effects
of fish oil on heart structure and function are inter-related. The larger left
ventricular internal diameters observed in FO animals are indicative of the greater
end diastolic volumes. Indeed greater end diastolic volumes have been observed
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in marmoset monkeys fed a fish oil diet. One possible explanation for greater
filling, in the absence of hypertrophy is improved diastolic relaxation of the
myocardium (McLennan et al. 1992a). The improved filling permits increased SV
by virtue of the Frank-Starling law of the heart (Frankel et al. 1998) (which
describes that as the heart fills more it contracts more powerfully) and enables
maintenance of cardiac output despite a lower HR.

The n-3 PUFA may act directly on the heart through the incorporation of n-3
PUFA from fish oil into cell membrane phospholipids. Membrane incorporation
of EPA and to a much greater extent, DHA, has been associated with several
cardioprotective effects of n-3 PUFA (McLennan et al. 2007). In the present
study (Chapter 3), similar marked increases in DHA incorporation have been
observed with low doses of fish oil and on the basis of effects of high intakes
suggests that other changes in normal heart function previously observed in
isolated hearts are also likely to be evident after small doses used here. These may
include increased efficiency of O2 use (Pepe & McLennan 2002; 2007),
protection against damaging effects of ischaemia (Abdukeyum et al. 2008) and
antiarrhythmic effects (McLennan et al. 1988; 1990).

These observations are the first to show the effects of such low doses of fish oil
supplementation. The demonstration of the HR lowering effect in these low doses
of fish oil in the present study increases the confidence in linking the mechanisms
identified in animal studies to the human epidemiological studies. The heart rate
lowering effect of fish oil and associated changes may therefore contribute to the
reduction of mortality from cardiovascular disease seen with fish consumption or
fish oil supplementation.
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7.4.2 Effects of age
The echocardiographically determined heart structure and contractile function
were in the same range as those reported for baseline rat heart structure and
function in male Sprague Dawley rats aged 10-18 weeks (Watson et al. 2004).
The differences in heart structure and function between the two age groups in the
present study are indicative of normal growth and development during that time
(Lakatta 1993; Watson et al. 2004) and establish that growth changes can be
differentiated in the rat. This suggests that progressive changes in structure and
function will be identifiable in rat models of hypertrophy and heart failure.

7.4.3 Conclusions, Limitations and future recommendations
The results of this study, showing significant dietary effects of fish oil on heart
function, indicate that echocardiography would be a useful tool in future studies.
As well as being non-invasive, it is sensitive enough to detect dietary and agerelated differences in heart function. There were, however, some limitations to the
present study that should be noted and addressed prior to further experimentation.
They include the anaesthetic used, temporal resolution of the echocardiographic
images and measurement sensitivity.

Pentobarbitone sodium was used as the anaesthetic agent in the present study. It is
well known that anaesthetic agents can interfere with normal heart function.
Barbiturates, including pentobarbitone sodium, have been shown to reduce stroke
volume, heart rate and blood pressure (Hildebrandt et al. 2008). Other anaesthetic
agents also affect the cardiovascular system in different ways (Plante et al. 2006;
Roth et al. 2002). It is essential to anaesthetise animals for echocardiographic

210

assessment to keep the animal restrained without undue stress (Hildebrandt et al.
2008). Consideration must therefore be given to these effects in selection of
anaesthetic to suit the purpose of the experiment. In the current study,
pentobarbitone was chosen because it has less pronounced and more stable effects
on heart function compared to the other commonly used injectable anaesthetic
ketamine/xylazine (Sawyer 1998) and inhalation anaesthetics and equipment
could not be used without room ventilation. An attempt was made to reduce any
conflicting effects of the anaesthetic on cardiac function by performing
echocardiography when the animals were under a similar level of anaesthesia i.e.
in the absence of the foot withdrawal reflex. The literature regarding anaesthetic
effects on the cardiovascular system is incomplete and direct comparisons
between all types of anaesthetic agents have not been made. Some more recent
studies appear to reinforce the use of pentobarbitone as the anaesthetic of choice.
Droogmans and co-workers demonstrate adverse effects of ketamine/xylazine
compared to pentobarbitone or inhaled isoflurane due to effects on blood pressure
which causes valve dysfunction (Droogmans et al. 2008) and proceed to use
pentobarbitone as anaesthetic of choice in investigation of age-related changes in
rat heart function(Droogmans et al. 2009). Future studies however would benefit
from further comparisons, resulting in more informed choice of appropriate
anaesthetic agent for a particular experimental purpose.

Temporal resolution, which refers to the frame rate of the images that can be
acquired per second (Hz), is an important consideration when using commercial,
human ultrasound systems for rodent echocardiography. This is particularly
important considering the high rodent heart rates compared to humans. With such
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high heart rates and relatively low frame rates of commercial ultrasound systems,
there may be some inaccuracies in observing the entire cardiac cycle and
determining the exact point of end diastole and end systole (Coatney 2001). This
may be a limitation in the present study with temporal resolution of 20-25 Hz and
heart rates of 300-400bpm resulting in approximately 5 frames per cardiac cycle.
Advances in ultrasound technology have resulted in the ability to improve
temporal resolution. The use of newer systems would therefore improve the
application of echocardiography in rodents. The major problem however in
implementing these newer systems is the high cost associated with these systems.
The best solution however is to measure more cycles and average these values.

Another limitation associated with the use of clinical ultrasound systems for
research purposes, particularly in small animal models, is that of measurement
resolution. While the measurement of human heart structure to 2 decimal places is
sufficient for diagnostic purposes, it is a considerable problem faced when
measuring small diameters and wall thicknesses such as those in rodents. This
may contribute to the lack of statistical significance observed in some cases where
a trend is evident but lacks significance statistically. The development and use of
computer programs to interpret ultrasound images and provide measurements to
more decimal places will allow greater accuracy in the determination of small
distances measured in rodent hearts and blood vessels (Woodman et al. 2001).
Again, high cost is an issue with these programs and this can be a significant
limitation to their use in research.
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Despite these limitations however, echocardiography revealed dietary differences
in normal heart function in the present study and represents an important tool for
future studies, by allowing the non-invasive assessment of disease progression in
the same animal and thus reducing animal use numbers and improving study
design.
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Chapter 8 GENERAL DISCUSSION
8.1.Fish oil in skeletal and cardiac muscle function
The present study has established effects of n-3 PUFA which suggest an integral
role in skeletal muscle and cardiac function. While the effects of fish oil in the
heart are well established, they have not been previously recorded for such low
doses. Furthermore, few studies have examined the role of n-3 PUFA in skeletal
muscle function and this study is the first to identify the effects of low doses. In
line with our hypotheses, dietary fish oil resulted in marked incorporation of n-3
PUFA into skeletal muscle and myocardial membranes even with low intakes and
this was accompanied by improvements in skeletal muscle and cardiac physiology
in both normal physiological circumstances and under pathophysiological
conditions.

The idea that fish oil may be beneficial in skeletal muscle has not been
extensively studied. In humans, fish oil reduces whole body O2 consumption
during exercise in healthy subjects (Peoples et al. 2008) and is associated with
improved exercise performance in patients with impairment caused by chronic
obstructive pulmonary disease (Broekhuizen et al. 2005) or paraplegia (Javierre et
al. 2006). With skeletal muscle being the major contributor to O2 consumption in
exercise it is the most likely site of action. Preliminary animal studies have
implicated fish oil in improved contractile function and resistance to fatigue as
well as reduced O2 consumption, accompanied by marked incorporation of n-3
PUFA into skeletal muscle membranes (Peoples 2004). That study identified
effects on muscle fatigue using a model of single twitch contractions. Twitch
contractions are the most basic form of muscle contraction and it is difficult to
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generalise the effect of fish oil observed in that preliminary study to fatigue as a
whole (Allen et al. 2008b). The consistent findings of fish oil effects across a
range of contraction types (tetanic contractions, single twitch isometric
contractions and repeated rapid trains of isometric contractions) in the present
study quash these concerns and validate the results of the preliminary study,
further strengthening the case for a role of n-3 PUFA in muscle function.
Furthermore, as well as improving function and fatigue resistance under normal
conditions, the present study revealed a favourable effect of fish oil in muscle
under stress, including greater recovery of contractile function after fatiguing
contraction bouts and modest fatigue resistance and protection from tissue damage
in muscles subjected to reduced perfusion. Thus, the most prominent effect of fish
oil in the current study was a consistent inhibition of muscle fatigue across a
number of contraction conditions.

The improved muscle function and fatigue resistance was associated with
heightened O2 consumption in FO animals. While the greater O2 consumption in
the present study is contrasting to earlier work in cardiac and skeletal muscle
(Peoples 2004; Pepe & McLennan 2002), it may suggest an important role of n-3
PUFA in tissue oxygenation and extraction in different conditions. During a 1Hz
single twitch stimulation protocol, O2 consumption is reduced, while during a 2Hz
stimulation protocol, O2 consumption rises over time due to increased demand,
however efficiency is increased when O2 consumption is compared to contractile
function (Peoples 2004). We were unable to obtain O2 readings from the lower
intensity 2Hz protocol in the current study, however, given past results, reduced
O2 consumption in FO animals at low intensity stimulation, combined with greater
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consumption in higher intensity stimulation protocols, such as that in the present
study, may represent a greater reserve for improving tissue oxygenation and
muscle function in fish oil-fed animals in times of stress.

Endothelial function was also improved in FO animals, with a heightened
vasodilatory effect across many different experimental conditions in the current
study. These included flow-mediated dilatation and active hyperaemia in response
to changes in flow rate, muscle activity or recovery. These results support
previous work where fish oil promotes vasodilation due to improved vascular
endothelial function (Goodfellow et al. 2000; Hall 2009; Hill et al. 2007; Khan et
al. 2003; Leeson et al. 2002; Shah et al. 2007). In the current study, blood flow
was controlled externally and therefore these vasodilatory effects cannot be
directly related to the improved contractile function and fatigue resistance
observed in FO animals in terms of increased total blood flow. The results may
however reflect redistribution of blood to the active muscles (nutritive pathway),
an effect which may be more prominent in normal physiological situations where
blood flow is not fixed. Combined with the greater O2 consumption in FO
animals, these results suggest a role of fish oil in maintaining sufficient
oxygenation of active tissues in times of stress.

In addition to improvements in skeletal muscle function, the present study has
provided further support for the well-documented effects of n-3 PUFA on the
heart that might contribute to the cardioprotective effects of fish oil. Normal
cardiac physiology was improved, as indicated by reduced resting HR and
increased stroke volume. The HR lowering effect is particularly important as high
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HR is an independent risk factor for cardiovascular mortality (Fox et al. 2007;
Kannel et al. 1987). As well as the effects in normal cardiac physiology, fish oil
also had a cardioprotective effect pertaining to a pathophysiological stimulus
(aortic banding), preventing and attenuating the development of cardiac
hypertrophy. The anti-hypertrophic effect was limited to when fish oil was
provided prior to the aortic banding, therefore suggesting a role in cell signalling
processes. These may involve interaction with the PKC pathway and Ca2+
handling, among others (Siddiqui et al. 2008; Siddiqui et al. 2000).

One aim of the current study was to assess the effect of fish oil on muscle
dysfunction associated with HF (Lunde et al. 2001b). This could not be evaluated
because there was no evidence of abnormal fatigue in association with cardiac
hypertrophy in the current study. Nevertheless, the positive results pertaining to
fish oil and skeletal muscle function under a variety of conditions, combined with
the favourable cardiac effects observed, suggest a role for improving muscle
function in heart failure and subsequently improving quality of life. Further
investigation is therefore warranted including assessing muscle fatigue in other,
more severe, models of heart failure where muscle dysfunction is known to occur.

8.2. Membrane incorporation of n-3 PUFA
Determination of the exact mechanisms behind the effect of n-3 PUFA in skeletal
muscle was beyond the scope of this study however, we did seek to identify
potential contributors. Based on evidence in the heart, the most likely contributors
to the effects of n-3 PUFA in skeletal muscle are alterations in Ca2+ homeostasis
and ROS. Both of these systems are involved in the fatigue process, especially in

217

the contractile conditions used in the current study (Allen et al. 2008b; Jones
1996). This implicates Ca2+ handling and ROS as potential mechanisms behind
the improved skeletal muscle function seen with fish oil feeding. The results of
the present study regarding Ca2+ handling, were inconclusive however the greater
tetanic contractions, the greater single twitch contractile force in the 2Hz protocol
as well as the fatigue resistance and potentially greater response to caffeine in the
5Hz protocol suggests that Ca2+ homeostasis may be involved in the effect of fish
oil and warrants further investigation. The findings of possible protection of
muscles in FO-fed animals from oxidative damage, especially under the stressful
conditions of low muscle perfusion, are promising and further investigation of
numerous other markers of oxidative stress would help to reveal the exact
relationship between n-3 PUFA and cellular redox balance.

The similarities between observations in skeletal muscle and those reported in the
heart regarding fish oil interaction with intracellular Ca2+ handling and ROS
(McLennan & Abeywardena 2005) suggest that a common mechanism may be
involved in the action of n-3 PUFA. Furthermore, the global effects observed
across a range of situations in skeletal and cardiac muscle in the present study as
well as improved function in both tissues in the same animal, support this notion.
Given the similarities in incorporation of DHA into skeletal muscle and
myocardial membranes, the likely common mechanism of fish oil action is the
alteration of membrane phospholipid fatty acid content, in particular the
incorporation of n-3 PUFA. Indeed this has been postulated in the past as a valid
hypothesis, especially in the heart (McLennan & Abeywardena 2005) but also in
skeletal muscle (Peoples 2004). In the present study, DHA was incorporated to a
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greater extent in the gastrocnemius muscle, the major muscle group in the bundle
studied that is likely to decline with fatigue (Delp & Duan 1996; Hintz et al. 1982;
Meyer & Terjung 1979). Due to it’s mixed fibre type (Delp & Duan 1996), the
gastrocnemius contributes significantly to fatigue due to the greater proportion of
the more fatigable glycolytic fibres (Hintz et al. 1982) compared to the soleus,
which consists of fatigue resistant, oxidative fibres (Delp & Duan 1996). The
resistance to fatigue observed in FO animals therefore may be attributed to the
greater concentration of DHA in skeletal muscle, especially gastrocnemius
muscle, membranes. In addition, the marked incorporation of DHA into
myocardial phospholipids in the current study is likely to have contributed to the
observed improvements in normal and pathological cardiac function.

8.3. Dose of fish oil
Perhaps the most notable and important aspect of the current study was the ability
to modulate membrane composition and cellular function with very low doses of
fish oil. Epidemiological studies and clinical trials consistently show
physiological effects of fish oil at doses of 1g/day or intake of 1-3 fish meals per
week (Albert et al. 1998; Burr et al. 1989; Hu et al. 2002; Hu et al. 2003; KrisEtherton et al. 2003; Kromhout et al. 1985; Marchioli et al. 2001; Mozaffarian et
al. 2005a; Mozaffarian et al. 2005b; Mozaffarian et al. 2006; Mozaffarian et al.
2004). Most animal studies that relate fish oil and membrane incorporation of
DHA to physiological effects in the heart and skeletal muscle use high doses of
fish oil (5-12%) that are unachievable in the human diet (Matthan et al. 2005;
Peoples 2004). The ability to directly relate the effects observed in animals at
supraphysiological doses to humans is therefore compromised, raising questions
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regarding the relevance of these studies. The current study attempted to address
this issue by using doses much lower than those used previously in animals and
that are within the range of human intakes. The 1.25% dose is at the higher end of
human consumption, representing 9g/day EPA+DHA that can be obtained from 8
serves of salmon per week or 7 fish oil capsules per day (see Table 1-1, based on
salmon n-3 content of 1.9g/100g and a typical fish oil capsule content of 330mg
EPA+DHA ). The 0.31% dose is equivalent to 0.6g/day EPA+DHA, which can be
obtained from 2 serves of salmon per week or 1.5 fish oil capsules per day.

Few studies have evaluated effects of fish oil in the human achievable range of
intakes. Significant incorporation of n-3 PUFA, especially DHA, into myocardial
and skeletal muscle membranes was more than doubled with a dose of 0.31% FO.
Further increasing dietary fish oil beyond the 1.25% FO upper concentration used
in the present study resulted in only small increases in membrane DHA
incorporation that did not parallel the dietary increments. It has been calculated
that membrane DHA concentration would be elevated by any intake above
0.0027% fish oil (Slee et al. 2010). This suggests saturation of the capacity of
membranes to incorporate DHA with high doses of fish oil. In terms of
physiological effects of low doses, the results seem to produce the same effects
seen at higher doses. For example, cardiac arrhythmias are prevented by doses of
1.25% fish oil or 0.5% purified DHA just as effectively as higher doses
(McLennan et al. 1996; McLennan et al. 2007). Arrhythmias were similarly
prevented and O2 consumption dose dependently reduced in isolated hearts at
doses of 3, 6 or 12% fish oil (Pepe & McLennan 2007). Furthermore, pressureoverload induced cardiac remodelling and dysfunction was prevented by doses
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equivalent to human intake of 1.6, 5.1 and 15.5g.d-1 EPA+DHA (Duda et al.
2009). Low doses have not been previously examined for their effects on skeletal
muscle.

This study is therefore one of the first to examine the effects of human equivalent
doses of dietary fish oil on cardiac, and especially skeletal, muscle function. The
findings of marked incorporation of DHA into skeletal muscle and myocardial
membranes, associated with physiological effects, validate the earlier findings
with supraphysiological doses and provides greater confidence in the translation
of even the effects of high doses of fish oil to human application. Furthermore, a
novel finding of the current study is that cardiac and skeletal muscle
improvements with fish oil feeding were obtained in the same animal. Membranes
in both cardiac and skeletal muscle within the same animal were highly sensitive
to incorporation of DHA. Furthermore, the echocardiographic findings of reduced
HR and increased stroke volume in normal animals, particularly at 15-20wk of
age, were observed in some of the same animals that underwent skeletal muscle
function assessment, which also revealed a beneficial effect of fish oil.
Collectively, these findings add weight to the proposition that only small amounts
of dietary fish oil are required to optimise skeletal muscle and cardiac physiology
(Owen et al. 2004; Slee et al. 2010).

8.4. Role of fish oil- pharmacological/therapeutic or correcting a deficiency?
The findings with low doses of fish oil show that only small doses are required to
impart membrane and physiological changes in cardiac and skeletal muscle. This
is in line with previous animal studies in the heart that demonstrate significant
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physiological effects with low doses that are not different from the effects
observed with higher doses (McLennan et al. 1996; McLennan et al. 2007).
Collectively,

this

suggests

that

rather

than

having

a

therapeutic

or

pharmacological effect, fish oil is acting to correct a subtle dietary deficiency,
thereby optimising tissue function.

This notion is supported by epidemiological studies that show the greatest effect
of fish oil on the relative risk of premature mortality is observed with 1-2 fish
meals per week compared to none and greater fish consumption only imparts
small incremental benefits (Albert et al. 1998; Harris et al. 2009; Hu et al. 2002;
Hu et al. 2003; Kris-Etherton et al. 2002; Kromhout et al. 1985; Mozaffarian &
Rimm 2006).

Furthermore, the make-up of the typical western diet today, in comparison to
more historical diets with which we may have evolved, also suggests that the
effect of dietary fish oil may be related to correcting a dietary deficiency rather
than having a therapeutic effect. The western diet consists of significantly higher
n-6 PUFA, with a n-6/n-3 PUFA ratio of about 16:1 while early diets consisted of
a ratio closer to 1-2:1 (Simopoulos 2004). The reasons for the difference in ratio
are increased dietary provision of n-6 PUFA and reduced n-3 PUFA intake, in line
with n-3 PUFA deficiency. A lower ratio is related to positive health effects
however, there is debate surrounding the use of the n-6/n-3 PUFA ratio for
explaining the effects observed with fish intake (Griffin 2008; Harris et al. 2006a;
Simopoulos 2004; Stanley et al. 2007; Wijendran & Hayes 2004; Willett 2007).
While increasing fish consumption would favourably reduce the ratio, the ratio is
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also reduced by reducing n-6 PUFA intake without changing n-3 PUFA intake.
The physiological effects are vastly different. For example, modulating the ratio
by reducing n-6 PUFA does not appear to impart the cardioprotective effects
observed with fish consumption (Griffin 2008; Harris et al. 2006a; Stanley et al.
2007; Wijendran & Hayes 2004). Therefore, the most likely contributor to an
effect of reducing the n-6/n-3 PUFA ratio is by increasing dietary n-3 PUFA
(Harris et al. 2006a; Stanley et al. 2007; Wijendran & Hayes 2004). This idea is
supported by a recent study using the rat, that by carefully manipulating n-3
PUFA intake with n-6 PUFA held constant at high and low intakes, indicates that
the only determinant for incorporation of n-3 PUFA into myocardial membranes
is the absolute amount of dietary long chain n-3 PUFA, not the ratio to n-6 PUFA
(Slee et al. 2010). Although it appears that increasing n-3 PUFA alone, especially
the long chain EPA and DHA, likely contributes to the effect of a lower ratio, the
ratio may be relevant when n-3 PUFA are obtained via plant sources (18:3n-3)
due to the well established competition for conversion to long-chain PUFA
(Geiger et al. 1993; Sprecher 2000; Tran et al. 2001). Nevertheless, it can be said
that the western diet has evolved to become somewhat deficient in n-3 PUFA
(Simopoulos 2004). This deficiency may be contributing to subtly impaired
function and small amounts of dietary n-3 PUFA may act to optimise
physiological processes and function.

8.5. Benefits of our model for skeletal muscle function assessment.
The current study used a novel model of skeletal muscle function that ensures
adequate provision of O2 (Hoy et al. 2009; Peoples 2004). The purpose of this
study was to assess the effects of dietary intervention on muscle function.
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Therefore a model that closely resembles normal physiological conditions is ideal.
Furthermore, given the potential relationship between fish oil and O2 consumption
(Peoples 2004; Pepe & McLennan 2002), it was imperative that the chosen model
provides optimal tissue oxygenation. In the dog, the auto-perfused hindlimb
preparation is a widely accepted model used for assessment of O2 dynamics in
skeletal muscle (Hogan et al. 1992; Hogan et al. 1998; Hogan et al. 1999a; Hogan
et al. 1996; Hogan et al. 1994; Hogan & Welch 1986).

Most of the studies that examine the mechanisms of muscle fatigue are performed
in vitro using isolated fibres or in situ perfusion of muscles in a dead animal.
These models however are associated with issues pertaining to impaired muscle
oxygenation and supraphysiological flow rates respectively (Bonen et al. 1994).
Although we cannot disregard the importance of the results of these studies, the
ultimate goal is to develop methods that allow us to examine these alterations,
observed in isolated fibres, in vivo and discover how these alterations are
integrated with each other under normal physiological conditions (in vivo). Based
on the canine model, the auto-perfused hindlimb preparation was recently adapted
in our laboratory for use in rats, allowing the assessment of skeletal muscle
function in near in vivo conditions, whilst still allowing experimental control of
parameters such as blood flow (Hoy et al. 2009; Peoples 2004).

The observations of fish oil effects across a number of conditions in the present
study provides further validation for the use of this model in small animals.
Furthermore, the use of this more physiologically relevant model allows us to
more closely relate the observed effects in rats to humans, especially given the
low doses used.
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8.6. Future research
Being one of the first to identify a role of fish oil in optimal skeletal muscle
function, this study has provided the basis for many future studies regarding the
use of dietary fish oil for improving skeletal muscle function in many relevant
situations. This area of interest is only slowly evolving and as such there is great
potential for future studies and applications of the current findings.

8.6.1. Extensions of the current study
Specifically related to the present study, a more extensive investigation is
warranted into the role of n-3 PUFA in skeletal muscle, especially pertaining to
potential mechanisms of action. Although inconclusive, we have identified that
Ca2+ handling and ROS may be involved in the beneficial effects of fish oil in
skeletal muscle. The validity of these results is emphasised by previous work in
the heart (and to a lesser extent in skeletal muscle) that n-3 PUFA may improve
Ca2+ homeostasis (McLennan & Abeywardena 2005) and precondition the heart in
terms of ROS so that it is more able to cope with subsequent stressors
(Abdukeyum et al. 2008). Future studies would therefore involve more specific
examination of various aspects of cellular Ca2+ cycling, including SR Ca2+
content, release and uptake, and a more thorough investigation into cellular redox
state encompassing a wide variety of oxidative stress biomarkers and antioxidant
defences

The promising effects of fish oil in claudication, especially in terms of protection
from tissue damage, suggest that further research into this area is warranted. The
non-atherosclerotic model of claudication indicates that fish oil may act in ways
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other than reducing the atherosclerotic plaque. These likely include direct effects
on the skeletal muscle, for example, membrane incorporation of DHA, as well as
effects on O2 consumption and vascular function.

The profound effect on cardiac hypertrophy, combined with improvements in
normal muscle function further highlight the potential role of fish oil in skeletal
muscle dysfunction in HF. This could not be examined in the current study due to
lack of obvious fatigue at the time point chosen, however the potential is
promising, especially by improving the model with the use of echocardiography to
specifically identify heart failure as it develops along with assessment of a
specific degree of cardiac hypertrophy. Although regular examination of heart
function within individual animals was not assessed in the present study, the
results indicate that echocardiography is sensitive enough to pick up small dietrelated changes in normal heart function at different ages. Furthermore, it has
been used previously in other studies as a tool for repeated non-invasive measures
of heart function (Watson et al. 2004). It would therefore be a useful tool in the
repeated regular assessment that would be required in the proposed improved HF
model.

8.6.2. Further applications of our findings
If fish oil feeding is indeed acting to correct a dietary deficiency, the potential
applications are numerous. As discussed earlier, it is reasonable to suggest that the
observed changes in muscle membrane composition and physiological function
would be more beneficial in situations where muscle function has declined. This
is evident in the current study in a model of claudication, with the potential to
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extend the findings into the setting of HF. Another example where fish oil may be
applicable is in Duchenne muscular dystrophy, a genetic disorder characterised by
muscle weakness associated with disturbances in Ca2+ homeostasis (Gillis 1995).
The interaction of fish oil with various aspects of cellular Ca2+ homeostasis, to
optimise muscle function, may represent the potential to improve quality of life
through dietary intervention.

The prominent effect of fish oil on muscle fatigue across a range of conditions in
the current study suggests that it may also be a useful intervention for alleviating
respiratory muscle fatigue associated with the increased work of breathing in
respiratory disorders (Loring et al. 2009; Syabbalo 1998).

Perhaps the most significant potential application of improved muscle function
with dietary intervention is in the growing ageing population. Loss of muscle
function, including endurance and strength is a characteristic of ageing
(Vandervoort 1992). Improving muscle function and fatigue resistance with
dietary fish oil has the potential to significantly enhance quality of life and reduce
the ever-increasing demand on the healthcare system.

As well as having significant impact on quality of life in situations where muscle
function is reduced or hampered, fish oil may also be helpful in other situations,
for example, in the average person, increasing the ability to perform daily
activities. Furthermore, it may be applied in athletes and sportspeople to optimise
performance, however, because fish oil is not necessarily therapeutic, the effects
in elite athletes and sportspeople may be limited as they are more likely to have
sufficient dietary n-3 PUFA intake.
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8.7. Final conclusions
This thesis has established effects of dietary fish oil in optimising skeletal muscle
and cardiac function, likely due to marked incorporation of DHA into cell
membranes. Of particular interest is that both membrane compositional changes
and physiological effects were observed with low doses of fish oil, equivalent to
that achievable in the human diet. These results therefore validate and extend
early animal work with supraphysiological doses of fish oil and provide the link
between human observations and animal mechanistic studies. Furthermore, based
on these findings and previous literature, it can be argued that the observations
regarding fish oil are related to correcting a subtle dietary deficiency, as opposed
to a therapeutic or pharmacological effect. The potential applications of this
research are huge. In addition to the improved skeletal muscle function in
claudication and potentially heart failure, identified in the current study, there is
the potential for fish oil to be advantageous in improving quality of life, especially
in those where muscle function is compromised.
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